AACE/TOS/ASMBS Guidelines

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, THE OBESITY SOCIETY, AND AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE PERIOPERATIVE NUTRITIONAL, METABOLIC, AND NONSURGICAL SUPPORT OF THE BARIATRIC SURGERY PATIENT

Jeffrey I. Mechanick, MD, FACP, FACE, FACN, Robert F. Kushner, MD, Harvey J. Sugerman, MD, J. Michael Gonzalez-Campoy, MD, PhD, FACE, Maria L. Collazo-Clavell, MD, FACE, Adam F. Spitz, MD, FACE, Caroline M. Apovian, MD, Edward H. Livingston, MD, FACS, Robert Brolin, MD, David B. Sarwer, PhD, Wendy A. Anderson, MS, RD, LDN and John Dixon, MD

American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice are systematically developed statements to assist health-care professionals in medical decision making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances.

The American Society for Parenteral & Enteral Nutrition fully endorses sections of these guidelines that address the metabolic and nutritional management of the bariatric surgical patient.

© AACE 2009.

1. PREFACE

Surgical therapy for obesity, or “bariatric surgery,” is indicated for certain high-risk patients, termed by the National Institutes of Health (NIH) as having “clinically severe obesity.” These clinical practice guidelines (CPG) are cosponsored by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), and the American Society for Metabolic & Bariatric Surgery (ASMBS). These guidelines represent an extension of the AACE/American College of Endocrinology Obesity Task Force position statements (1 (evidence level or EL 4), 2 (EL 4)) and the National Heart, Lung, and Blood Institute and the North American Association for the Study of Obesity Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (3 (EL 4)). These CPG will focus on the nonsurgical aspects of perioperative management of the bariatric surgery patient, with special emphasis on nutritional and metabolic support. The organization of these CPG is as follows: (i) an introduction section to familiarize the reader with the principles of bariatric surgery, (ii) a Methods section to outline the a priori evidence-based system of recommendations,
(iii) an Executive Summary section of specific, practical evidence-based recommendations, (iv) an Appendix section containing in-depth discussions and ratings of the clinical evidence referred to in the Executive Summary of Recommendations, and lastly (v) an extensive Reference section in which each clinical report or study is assigned an evidence level (for further details, see Section 7.3).

2. HISTORY OF BARIATRIC SURGERY
The original bariatric surgical procedure was the jejunocolic bypass, followed shortly thereafter by the jejunoileal bypass. This approach was introduced in 1954 and consisted of 14 inches (35.6 cm) of jejunum connected to 4 inches (10.2 cm) of ileum as either an end-to-end or an end-to-side anastomosis, which bypassed most of the small intestine (4 (EL 4), 5 (EL 3)). This procedure resulted in substantial weight loss but with an unacceptably high risk of unanticipated early and late complications, including life-threatening hepatic failure and cirrhosis, renal failure, oxalate nephropathy, immune complex disease, and multiple nutritional deficiencies (6 (EL 4)). Because of these complications, the jejunoileal bypass procedure is no longer performed. Nevertheless, because there may still be patients who have had this procedure who seek nutritional and metabolic management from their health-care providers, familiarity with this outdated procedure is justified.

In the late 1970s, the gastric bypass was developed on the basis of information gathered from gastrectomy procedures and then modified to a Roux-en-Y anastomosis. This procedure was found to have equivalent weight loss to the jejunoileal bypass but with a much lower risk of complications (7 (EL 3)). At present, there are three broad categories of bariatric procedures: (i) purely gastric restriction, (ii) gastric restriction with some malabsorption, as represented by the Roux-en-Y gastric bypass (RYGB), and (iii) gastric restriction with significant intestinal malabsorption. Estimates suggest that the number of bariatric procedures performed in the United States increased from 13,365 in 1998 to nearly 150,000 in 2005 (8 (EL 4)) and to ~200,000 procedures in 2007, according to the ASMBS. In 1998 in the United States, there were ~250 bariatric surgeons, which increased to ~700 in 2001 and expanded to nearly 1,100 by 2003 (9 (EL 4), 10 (EL 4)). Currently, RYGB procedures account for >80% of bariatric operations according to unpublished data from the ASMBs, although the proportion is changing with the advent of the laparoscopic adjustable gastric band (LAGB) procedure (11 (EL 2)). The majority of patients (80%) are female, from a higher socioeconomic class, privately insured, and between 40 and 64 years of age (12 (EL 3)). When one considers the prevalence of class three obesity among US adults of nearly 5% of the population—which equals ~10 million individuals (13 (EL 3))—there are almost 10,000 potential surgical candidates for every bariatric surgeon (9 (EL 4), 14 (EL 3)).

3. INDICATIONS FOR BARIATRIC SURGERY
Overweight and obesity are at epidemic proportions in the United States, affecting nearly 65% (or ~130 million) of the adult population (13 (EL 3)). Obesity is defined as a BMI (weight in kg/(height in meters)²) ≥30 kg/m², in an overall classification in which the healthy range of weight is 18.5–24.9 kg/m², overweight is 25–29.9 kg/m², class 1 obesity is 30–34.9 kg/m², class 2 obesity is 35–39.9 kg/m², and class 3 obesity is >40 kg/m². Some groups further subcategorize this last entity into class 4 obesity (superobesity) as >50–59.9 kg/m² and class 5 obesity (super-superobesity) (15 (EL 3)) as >60 kg/m² (16 (EL 4)). The older terminology of morbid obesity, empirically defined as >100 lb (45.4 kg) or 100% over ideal body weight, has been replaced with newer descriptive terms, including class 3 obesity, extreme obesity, or clinically severe obesity. “Morbid obesity,” however, is still listed in the International Classification of Diseases, Ninth Revision, Clinical Modification. The term “morbid obesity” is used for coding and is also used by the National Library of Medicine and in medical journals and texts. In these guidelines, these terms are used interchangeably. Class 3 obesity was present in 3.1% of the 2005 American adult population (17 (EL 4)). Its prevalence had quadrupled between 1986 and 2000 (class 4 obesity increased fivefold during the same period) and increased another twofold between 2000 and 2005 (class 4 obesity increased threefold during the same period) (17 (EL 4), 18 (EL 4)). Class 3 obesity has also been associated with a notable increase in mortality, especially for male subjects, in comparison with that for nonobese patients (19 (EL 4)). A BMI ≥45 kg/m² is associated with a decrease of 13 and 8 years of life expectancy for white male and female subjects, respectively, and a decrease of 20 years for the younger black male population (20 (EL 4)). Cardiovascular mortality is 50% greater in obese people and 90% greater in severely obese persons in comparison with that for people of average weight (21 (EL 3)). More than $238 billion has been spent annually on obesity in the United States (9 (EL 4)). In sum, because of the dramatically increased risk of morbidity and mortality associated with extreme obesity, such patients who do not achieve a significant weight reduction with therapeutic lifestyle changes or pharmacotherapy (or both) would benefit from surgical treatment.

The 1991 NIH Consensus Development Conference Panel (22 (EL 4), 23 (EL 4)) established the following general criteria for eligibility for bariatric surgery: patients with BMI ≥40 kg/m² could be considered surgical candidates; patients with less severe obesity (BMI ≥35 kg/m²) could be considered if they had high-risk comorbid conditions such as life-threatening cardiopulmonary problems (for example, severe sleep apnea, pickwickian syndrome, or obesity-related cardiomyopathy) or uncontrolled type 2 diabetes mellitus (T2DM). Other possible indications for patients with BMIs between 35 and 40 kg/m² include obesity-induced physical problems interfering with lifestyle (for example, joint disease treatable but for the obesity, or body size problems precluding or severely interfering with employment, family function, and ambulation) (22 (EL 4), 23 (EL 4)).

Since the 1991 NIH consensus conference, there have been at least 13 systematic reviews of the bariatric surgery literature (24–36 (EL 4)). Although there have been new procedures and techniques since 1991, these assessments deviate little from the NIH recommendations. One review, however, is substantially
different. Medicare initiated an internal, evidence-based review of the bariatric surgical literature (30 (EL 4)). In November 2004, the National Coverage Advisory Committee received input from experts and the lay community such that they could evaluate the available evidence in the proper context of clinical needs in relationship to evidence (30 (EL 4)). After this extensive analysis, the panel concluded that bariatric surgery could be offered to Medicare beneficiaries with BMI ≥35 kg/m² who have at least one comorbidity associated with obesity and have been unsuccessful previously with medical treatment of obesity (http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5013.pdf) (30 (EL 4)). Initially, the panel concluded that the evidence did not support bariatric surgery for patients ≥65 years of age, and the initial decision did not support bariatric surgery in this age-group (30 (EL 4)). Older surgical patients most likely will have more complications and deaths (37–40 (EL 3)); however, some case series have reported excellent outcomes (41–45 (EL 2–3)). The National Coverage Advisory Committee panel carefully considered the surgical risks for older patients and could not conclude that these procedures should not be offered to older individuals (30 (EL 4)). Hence, the National Coverage Decision for bariatric surgery issued in February 2006 did not stipulate an age limit for such surgical procedures (46 (EL 4)).

In 2006, the US Department of Veterans Affairs and the Department of Defense published their evidence-based CPG for Management of Overweight and Obesity, in which bariatric surgery is reported to be associated with successful weight loss and improvement of comorbid conditions, quality of life, and long-term survival (>5 years) (47 (EL 4)).

Currently, a consensus does not exist on the possible contraindications to bariatric surgery. Suggested contraindications would include an extremely high operative risk (such as severe congestive heart failure or unstable angina), active substance abuse, or a major psychopathologic condition (48 (EL 4)). Patients who cannot comprehend the nature of the surgical intervention and the lifelong measures required to maintain an acceptable level of health should not be offered these procedures. A controversial issue that is reflected by the divergent preoperative strategies among various bariatric programs in the United States is whether or not patients should lose weight (~10%) before bariatric surgery. Two studies suggested that preoperative weight loss was associated with greater weight loss 1 year postoperatively (49 (EL 3), 50 (EL 2)). In a randomized study of 100 patients undergoing RYGB, Alami et al. (51 (EL 2)) found that preoperative weight loss of 10% was associated with improved short-term (6 months) but not long-term weight loss. In contrast, another study found that insurance-mandated preoperative weight loss did not improve postoperative weight loss and was associated with increased dropout rates before gastric bypass surgery (52 (EL 3)). Individuals who seek bariatric surgery typically report an extensive dieting history, which further calls into question the utility of insurance-mandated weight loss preoperatively (53 (EL 3)). A recent study, however, suggested a more functional benefit of preoperative weight loss. In this prospective trial, at least 2 weeks of a very-low-calorie meal plan preoperatively significantly reduced liver volume and thereby potentially improved operative exposure (54 (EL 2)). On balance, consideration should be given to recommendation of preoperative weight loss, particularly in patients with hepatomegaly.

4. TYPES OF BARIATRIC SURGERY Various bariatric procedures are available for management of high-risk obese patients (Table 1 and Figure 1). Minimal scientific data exist for establishing which procedure should be performed for which patient. Currently, most bariatric procedures are being performed laparoscopically. This approach has the advantages of fewer wound complications, less postoperative pain, a brief hospital stay, and more rapid postoperative recovery with comparable efficacy (55–59 (EL 2–4)). These advantages, however, may be offset by more frequent complications associated with techniques used for laparoscopic gastrojejunostomy creation, anastomotic strictures, and higher rates of postoperative bowel obstructions (60 (EL 4), 61 (EL 3), 62 (EL 2)).

Table 1 Types of bariatric surgical procedures

<table>
<thead>
<tr>
<th>Primary</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vertical banded gastroplasty</td>
<td></td>
</tr>
<tr>
<td>Gastric banding</td>
<td></td>
</tr>
<tr>
<td>Silastic ring gastroplasty</td>
<td></td>
</tr>
<tr>
<td>Laparoscopic adjustable gastric band (LAGB)</td>
<td></td>
</tr>
<tr>
<td>Roux-en-Y gastric bypass</td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td></td>
</tr>
<tr>
<td>Long-limb</td>
<td></td>
</tr>
<tr>
<td>Distal</td>
<td></td>
</tr>
<tr>
<td>Biliopancreatic diversion (BPD)</td>
<td></td>
</tr>
<tr>
<td>BPD with duodenal switch (BPD/DS)</td>
<td></td>
</tr>
<tr>
<td>Staged restrictive and malabsorptive procedure</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reversal of gastric restriction</td>
<td></td>
</tr>
<tr>
<td>Revision of Roux-en-Y gastric bypass</td>
<td></td>
</tr>
<tr>
<td>Revision of BPD</td>
<td></td>
</tr>
<tr>
<td>Revision of BPD/DS</td>
<td></td>
</tr>
<tr>
<td>Conversion of LAGB to Roux-en-Y gastric bypass</td>
<td></td>
</tr>
<tr>
<td>Conversion of LAGB to BPD or BPD/DS</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigational</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric bypass with LAGB</td>
<td></td>
</tr>
<tr>
<td>Robotic procedures</td>
<td></td>
</tr>
<tr>
<td>Endoscopic (oral)-assisted techniques</td>
<td></td>
</tr>
<tr>
<td>Gastric balloon</td>
<td></td>
</tr>
<tr>
<td>Gastric pacer</td>
<td></td>
</tr>
<tr>
<td>Vagus nerve pacing</td>
<td></td>
</tr>
<tr>
<td>Vagus nerve block</td>
<td></td>
</tr>
<tr>
<td>Sleeve gastrectomy</td>
<td></td>
</tr>
</tbody>
</table>
4.1. Gastric Restriction

The purposes of a gastric restriction procedure are to produce early satiety, limit food intake, and thus induce weight loss. Gastric restriction can be performed by the vertical banded gastroplasty (VBG) by means of (i) limiting the volume of an upper gastric pouch, into which the esophagus empties, to 15–45 ml and (ii) limiting the pouch outlet to the remaining stomach to 10–11 mm. Currently, the LAGB has almost completely replaced the VBG because it is less invasive, is adjustable, and is reversible, and it has better outcomes (8 (EL 4)).

The LAGB procedure is associated with not only substantially better maintenance of weight loss than lifestyle intervention alone (4 (EL 4), 63 (EL 2)) but also a very low operative mortality rate (0.1%). In one randomized, prospective trial, however, it was associated with significantly less excess weight loss than RYGB at 5 years (11 (EL 2)), which is consistent with the findings of the 10-year Swedish Obese Subjects (SOS) Study that used a nonadjustable gastric band (64 (EL 3), 65 (EL 3)). In a systematic literature search and review, LAGB was associated with less loss of fat-free mass (lean tissue such as muscle) compared with RYGB and biliopancreatic diversion (BPD) (62 (EL 2)). Factors that are associated with greater weight loss after LAGB include an initial BMI <45 kg/m² and the presence of postprandial satiety postoperatively (66 (EL 2)). The LAGB procedure has also been demonstrated to be safe among patients >55 years of age (67 (EL 3)). Complications associated with the LAGB include band slippage, band erosion, balloon failure, port malposition, band and port infections, and esophageal dilatation. Some of these problems have been decreased by a different method of band insertion (the pars flaccida instead of the peri gastric approach) and revision of the port connection (63 (EL 2), 68 (EL 2)). Overall, complication and mortality rates are much lower for LAGB than for RYGB.

4.2. RYGB

Currently, in the United States, RYGB is the most commonly performed bariatric procedure (8 (EL 4), 69 (EL 3)). The weight loss achieved with RYGB is greater than that attained with pure gastric restrictive procedures (11 (EL 2), 64 (EL 3), 65 (EL 3), 70 (EL 2)). In RYGB, the upper part of the stomach is transected; thus, a very small proximal gastric pouch, measuring 10–30 ml, is created. The gastric pouch is anastomosed to a Roux-en-Y proximal jejunal segment, bypassing the remaining stomach, duodenum, and a small portion of jejunum. The standard Roux (alimentary) limb length is ~50–100 cm, and the biliopancreatic limb is 15–50 cm. As a result, the RYGB limits food intake and induces some nutrient malabsorption. In procedures that result in much longer Roux limbs (“distal gastric bypass”) and a short common channel, macronutrient malabsorption can be significant (71 (EL 3), 72 (EL 3)). Another modification that has been used involves combining the gastric band with the RYGB (“banded RYGB”) (73 (EL 3), 74 (EL 4), 75 (EL 3)). Studies have been published regarding conversion of VBG and LAGB procedures to RYGB for band-related complications, staple-line disruptions, and inadequate weight loss (76–78 (EL 3)).

4.3. BPD

The BPD was developed by Scopinaro et al. (79 (EL 3)) as a hybrid bariatric surgical procedure incorporating gastric restrictive and extensive malabsorptive components. In this procedure, a subtotal gastrectomy is performed, and a proximal gastric pouch of 200–500 ml is created. The distal 250-cm segment of small intestine is isolated from the proximal small intestinal segment. The proximal portion of this distal segment is anastomosed to the gastric remnant (alimentary limb). The distal portion of the proximal segment (biliopancreatic limb) is anastomosed to the distal part of the ileum 50 cm from the ileocecal valve. Consequently, digestion and absorption of macronutrients and micronutrients are largely limited to this 50-cm “common channel” where biliopancreatic enzymes have the opportunity to mix with food delivered by the alimentary limb. In a variant of this procedure with no gastric restriction, weight loss is less, but the lipid status and glycemic control are improved in patients with dyslipidemia and diabetes, respectively (80 (EL 3)). Postoperative weight loss is principally due to caloric and fat malabsorption after BPD (81 (EL 3)). The procedure may be associated with protein–calorie malabsorption, which necessitates surgical lengthening of the common channel. The steatorrhea after BPD may produce foul-smelling flatus and stools. The BPD may be associated with a variety of nutrient deficiencies and metabolic derangements, such as iron deficiency anemia, deficiencies in the fat-soluble vitamins (A, D, E, and K), and metabolic bone disease.

4.4. BPD With Duodenal Switch

The BPD was modified by Hess and Hess (82 (EL 3)) with a vertical, subtotal, pylorus-preserving gastrectomy (parietal or sleeve...
gastrectomy) that channels orally ingested nutrients through a type of duodenal switch (BPD/DS), as described originally for bile reflux gastritis (83 (EL 3)). An additional modification of the original BPD procedure was to increase the length of the common channel from 50 to 100 cm, leaving the nutrient limb at 250 cm (84 (EL 3)). Recently, banded BPD/DS procedures have been developed, resulting in weight loss comparable to that for patients with RYGB (85 (EL 3)). Laparoscopic BPD/DS was first performed in 1999 by Ren et al. (86 (EL 3)). Morbidity and mortality were increased in patients with a preoperative BMI >65 kg/m² (86 (EL 3)). Patients with BPD/DS have also been found to have various postoperative nutritional and metabolic complications.

4.5. Staged Bariatric Surgical Procedures

Although the aforementioned surgical procedures represent the generally accepted weight loss operations, some surgeons have used other surgical variations in high-risk patients. Staging the bariatric procedure has been suggested for patients at high risk for complications. In the first stage, a restrictive procedure such as a sleeve (longitudinal) gastrectomy is performed, which can be associated with a 33–45% loss of excess body weight (EBW) at 1 year (87–92 (EL 3)). Then, after a 6- to 12-month period to allow significant weight loss and improvement in comorbidities, a more definitive procedure (RYGB or BPD/DS) is performed. In a prospective study of 126 patients undergoing sleeve gastrectomy with a mean BMI of >65 kg/m² and a median of 10 comorbid conditions per patient, Cottam et al. (92 (EL 3)) achieved a mean 46% loss of EBW, in conjunction with no deaths and an 8% rate of major complications.

In cases in which there is increased volume of the left lobe of the liver, common in patients with a BMI >60 kg/m², the poor visualization of the gastroesophageal junction and angle of His makes construction of the sleeve gastrectomy difficult (93 (EL 4)). Thus, in another type of staged procedure, the surgeon performs an initial modified RYGB with a low gastrojejunal anastomosis and larger gastric pouch, and then 6–12 months later, a completion sleeve gastrectomy and revision of the gastrojejunalostomy are performed. This approach is investigational.

In several recent studies, the sleeve gastrectomy was performed as a stand-alone procedure (87–92 (EL 3)). One randomized, prospective trial has shown better weight loss after sleeve gastrectomy in comparison with the LAGB at 3 years (94 (EL 2)) and with the intragastric balloon at 6 months (95 (EL 3)); however, strong and confirmatory long-term data are lacking. Overall, there are several EL 3 publications supporting a role for staged bariatric procedures involving an initial sleeve gastrectomy; nevertheless, these operations remain investigational at the current time.

5. MORTALITY FROM BARIATRIC PROCEDURES

Considerable concern has been raised regarding the mortality associated with bariatric surgical procedures. One study using statewide outcome data for bariatric surgery found a 1.9% risk of death in the state of Washington; however, procedures performed by more experienced surgeons were associated with a much lower risk of death (40 (EL 3)). Another study that used similar methods found that the risk of intraoperative death was 0.18% and the 30-day mortality was 0.33% for gastric bypass surgery in the state of California (96 (EL 3)). In a national inpatient sample for bariatric surgical procedures, Santry et al. (8 (EL 4)) noted a 0.1–0.2% in-patient mortality nationwide. The Surgical Review Corporation noted a 0.14% in-hospital mortality, a 0.29% 30-day mortality, and a 0.35% 90-day mortality on the basis of 55,567 bariatric surgery patients (97 (EL 4)). The Agency for Healthcare Research and Quality identified a 0.19% in-hospital mortality for all bariatric discharges in the United States for 2004 (98 (EL 3)). In a meta-analysis, the operative mortality rates were 0.1% for LAGB, 0.5% for RYGB, and 1.1% for other malabsorptive procedures (99 (EL 1)). In a multi-institutional consecutive cohort study involving US academic medical centers by Nguyen et al. (100 (EL 3)), the following conclusions were offered as benchmark figures:

- For restrictive procedures (N = 94), 92% were performed laparoscopically with no conversions, an overall complication rate of 3.2%, a 30-day readmission rate of 4.3%, and a 30-day mortality rate of 0%.
- For gastric bypass procedures (N = 1,049), 76% were performed laparoscopically with a conversion rate of 2.2%, an overall complication rate of 16%, an anastomotic leak rate of 1.6%, a 30-day readmission rate of 6.6%, and a 30-day mortality rate of 0.4%.

DeMaria et al. (101 (EL 4)) proposed an “obesity surgery mortality risk score” for RYGB based on BMI, male sex, hypertension, risk of pulmonary embolus (PE), and patient age. The mortality in low-risk patients (class A) was 0.31%, in intermediate-risk patients (class B) was 1.9%, and in high-risk patients (class C) was 7.56% (101 (EL 4)). Thus, it appears that bariatric surgery is not uniformly a “low-risk” procedure, and judicious patient selection and diligent perioperative care are imperative.

To define contemporary morbidity and mortality outcomes better, the NIH recently initiated the 3-year multicenter prospective Longitudinal Assessment of Bariatric Surgery study (102 (EL 4)). This observational study will assess the safety and clinical response of bariatric surgery by using standardized techniques and measurements.

6. BENEFITS OF BARIATRIC SURGERY

The purpose of bariatric surgery is to induce substantial, clinically important weight loss that is sufficient to reduce obesity-related medical complications to acceptable levels (103–107 (EL 3)) (Table 2). The loss of fat mass, particularly visceral fat, is associated with improved insulin sensitivity and glucose disposal, reduced flux of free fatty acids, increased adiponectin levels, and decreased interleukin-6, tumor necrosis factor-α, and highly sensitive C-reactive protein levels. Loss of visceral fat also reduces intra-abdominal pressure, and this change may result in improvements in urinary incontinence, gastroesophageal reflux, systemic hypertension, pseudotumor cerebri, venous stasis disease, and hypoventilation (108–114 (EL 2–4)). Foregut
bypass leads to improvement in the physiologic responses of gut hormones involved in glucose regulation and appetite control, including ghrelin, glucagon-like peptide-1 (GLP-1), and peptide YY, respectively (115 (EL 4), 116 (EL 4)). Mechanical improvements include less weight bearing on joints, enhanced lung compliance, and decreased fatty tissue around the neck, which relieves obstruction to breathing and sleep apnea.

Fluid and hemodynamic changes that lower the blood pressure after bariatric surgery include diuresis, natriuresis, and decreases in total body water, blood volume, and indices of sympathetic activity. Other clinical benefits include improvements in T2DM, obesity-related cardiomyopathy, cardiac function, lipid profile, respiratory function, disordered sleep, degenerative joint disease, obesity-related infections, mobility, venous stasis, nonalcoholic fatty liver disease (NAFLD), asthma, polycystic ovary syndrome (PCOS), infertility, and complications of pregnancy (44 (EL 3)). Most bariatric surgery patients also experience considerable improvements in psychosocial status and quality of life postoperatively (48 (EL 4), 117–119 (EL 4)).

In an extensive meta-analysis of 22,000 bariatric surgery patients, Buchwald et al. (99 (EL 1)) found that an average EBW loss of 61% was accompanied by improvements in T2DM, hypertension, sleep apnea, and dyslipidemia. In another meta-analysis, Maggard et al. (120 (EL 1)) found that bariatric surgery resulted in a weight loss of 20–30 kg maintained up to 10 years in association with reduction of comorbidities and an overall mortality rate <1%. These benefits were conclusive for those patients with a BMI ≥40 kg/m² but not <40 kg/m². The nonrandomized, prospective, controlled SOS Study involved obese subjects who underwent gastric surgical procedures (mostly gastroplasties and nonadjustable bands) and contemporaneously matched, obese control subjects treated conventionally (64 (EL 3), 65 (EL 3)). Two- and 10-year improvement rates in T2DM, hypertriglyceridemia, low levels of high-density lipoprotein (HDL) cholesterol, and hyperuricemia were more favorable in the surgically treated group than in the control group. Recovery from hypercholesterolemia and hypertension did not differ between the groups at 10 years (64 (EL 3)). In contrast, at 8 years the 6% of patients who underwent RYGB had a significant decrease in both the systolic and the diastolic blood pressure (121 (EL 2)).

The beneficial effect of bariatric surgery on T2DM is one of the most important outcomes observed. Control rates for most procedures currently performed vary from 40 to 100%. Gastric bypass and malabsorptive procedures offer the highest rates of remission of T2DM (Table 3) (14 (EL 3), 84 (EL 3), 122–129 (EL 3–4)). A shorter duration of T2DM and greater weight loss are independent predictors of T2DM remission (130 (EL 3)). Improvements in fasting blood glucose levels occur before significant weight loss (131–135 (EL 3)). Insulin-treated patients experience substantial decreases in insulin requirements, with the majority of patients with T2DM able to discontinue insulin therapy by 6 weeks after bariatric surgery (136 (EL 3)). Euglycemia has been maintained up to 14 years after RYGB, a superior outcome when compared with solely gastric restrictive procedures (103 (EL 3), 137–139 (EL 3)). BPD and BPD/DS may be even more effective at improvement of the metabolic abnormalities of T2DM, leading to discontinuation of glucose-lowering therapy in most patients (84 (EL 3), 125 (EL 3), 140 (EL 4)). The LAGB procedure has also been shown to improve T2DM, albeit at a slower rate (64–71% remission rates within the first year) than RYGB, BPD, or BPD/DS (141–143 (EL 2)).

Prevention of the development of T2DM has also been reported with bariatric surgery. Significantly, in a longitudinal observational study of a nonrandomized cohort (144 (EL 2), 145 (EL 2)) and a randomized controlled study (63 (EL 2)), LAGB was associated with decreased insulin resistance and a dramatic reduction in fulfillment of the criteria for the metabolic syndrome. Long et al. (146 (EL 2)) reported a 30-fold decrease in the risk for T2DM among patients with preexisting hyperglycemia who underwent RYGB. In a prospective, controlled study of 18 nondiabetic patients with a mean BMI of 54 ± 9 kg/m² undergoing RYGB, insulin sensitivity improved by 5 months, with continued improvement through 16 months postoperatively, although still not achieving normal levels (147 (EL 3)). The prevalence of the metabolic syndrome also decreases after RYGB (148 (EL 3)). In contrast, after BPD, insulin sensitivity normalized by 6 months and reached supranormal values by 24 months despite a BMI still exceeding 30 kg/m² (147 (EL 3)). Moreover, in patients with BPD, glucose-induced thermogenesis and insulin-glucose metabolism are normalized postoperatively (149 (EL 3)). Furthermore, in a retrospective review of 312 patients after

### Table 2 Effects of bariatric surgery on obesity-related comorbidities

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Preoperative incidence (%)</th>
<th>Remission &gt;2 years postoperatively (%)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2DM, IFG, or IGT</td>
<td>34</td>
<td>85</td>
<td>103</td>
</tr>
<tr>
<td>Hypertension</td>
<td>26</td>
<td>66</td>
<td>104</td>
</tr>
<tr>
<td>Hypertriglyceridemia and low HDL cholesterol</td>
<td>40</td>
<td>85</td>
<td>105</td>
</tr>
<tr>
<td>Sleep apnea (in men)</td>
<td>22</td>
<td>40</td>
<td>106</td>
</tr>
<tr>
<td>(in women)</td>
<td>1</td>
<td>76</td>
<td>107</td>
</tr>
<tr>
<td>Obesity-hyperventilation syndrome</td>
<td>83–92</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HDL, high-density lipoprotein; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus.

*Adapted from Greenway (4).

### Table 3 Rates for remission of type 2 diabetes mellitus reported after bariatric surgery

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Remission rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vertical banded gastroplasty</td>
<td>75–83</td>
</tr>
<tr>
<td>Laparoscopic adjustable silicone gastric banding</td>
<td>40–47</td>
</tr>
<tr>
<td>Roux-en-Y gastric bypass</td>
<td>83–92</td>
</tr>
<tr>
<td>Biliopancreatic diversion</td>
<td>95–100</td>
</tr>
</tbody>
</table>

*Data from Greenway (4).
BPD, all the major components of the metabolic syndrome were found to be reversed throughout a 10-year follow-up period: hyperglycemia decreased from 100 to 3%, hypertriglyceridemia declined from 38 to 1%, hypercholesterolemia diminished from 63 to 0%, and arterial hypertension abated from 86 to 26% (150 (EL 3)).

Eight studies have documented a decreased mortality in patients who have undergone bariatric surgery when compared with those who have not. Two of these studies were comparisons with patients who were evaluated for bariatric surgery but for some reason (for example, lack of insurance coverage or patient decision) did not undergo a surgical procedure (151 (EL 3), 152 (EL 3)). One study in the state of Washington found a decreased mortality among patients who underwent bariatric surgery in comparison with severely obese patients who had not, excluding the high operative mortality in that state (39 (EL 3)). Five studies were comparisons with a matched medical cohort (65 (EL 3), 141 (EL 2), 153 (EL 3), 154 (EL 2), 155 (EL 3)). The reduced mortality was due to decreases in occurrence of myocardial infarction (MI), diabetes, and cancer-related deaths (65 (EL 3), 153 (EL 3), 154 (EL 2)). Adams et al. (154 (EL 2)) also found, however, that bariatric surgery was associated with a 58% increased rate of death not caused by disease, such as accidents and suicide (11.1 vs. 6.4 per 10,000 person-years).

Weight loss after malabsorptive bariatric surgery reaches a nadir ~12–18 months postoperatively, with an approximate 10% regain of weight during the next decade (64 (EL 3), 65 (EL 3)) (Table 4). Weight loss is more gradual for the restrictive LAGB procedure but may continue for several years (63 (EL 2)). In purely restrictive procedures, failure to experience optimal weight loss has been associated with consumption of calorically dense liquids that can pass through the stoma without producing satiety (70 (EL 2), 156 (EL 2)), although this finding has not been confirmed in other studies (157 (EL 3), 158 (EL 3)).

Table 4 Reported weight loss as percentage of excess body weight after bariatric surgery

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Follow-up period (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1–2</td>
</tr>
<tr>
<td>Vertical banded gastroplastya</td>
<td>50–72</td>
</tr>
<tr>
<td>Gastric bandingb</td>
<td>29–87</td>
</tr>
<tr>
<td>Sleeve gastrectomye</td>
<td>33–58</td>
</tr>
<tr>
<td>Banded Roux-en-Y gastric bypassg</td>
<td>73–80</td>
</tr>
<tr>
<td>Long-limb Roux-en-Y gastric bypass/</td>
<td>53–74</td>
</tr>
<tr>
<td>Biliopancreatic diversion ± DSi</td>
<td>65–83</td>
</tr>
</tbody>
</table>

DS, duodenal switch.

References 429, 430, 734–736.


References 87, 88, 90–92, 94, 95.

References 11, 70, 73, 156, 212, 294, 356, 424, 467, 480, 503, 574, 758–768.

References 73–75.

References 72, 762, 764, 769.

References 125, 335, 338, 347, 495, 518, 574, 770–774.

7. METHODS FOR DEVELOPMENT OF AACE-TOS-ASMBLS CPG

In 2004, the AACE Protocol for Standardized Production of CPG was published in Endocrine Practice (159 (EL 4)). These CPG for perioperative nonsurgical management of the bariatric surgery patient are in strict accordance with the AACE Task Force CPG protocols and have been approved by TOS and ASMBLS. Important production attributes unique to these CPG are described in the subsequent material.

7.1. Mandate, Review Process, Objectives, and Target Audience

AACE, TOS, and ASMBLS task forces were assembled concurrently to produce these CPG, as mandated by their respective Board of Directors. Cochairmen and primary writing teams were assigned, and their initial draft was then reviewed by additional AACE, TOS, and ASMBLS members before further review by various AACE, TOS, and ASMBLS committees. Finally, the cochairmen performed a review prior to publication. These CPG will expire in 2011 and will be updated by AACE, TOS, and ASMBLS at a time determined by the societies. At present, implementation and evaluation of these CPG are at the discretion of AACE, TOS, and ASMBLS Board of Directors.

The objectives of these CPG are to provide the following:

1. An overview of the important principles of bariatric surgery as context for interpretation of subsequent evidence-based recommendations.
2. An evidence-based resource for the perioperative nonsurgical management, especially nutritional and metabolic support, of the bariatric surgery patient.
3. Specific recommendations regarding the selection of appropriate patients for bariatric surgery.
4. Specific recommendations regarding the preoperative evaluation for the bariatric surgical patient.
5. Specific recommendations regarding postoperative nonsurgical management of the bariatric surgery patient.
6. Specific recommendations regarding the recognition and management of postoperative complications.
7. Specific recommendations regarding selection of patients for a second (staged) bariatric surgical procedure or a revision or reversal of a previous bariatric surgical procedure.

The target audiences for these CPG are as follows:

1. Endocrinologists.
2. Specialists in metabolic and gastrointestinal disorders, obesity, clinical nutrition, nutrition support, or other disciplines that manage obese patients.
4. Surgeons who encounter patients considering bariatric surgery or who have already had a bariatric surgical procedure.

7.2. Guidelines for CPG

Current guidelines for CPG in clinical medicine emphasize an evidence-based approach rather than simply expert opinion...
(159 (EL 4), 160 (EL 4)). Even though a purely evidence-based approach lacks applicability to all actual clinical scenarios, its incorporation in these CPG provides objectivity.

7.3. Transparency: Levels of Scientific Substantiation and Recommendation Grades

All clinical data that are incorporated in these CPG have been evaluated in terms of levels of scientific substantiation (evidence levels (EL); Table 5). This evidence rating system has one minor modification in comparison with the original AACE protocol (159 (EL 4)) in that level 2 ((EL 2)) prospective studies may be randomized or nonrandomized to allow for well-designed cohort studies. This modification was incorporated because it is difficult to perform well-controlled, randomized clinical trials in surgery, unlike what physicians have been accustomed to in pharmaceutical trials. Another point worth mentioning is that when consensus statements are cited, even if based on a synthesis of evidence as in a published “evidence-based report,“ then an evidence level 4 (EL 4) has been assigned. Every clinical reference was assigned an evidence rating, which has then been inserted in brackets at the end of the citation in both the text and the reference sections. The “best evidence” rating level (BEL) corresponds to the best conclusive evidence found. The BEL accompanies the recommendation Grade in the Executive Summary and maps to the text in the Appendix section, where transparency is paramount. In the Executive Summary, BEL 2 ratings have been designated as “randomized,” “nonrandomized,” or both for additional transparency. Final recommendation Grades (Table 6) incorporate EL ratings, and in situations in which there was no clinical evidence, various subjective factors were considered: physician preferences, costs, risks, and regional availability of specific technologies and expertise. Hence, recommendation grades are generally based on strong BEL (Grade A; BEL 1), intermediate BEL (Grade B; BEL 2), weak BEL (Grade C; BEL 3), or subjective factors when there is no clinical evidence, inconclusive clinical evidence, or contradictory clinical evidence (Grade D; BEL 4). All recommendations resulted from a consensus among the AACE, TOS, and ASMBS primary writers and influenced by input from reviewers. If subjective factors take priority over the BEL on the basis of the expert opinion of the task force members, then this is described explicitly. Thus, some recommendations may be “upgraded” or “downgraded” according to explicitly stated subjective factors. Furthermore, the correctness of the recommendation Grades and EL was subject to review at several levels. Also, recommendation Grades were assigned only if a specific action is recommended. The action may be ordering a particular diagnostic test, using a particular drug, performing a particular procedure, or adhering to a particular algorithm.

Shortcomings of this evidence-based methodology in these CPG are (i) relative paucity of strong (level 1 and 2) scientific

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Prospective, randomized, controlled trials—large</td>
<td>Data are derived from a substantial number of trials, with adequate statistical power involving a substantial number of outcome data subjects. Large meta-analyses using raw or pooled data or incorporating quality ratings. Well-controlled trial at one or more centers. Consistent pattern of findings in the population for which the recommendation is made (generalizable data). Compelling nonexperimental, clinically obvious, evidence (for example, use of insulin in diabetic ketoacidosis); “all-or-none” indication.</td>
</tr>
<tr>
<td>2</td>
<td>Prospective controlled trials with or without randomization—limited body of outcome data</td>
<td>Limited number of trials, small population sites in trials. Well-conducted single-arm prospective cohort study. Limited but well-conducted meta-analyses. Inconsistent findings or results not representative for the target population. Well-conducted case-controlled study.</td>
</tr>
<tr>
<td>3</td>
<td>Other experimental outcome data and nonexperimental data</td>
<td>Nonrandomized, controlled trials. Uncontrolled or poorly controlled trials. Any randomized clinical trial with one or more major or three or more minor methodologic flaws. Retrospective or observational data. Case reports or case series. Conflicting data with weight of evidence unable to support a final recommendation.</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion</td>
<td>Inadequate data for inclusion in level 1, 2, or 3; necessitates an expert panel’s synthesis of the literature and a consensus. Experience-based. Theory-driven.</td>
</tr>
</tbody>
</table>

*Levels 1, 2, and 3 represent a given level of scientific substantiation or proof. Level 4 or Grade D represents unproven claims. It is the “best evidence” based on the individual ratings of clinical reports that contributes to a final grade recommendation (Table 6).
The final recommendation grades were determined by the primary writers by consensus on the basis of (i) “best evidence” ratings (see Table 5) and (ii) subjective factors (see Methods Section 7.3 on Transparency).

8. EXECUTIVE SUMMARY OF RECOMMENDATIONS

The following recommendations (labeled “R”) are evidence-based (Grades A, B, and C) or based on expert opinion because of a lack of conclusive clinical evidence (Grade D). BEL, which corresponds to the best conclusive evidence found, accompanies the recommendation grade in this Executive Summary. Details regarding the mapping of clinical evidence to these recommendation grades are provided in the Appendix (Section 9, “Discussion of the Clinical Evidence”).

8.1. Which Patients Should Be Offered Bariatric Surgery?

The selection criteria and exclusion factors for bariatric surgery are outlined in Table 7.

- **R1.** Patients with a BMI ≥40 kg/m² for whom bariatric surgery would not be associated with excessive risk should be eligible for one of the procedures (Grade A; BEL 1).

- **R2.** Patients with a BMI ≥35 kg/m² and one or more severe comorbidities, including coronary artery disease (CAD), T2DM, obstructive sleep apnea (OSA), obesity-hypoventilation syndrome (OHS), pickwickian syndrome (a combination of OSA and OHS), NAFLD or nonalcoholic steatohepatitis, hypertension, dyslipidemia, pseudotumor cerebri, gastroesophageal reflux disease (GERD), asthma, venous stasis disease, severe urinary incontinence, debilitating arthritis, or considerably impaired quality of life, may also be offered a bariatric procedure if the surgical risks are not excessive (Grade A; BEL 1).

- **R3.** Currently, insufficient data are available to recommend bariatric surgery for patients with a BMI <35 kg/m² (Grade D).

- **R4.** There is insufficient evidence for recommending bariatric surgery specifically for glycemic control independent of BMI criteria (Grade D).

8.2. Which Bariatric Surgical Procedure Should Be Offered?

The best choice for any bariatric procedure (type of procedure and type of approach) depends on the available local–regional expertise (surgeon and institution), patient preferences, risk stratification, and other idiosyncratic factors, with which the referring physician (or physicians) must...
Table 7 Selection criteria for bariatric surgery

<table>
<thead>
<tr>
<th>Factor</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (adults)</td>
<td>BMI ≥40 kg/m² with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>BMI ≥35 kg/m² with obesity-associated comorbidity</td>
</tr>
<tr>
<td>Weight-loss history</td>
<td>Failure of previous nonsurgical attempts at weight reduction, including nonprofessional programs (for example, Weight Watchers, Inc)</td>
</tr>
<tr>
<td>Commitment</td>
<td>Expectation that patient will adhere to postoperative care</td>
</tr>
<tr>
<td></td>
<td>Follow-up visits with physician(s) and team members</td>
</tr>
<tr>
<td></td>
<td>Recommended medical management, including the use of dietary supplements</td>
</tr>
<tr>
<td></td>
<td>Instructions regarding any recommended procedures or tests</td>
</tr>
<tr>
<td>Exclusion</td>
<td>Reversible endocrine or other disorders that can cause obesity</td>
</tr>
<tr>
<td></td>
<td>Current drug or alcohol abuse</td>
</tr>
<tr>
<td></td>
<td>Uncontrolled, severe psychiatric illness</td>
</tr>
<tr>
<td></td>
<td>Lack of comprehension of risks, benefits, expected outcomes, alternatives, and lifestyle changes required with bariatric surgery</td>
</tr>
</tbody>
</table>

BMI, body mass index.

become familiar (Grade D). At this time, there is insufficient conclusive evidence to recommend specific bariatric surgical procedures for the general severely obese population (Grade D). Specialists in bariatric medicine, however, must also familiarize themselves with the outcome data among the various bariatric surgical procedures (Grade D). Physicians should exercise caution when recommending BPD, BPD/DS, or related procedures because of greater associated risks reported in the literature (Grade C; BEL 3).

- R6. Although risks and benefits are associated with both approaches, laparoscopic bariatric procedures are preferred over open bariatric procedures if sufficient surgical expertise is available (Grade B; BEL 2 (randomized and nonrandomized)).

- R7. A first-stage sleeve gastrectomy may be performed in high-risk patients to induce an initial weight loss (25–45 kg), with the possibility of then performing a second-stage RYGB or BPD/DS after the patient’s operative risk has improved. This is currently an investigational procedure (Grade C; BEL 3).

8.3. How Should Potential Candidates for Bariatric Surgery Be Managed Preoperatively?

- R8. All patients should undergo evaluation for causes and complications of obesity, with special attention directed to those factors that could affect a recommendation for bariatric surgery (Table 8) (Grade A; BEL 1).

- R9. The preoperative evaluation must include a comprehensive medical history, physical examination, and appropriate laboratory testing (Grade A; BEL 1).

- R10. The medical necessity for bariatric surgery should be documented (Grade D).

- R11. There should be a thorough discussion with the patient regarding the risks and benefits, procedural options, and choices of surgeon and medical institution (Grade D).

- R12. Patients should be provided with educational materials and access to preoperative educational sessions at prospective bariatric surgery centers (Grade D).

- R13. Financial counseling should be provided, and the physician should be able to provide all necessary clinical material for documentation so that third-party payer criteria for reimbursement are met (Grade D).

- R14. Preoperative weight loss should be considered in patients in whom reduction of liver volume can improve the technical aspects of surgery (Grade B; BEL 2 (nonrandomized)).

8.4. System-oriented Approach to Medical Clearance for Bariatric Surgery

8.4.1. Endocrine

8.4.1.1. Diabetes

- R15. Preoperative glycemic control should be optimized with use of medical nutrition therapy and physical activity; orally administered agents and insulin should be introduced as needed (Grade D).

- R16. Reasonable targets for preoperative glycemic control should be a hemoglobin A1c value of ≤7.0%, a fasting blood glucose level of ≤110 mg/dl, and a 2-h postprandial blood glucose concentration of ≤140 mg/dl (see http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf), but these variables are based on evidence related to long-term outcome and may not be applicable in this setting (Grade D).

- R17. A protocol for perioperative glycemic control should be reviewed before the patient undergoes bariatric surgery (Grade D).

8.4.1.2. Thyroid

- R18. Routine screening recommendations for hypothyroidism are conflicting. When thyroid disease is suspected, a sensitive serum thyroid-stimulating hormone level should be ordered (Grade D).

- R19. In patients found to have thyroid dysfunction, treatment should be initiated before bariatric surgery (Grade D).

8.4.1.3. Lipids

- R20. A fasting lipid panel should be obtained in all patients with obesity (Grade A; BEL 1).
PERIO OPERATIVE BARIATRIC GUIDELINES

Table 8 Metabolic complications of bariatric surgery

<table>
<thead>
<tr>
<th>Complication</th>
<th>Clinical features</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid-base disorder</td>
<td>Metabolic acidosis, ketosis</td>
<td>Bicarbonate orally or intravenously; adjust</td>
</tr>
<tr>
<td></td>
<td>Metabolic alkalosis</td>
<td>acetate content in PN</td>
</tr>
<tr>
<td>Bacterial overgrowth (primarily with BPD, BPD/DS)</td>
<td>Abdominal distention</td>
<td>Antibiotics (metronidazole)</td>
</tr>
<tr>
<td></td>
<td>Pseudo-obstruction</td>
<td>Probiotics</td>
</tr>
<tr>
<td></td>
<td>Nocturnal diarrhea</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proctitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute arthralgia</td>
<td></td>
</tr>
<tr>
<td>Electrolyte abnormalities (primarily with BPD, BPD/DS)</td>
<td>Low Ca, K, Mg, Na, P</td>
<td>Enteral or parenteral repletion</td>
</tr>
<tr>
<td></td>
<td>Arrhythmia, myopathy</td>
<td></td>
</tr>
<tr>
<td>Fat-soluble vitamin deficiency</td>
<td>Vitamin A—night vision</td>
<td>Vitamin A, 5,000–10,000 U/day</td>
</tr>
<tr>
<td></td>
<td>Vitamin D—osteomalacia</td>
<td>Vitamin D, 400–50,000 U/day</td>
</tr>
<tr>
<td></td>
<td>Vitamin E—rash, neurologic</td>
<td>Vitamin E, 400 U/day</td>
</tr>
<tr>
<td></td>
<td>Vitamin K—coagulopathy</td>
<td>Vitamin K, 1 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ADEK, two tablets twice a day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(<a href="http://www.scandipharm.com">http://www.scandipharm.com</a>)</td>
</tr>
<tr>
<td>Folic acid deficiency</td>
<td>Hyperhomocysteinemia</td>
<td>Folic acid supplementation</td>
</tr>
<tr>
<td></td>
<td>Anemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fetal neural tube defects</td>
<td></td>
</tr>
<tr>
<td>Iron deficiency</td>
<td>Anemia</td>
<td>Ferrous fumarate, sulfate, or gluconate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Up to 150–300 mg elemental iron daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Add vitamin C and folic acid</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>Fractures</td>
<td>DXA, calcium, vitamin D, and consider bisphosphonates</td>
</tr>
<tr>
<td>Oxalosis</td>
<td>Kidney stones</td>
<td>Low oxalate diet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Potassium citrate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Probiotics</td>
</tr>
<tr>
<td>Secondary hyperparathyroidism</td>
<td>Vitamin D deficiency</td>
<td>DXA</td>
</tr>
<tr>
<td></td>
<td>Negative calcium balance</td>
<td>Serum intact PTH level</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis</td>
<td>25-Hydroxyvitamin D levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Calcium and vitamin D supplements</td>
</tr>
<tr>
<td>Thiamine deficiency (vitamin B₁)</td>
<td>Wernicke–Korsakoff encephalopathy</td>
<td>Thiamine intravenously followed by large-dose</td>
</tr>
<tr>
<td></td>
<td>Peripheral neuropathy</td>
<td>thiamine orally</td>
</tr>
<tr>
<td></td>
<td>Beriberi</td>
<td></td>
</tr>
<tr>
<td>Vitamin B₁₂ deficiency</td>
<td>Anemia</td>
<td>Parenteral vitamin B₁₂</td>
</tr>
<tr>
<td></td>
<td>Neuropathy</td>
<td>Methylmalonic acid level</td>
</tr>
</tbody>
</table>

BPD, biliopancreatic diversion; BPD/DS, BPD with duodenal switch; DXA, dual-energy X-ray absorptiometry; PN, parenteral nutrition; PTH, parathyroid hormone.

- R21. Treatment should be initiated according to the National Cholesterol Education Program Adult Treatment Panel III guidelines (see http://www.nhlbi.nih.gov/guidelines/cholesterol/) (Grade D).

8.4.1.4. PCOS and fertility

- R22. Candidates for bariatric surgery should minimize the risk of pregnancy for at least 12 months perioperatively (Grade C; BEL 3).

- R23. All women of reproductive age should be counseled on contraceptive choices (Grade D).

- R24. Women with an LAGB should be closely monitored during pregnancy because band adjustment may be necessary (Grade B; BEL 2 (nonrandomized)).

- R25. Estrogen therapy should be discontinued before bariatric surgery (one cycle of oral contraceptives in premenopausal women; 3 weeks of hormone replacement therapy in postmenopausal women) to reduce the risks for postoperative thromboembolic phenomena (Grade D).

- R26. Women with PCOS should be advised that their fertility status may be improved postoperatively (Grade D).

8.4.1.5. Exclusion of endocrine causes of obesity

- R27. Routine laboratory testing to screen for rare causes of obesity (for example, Cushing syndrome, hypothalamic obesity syndromes, melanocortin-4 mutations, and leptin deficiency obesity) is not cost-effective and not recommended (Grade D).
• R28. Case-by-case decisions to screen for rare causes of obesity should be based on specific historical and physical findings (Grade D).

8.4.2. Cardiology and Hypertension
• R29. Noninvasive testing beyond an electrocardiogram is determined on the basis of the individual risk factors and findings on history and physical examination (Grade D).

• R30. Patients with known cardiac disease should have a formal cardiology consultation before bariatric surgery (Grade D).

• R31. Patients at risk for heart disease should undergo evaluation for perioperative β-adrenergic blockade (Grade A; BEL 1).

8.4.3. Pulmonary and Sleep Apnea
• R32. All patients considered for bariatric surgery should have a chest radiograph preoperatively (Grade D).

• R33. Patients with intrinsic lung disease or disordered sleep patterns should have a formal pulmonary evaluation, including arterial blood gas measurement and polysomnography, when knowledge of the results would alter patient care (Grade D).

• R34. Patients should stop smoking at least 8 weeks before bariatric surgery and should plan to quit smoking or to participate in a smoking cessation program postoperatively (Grade C; BEL 3).

8.4.4. Venous Disease
• R35. Patients at risk for, or with a history of, deep venous thrombosis (DVT) or cor pulmonale should undergo an appropriate diagnostic evaluation for DVT (Grade D).

• R36. A prophylactic vena caval filter should be considered for patients with a history of prior PE, prior iliofemoral DVT, evidence of venostasis, known hypercoagulable state, or increased right-sided heart pressures (Grade C; BEL 3).

8.4.5. Gastrointestinal
• R37. All gastrointestinal symptoms should be evaluated and treated before bariatric surgery (Grade D).

• R38. All patients considered for bariatric surgery who have increased liver function test results (2–3 times the upper limit of normal) should undergo abdominal ultrasonography and a viral hepatitis screen (Grade D).

• R39. There is inconsistent evidence to recommend routine screening for the presence of Helicobacter pylori before bariatric surgery (Grade D).

8.4.6. Rheumatologic and Metabolic Bone Disease
• R40. There are no evidence-based, routine preoperative tests required for evaluation of rheumatologic problems (Grade D).

• R41. There are insufficient data to warrant routine preoperative assessment of bone mineral density (BMD) with dual-energy X-ray absorptiometry (Grade D).

8.4.7. Psychiatric
• R42. A psychosocial–behavioral evaluation, which assesses environmental, familial, and behavioral factors, should be considered for all patients before bariatric surgery (Grade D).

• R43. Any patient considered for bariatric surgery with a known or suspected psychiatric illness should undergo a formal mental health evaluation before performance of the surgical procedure (Grade C; BEL 3).

• R44. All patients should undergo evaluation of their ability to incorporate nutritional and behavioral changes before and after bariatric surgery (Grade D).

8.4.8. Nutritional
• R45. All patients should undergo an appropriate nutritional evaluation, including selective micronutrient measurements (see Tables 13 and 17), before any bariatric surgical procedure (Grade C; BEL 3). In comparison with purely restrictive procedures, more extensive perioperative nutritional evaluations are required for malabsorptive procedures.

8.5. Early Postoperative Care (<5 Days)
8.5.1. Nutrition
• R46. A clear liquid-meal program can usually be initiated within 24 h after any of the bariatric procedures, but this schedule should be discussed with the surgeon (Grade C; BEL 3).

• R47. A consultation should be arranged with a registered dietitian who is a member of the bariatric surgery team (Grade D).

• R48. A protocol-derived staged meal progression, based on the type of surgical procedure, should be provided to the patient. Sample protocols are shown in Tables 9–11 (Grade D).

• R49. Nutrition and meal-planning guidance should be provided to the patient and family before bariatric surgery and during the postoperative hospital course and reinforced during future outpatient visits (Grade D).

• R50. Patients should adhere to a plan of multiple small meals each day, chewing their food thoroughly without...
Table 9  Suggested meal progression after Roux-en-Y gastric bypass

<table>
<thead>
<tr>
<th>Diet stage*</th>
<th>Begin</th>
<th>Fluids/food</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>Postop days 1 and 2</td>
<td>Clear liquids</td>
<td>On postop day 1, patients undergo a Gastrografin swallow test for leaks; once tested, begin sips of clear liquids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncarbonated; no calories</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No sugar; no caffeine</td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>Postop day 3 (discharge diet)</td>
<td>Clear liquids</td>
<td>Patients should consume a minimum of 48–64 fluid ounces of total fluids per day; ≥24–32 ounces of clear liquids plus 24–32 ounces of any combination of full liquids:</td>
</tr>
<tr>
<td>Begin supplementation:</td>
<td></td>
<td>• Variety of no-sugar liquids or artificially sweetened liquids</td>
<td></td>
</tr>
<tr>
<td>Chewable multivitamin with minerals, ×2/day</td>
<td></td>
<td>• Encourage patients to have salty fluids at home</td>
<td></td>
</tr>
<tr>
<td>Chewable or liquid</td>
<td></td>
<td>• Solid liquids: sugar-free ice pops</td>
<td></td>
</tr>
<tr>
<td>calcium citrate with vitamin D</td>
<td></td>
<td>Plus full liquids</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≤15 g of sugar per serving</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Protein-rich liquids (limit 20 g protein per serving of added powders)</td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>Postop days 10–14*</td>
<td>Increase clear liquids (total liquids 48–64+ ounces per day) and replace full liquids with soft, moist, diced, ground or pureed protein sources as tolerated</td>
<td>Protein food choices are encouraged for 4–6 small meals per day; patients may be able to tolerate only a couple of tablespoons at each meal or snack</td>
</tr>
<tr>
<td>Stage III, week 1</td>
<td>4 weeks postop</td>
<td>Eggs, ground meats, poultry, soft, moist fish, added gravy, bouillon, light mayonnaise to moisten, cooked bean, hearty bean soups, cottage cheese, low-fat cheese, yogurt</td>
<td>Chew foods thoroughly prior to swallowing (to consistency of applesauce)</td>
</tr>
<tr>
<td>Stage III, week 2</td>
<td>5 weeks postop</td>
<td>Advance diet as tolerated; if protein foods, add well-cooked, soft vegetables and soft and/or peeled fruit</td>
<td>Encourage patients not to drink with meals and to wait ~30 min after each meal before resuming fluids. Advise eating from small plates and using small utensils to help control portions</td>
</tr>
<tr>
<td>Stage III, week 3</td>
<td>6 weeks postop</td>
<td>Continue to consume protein with some fruit or vegetable at each meal; some people tolerate salads at 1 month postop</td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td>As hunger increases and more food is tolerated</td>
<td>Healthy solid food diet</td>
<td>Healthy, balanced diet consisting of adequate protein, fruits, vegetables, and whole grains. Advise eating from small plates and using small utensils to help control portions. Calorie needs based on height, weight, and age</td>
</tr>
</tbody>
</table>

Postop, postoperative.
*There is no standardization of diet stages; there is a wide variety of nutrition therapy protocols for how long patients stay on each stage and what types of fluids and foods are recommended.
*Nutritional laboratory studies should be monitored (see Table 13); bone density test at baseline and about every 2 years.
Reprinted with permission from Susan Cummings, MS, RD. MGH Weight Center, Boston, Massachusetts.
Table 10  Suggested meal progression after laparoscopic adjustable gastric band procedure

<table>
<thead>
<tr>
<th>Diet stage</th>
<th>Begin</th>
<th>Fluids/food</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stage I</strong></td>
<td>Postop days 1 and 2</td>
<td>Clear liquids; Noncarbonated; no calories</td>
<td>On postop day 1, patients may begin sips of water and Crystal Light; avoid carbonation</td>
</tr>
<tr>
<td><strong>Stage II</strong> Begin supplementation: Postop days 2–3</td>
<td>Clear liquids</td>
<td>Patients should consume a minimum of 48–64 ounces of total fluids per day: ≥24–32 ounces of clear liquids plus 24–32 ounces of any combination of full liquids:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(discharge diet)</td>
<td>• Variety of no-sugar liquids or artificially sweetened liquids</td>
<td>• 1% or skim milk mixed with whey or soy protein powder (limit 20 g protein per serving)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Plus full liquids</td>
<td>• Lactaid milk or soy milk mixed with soy protein powder</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≤15 g of sugar per serving</td>
<td>• Light yogurt, blended</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Protein-rich liquids (≤3 g fat per serving)</td>
<td>• Plain yogurt</td>
</tr>
<tr>
<td><strong>Stage III</strong></td>
<td>Postop days 10–14†</td>
<td>Increase clear liquids (total liquids ≥48–64 fluid ounces per day) and replace full liquids with soft, moist, diced, ground or pureed protein sources as tolerated</td>
<td>Note: Patients should be reassured that hunger is common and normal postop. Protein (moist, ground) food choices are encouraged for 3–6 small meals per day, to help with satiety, since hunger is common within ~1 week postop. Mindful, slow eating is essential. Encourage patients not to drink with meals and to wait ~30 min after each meal before resuming fluids. Advise eating from small plates and using small utensils to help control portions</td>
</tr>
<tr>
<td><strong>Stage III, week 2</strong></td>
<td>4 weeks postop</td>
<td>Advance diet as tolerated; if protein foods tolerated in week 1, add well-cooked, soft vegetables and soft and/or peeled fruit</td>
<td>Adequate hydration is essential and a priority for all patients during the rapid weight-loss phase. Consume protein at every meal and snack, especially if increased hunger noted before initial fill or adjustment. Very well-cooked vegetables may also help to increase satiety</td>
</tr>
<tr>
<td><strong>Stage III, week 3</strong></td>
<td>5 weeks postop</td>
<td>Continue to consume protein with some fruit or vegetable at each meal; some people tolerate salads at 1 month postop</td>
<td>If patient is tolerating soft, moist, ground, diced, and/or pureed proteins with small amounts of fruits and vegetables, may add crackers (use with protein)</td>
</tr>
<tr>
<td><strong>Stage IV</strong> Vitamin and mineral supplementation daily§</td>
<td>As hunger increases and more food is tolerated</td>
<td>Healthy solid food diet</td>
<td>Avoid rice, bread, and pasta</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Healthy, balanced diet consisting of adequate protein, fruits, vegetables, and whole grains. Advise eating from small plates and using small utensils to help control portions. Calorie needs based on height, weight, and age</td>
</tr>
<tr>
<td><strong>Fill/adjustment</strong></td>
<td>As hunger increases and more food is tolerated</td>
<td>Full liquids × 2–3 days postfill, then advance to Stage III, week 1 guidelines above, as tolerated for another 2–3 days, then advance to the final stage and continue</td>
<td>Same as Stage II liquids above × 48–72 h (and/or as otherwise advised by surgeon)</td>
</tr>
</tbody>
</table>

Note: When diet is advanced to soft solids, special attention should be paid to mindful eating and chewing until food is in liquid form, since more restriction may increase risk for obstruction above stoma of band if food is not thoroughly chewed (to consistency of applesauce)

Postop, postoperative.

†There is no standardization of diet stages; there is a wide variety of nutrition therapy protocols for how long patients stay on each stage and what types of fluids and foods are recommended.

§Nutritional laboratory studies should be monitored (see Table 13); bone density test at baseline and about every 2 years.

Reprinted with permission from Susan Cummings, MS, RD. MGH Weight Center, Boston, Massachusetts.
### Table 11  Suggested meal progression after biliopancreatic diversion (± duodenal switch)

<table>
<thead>
<tr>
<th>Diet stage*</th>
<th>Begin</th>
<th>Fluids/food</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>Postop days 1 and 2</td>
<td>Clear liquids&lt;sup&gt;a&lt;/sup&gt; Noncarbonated; no calories No sugar; no caffeine</td>
<td>Clear liquids started after swallow test</td>
</tr>
<tr>
<td>Stage II</td>
<td>Postop day 3</td>
<td>Clear liquids</td>
<td>Protein malnutrition is the most severe macronutrient complication after BPD/DS; regular monitoring and assessment of protein intake and status are very important</td>
</tr>
<tr>
<td>Begin supplementation:</td>
<td></td>
<td></td>
<td>Approximately 90 g of protein a day is recommended; since early postop this is difficult for most patients, set goal to consume ≥60 g of protein per day plus clear liquids, and increase as tolerated. Patients should consume a minimum of 64 ounces of total fluids per day; ≥24–32 ounces of clear liquids plus 4–5 eight-ounce servings a day of any combination of full liquids—1% or skim milk, Lactaid nonfat milk, or nonfat soy milk fortified with calcium mixed with:</td>
</tr>
<tr>
<td>Chewable multivitamin with minerals, ×2/day</td>
<td></td>
<td></td>
<td>• Whey or soy protein powder (20–25 g protein per serving of protein powder)</td>
</tr>
<tr>
<td>Vitamin B&lt;sub&gt;2&lt;/sub&gt;; at least 350–500 μg crystalline daily; might need vitamin B&lt;sub&gt;12&lt;/sub&gt; intramuscularly</td>
<td></td>
<td></td>
<td>• Light yogurt, blended</td>
</tr>
<tr>
<td>Fat-soluble vitamins: A, D, E, K</td>
<td></td>
<td></td>
<td>• Plain yogurt; Greek yogurt</td>
</tr>
<tr>
<td>• High risk for fat-soluble vitamin deficiencies</td>
<td></td>
<td></td>
<td>Protein food choices are encouraged for 3–6 small meals per day; patients may be able to tolerate only a couple of tablespoons at each meal or snack</td>
</tr>
<tr>
<td>• A: 5,000–10,000 IU/day</td>
<td></td>
<td></td>
<td>Encourage patients not to drink with meals and to wait ≥30 min after each meal before resuming fluids</td>
</tr>
<tr>
<td>• D: 600–500,000 IU/day</td>
<td></td>
<td></td>
<td>Patients might need to continue with supplementation of protein drinks to meet protein needs (90 g of protein daily is the goal)</td>
</tr>
<tr>
<td>• E: 400 IU/day</td>
<td></td>
<td></td>
<td>Patients should be counseled to focus on protein at every meal and snack and to avoid starches or concentrated carbohydrates; 10–12 ounces of lean meats, poultry, fish, or eggs or some combination of high biologic value protein and protein supplement powders. Adequate hydration is essential and a priority for all patients during the rapid weight-loss phase. Wait ≥30 min after meals before resuming liquids</td>
</tr>
<tr>
<td>• K: 1 mg/day</td>
<td></td>
<td></td>
<td>Avoid rice, bread, and pasta until patient is comfortably consuming 90 g of protein per day plus fruits and vegetables</td>
</tr>
</tbody>
</table>

**Postop, postoperative.**

*There is no standardization of diet stages; there is a wide variety of nutrition therapy protocols for how long patients stay on each stage and what types of fluids and foods are recommended.

<sup>a</sup>Clear and full liquids for biliopancreatic diversion with duodenal switch (BPD/DS) are the same as for Roux-en-Y gastric bypass (see Table 9). Reprinted with permission from Susan Cummings, MS, RD. MGH Weight Center, Boston, Massachusetts.
8.5.2. Diabetes

- **R51.** Patients should be advised to adhere to a balanced meal plan that consists of more than five servings of fruits and vegetables daily for optimal fiber consumption, colonic function, and phytochemical consumption (Grade D).

- **R52.** Protein intake should average 60–120 g daily (Grade D).

- **R53.** Concentrated sweets should be avoided after RYGB to minimize symptoms of the dumping syndrome or after any bariatric procedure to reduce caloric intake (Grade D).

- **R54.** Minimal nutritional supplementation includes one to two adult multivitamin–mineral supplements containing iron, 1,200–1,500 mg/day of calcium, and a vitamin B-complex preparation (Grade B; BEL 2 (nonrandomized)).

- **R55.** Fluids should be consumed slowly and in sufficient amounts to maintain adequate hydration (>1.5 l daily) (Grade D).

- **R56.** Parenteral nutrition (PN) should be considered in high-risk patients, such as critically ill patients unable to tolerate sufficient enteral nutrition for >5–7 days or non-critically ill patients unable to tolerate sufficient enteral nutrition for >7–10 days (Grade D).

8.5.3. Cardiology

- **R62.** Patients with known or presumed CAD and high perioperative risk should be managed in an ICU setting for the first 24–48 h postoperatively (Grade D).

- **R63.** Therapy with β-adrenergic blocking agents should be considered perioperatively for cardioprotection (Grade D).

8.5.4. Pulmonary

- **R64.** Appropriate pulmonary management includes aggressive pulmonary toilet and incentive spirometry, oxygen supplementation to avoid hypoxemia, and early institution of continuous positive airway pressure (CPAP) when clinically indicated (Grade D).

- **R65.** Prophylaxis against DVT is recommended for all patients (Grade B; BEL 2 (randomized)) and may be continued until patients are ambulatory (Grade D). Early ambulation is encouraged (Grade C; BEL 3).

- **R66.** Currently recommended prophylactic regimens include sequential compression devices (Grade C; BEL 3), as well as subcutaneously administered unfractionated heparin or low-molecular-weight heparin for 3 days before and after bariatric surgery (Grade B; BEL 2 (randomized)), and inferior vena cava filter placement in patients at high risk for mortality after PE or DVT (Grade C; BEL 3), with known pulmonary artery pressure exceeding 40 mm Hg (Grade D), or with known hypercoagulable states (Grade C; BEL 3).

- **R67.** Respiratory distress or failure to wean from ventilatory support should raise suspicion and prompt an evaluation for an acute postoperative complication, such as PE or anastomotic leak (Grade D).

8.5.5. Monitoring for Surgical Complications

- **R68.** In the clinically stable patient, meglumine diatrizoate (Gastrografin) upper gastrointestinal (UGI) studies or computed tomography (CT) may identify anastomotic leaks (Grade C; BEL 3).

- **R69.** Exploratory laparotomy is recommended in the setting of high clinical suspicion for anastomotic leaks despite a negative study (Grade C; BEL 3).

- **R70.** The presence of a new sustained pulse rate of >120 beats/min for longer than 4 h should raise suspicion for an anastomotic leak (Grade D).

- **R71.** A routine Gastrografin UGI study may be considered to identify any subclinical leaks before discharge of the patient from the hospital (Grade C; BEL 3).

8.5.6. Fluid Management

- **R72.** The goals of fluid management during the early postoperative period after bariatric surgery are maintaining a urine volume of 1–1.5 l daily (Grade A; BEL 1).

- **R73.** Concentrated sweets should be avoided after RYGB.

- **R74.** Use of all insulin secretagogue drugs (sulfonylureas and meglitinides) should be discontinued (Grade D).

- **R75.** In patients with T2DM, periodic fasting blood glucose concentrations should be determined. Preprandial and bedtime reflectance meter glucose (“finger-stick”) determinations in the home setting should be encouraged, depending on the patient’s ability to test and the level of glycemic control. Finger-stick glucose determinations should also be performed if symptoms of hypoglycemia occur (Grade A; BEL 1).

- **R76.** Use of all insulin secretagogue drugs (sulfonylureas and meglitinides) should be discontinued (Grade D).

- **R77.** In nonintensive care unit (ICU) hospitalized patients, a rapid-acting insulin analogue should be administered before meals and at bedtime to maintain maximal postprandial values <180 mg/dl (Grade D).

- **R78.** In non-ICU hospitalized patients, fasting blood glucose levels should be maintained between 80 and 110 mg/dl with the use of a long-acting insulin analogue, such as insulin glargine (Lantus) or detemir (Levemir) (Grade D).

- **R79.** In the ICU, all blood glucose levels should be maintained ideally within the range of 80–110 mg/dl by using an intravenous insulin infusion (Grade A; BEL 1).
output of >40 ml/h, avoiding volume overload, maintaining normal serum electrolyte levels, and limiting dextrose-containing solutions to avoid hyperglycemia (Grade D).

- **R73.** Postoperative urine output must be monitored, with a target of >30 ml/h or 240 ml per 8-h shift (Grade D).

### 8.6. Late Postoperative Management (≥5 Days)

#### 8.6.1. Follow-up

- **R74.** Patients should have adequate padding at all pressure points during bariatric surgery (Grade D).

- **R75.** When rhabdomyolysis is suspected, creatine kinase (CK) levels should be determined (Grade C; BEL 3).

#### 8.6.2. Weight Loss

- **R76.** The indications for transfusions of blood products after bariatric surgery are the same as for other surgical procedures (Grade D).

- **R77.** Persistence of anemia without evidence of blood loss should be evaluated in terms of nutritional deficiencies during the late postoperative period (Grade D).

#### 8.6.3. Metabolic and Nutritional Management

- **R80.** The assessment of inadequate weight loss after bariatric surgery should include imaging studies to determine the integrity of the gastric pouch, ascertaining of the patient's understanding of the meal plan and compliance, and psychologic evaluation (Grade D).

- **R81.** Inadequate weight loss after a bariatric procedure without resolution or a recurrence of a major comorbidity may necessitate a surgical revision, such as conversion of an LAGB to either an RYGB or a BPD/DS (Grade D).

### Table 12 Consensus for follow-up nutrition and metabolic consultations after bariatric surgery, stratified by type of procedure performed and presence of comorbidities (Grade D)*

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Nutritional or metabolic comorbidities</th>
<th>First 6 months</th>
<th>Second 6 months</th>
<th>Next year</th>
<th>Thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>VBG</td>
<td>No</td>
<td>q 3–6 mo</td>
<td>Once</td>
<td>Annually</td>
<td>Annually</td>
</tr>
<tr>
<td>LAGB</td>
<td>Yes</td>
<td>q 1–2 mo</td>
<td>Twice</td>
<td>q 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>q month prn</td>
<td>Once</td>
<td>Annually</td>
<td>Annually</td>
</tr>
<tr>
<td>RYGB</td>
<td>Yes</td>
<td>q 2–3 mo</td>
<td>Twice</td>
<td>q 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td>BPD/DS</td>
<td>No</td>
<td>q 2–3 mo</td>
<td>Once</td>
<td>q 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>q 1–2 mo</td>
<td>q 3–6 mo</td>
<td>q 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>q 1–2 mo</td>
<td>q 6–12 mo</td>
<td>q 6–12 mo</td>
<td>q 6–12 mo</td>
</tr>
</tbody>
</table>

*R73. These consultations are to be performed by a physician with expertise in nutritional and metabolic medicine.

*BPD/DS, biliopancreatic diversion with duodenal switch; LAGB, laparoscopic adjustable gastric band; mo, months; prn, as the circumstances require; q, every; RYGB, Roux-en-Y gastric bypass; VBG, vertical banded gastropasty.

**The first follow-up visit is within the first postoperative month. Subsequent visit frequency depends on the severity of any complications and behavioral issues. After years 1–3, intestinal adaptation occurs, and metabolic derangements and weight loss should stabilize.
- R87. All patients should be encouraged to participate in ongoing support groups after discharge from the hospital (Grade D).

8.6.3.1. Association of malabsorptive surgical procedures with nutritional deficiencies
- R88. The frequency and recommended nutritional surveillance in patients who have had a malabsorptive bariatric procedure are outlined in Table 13 (Grade C; BEL 3).

- R89. The recommended empiric vitamin and mineral supplementation after malabsorptive bariatric surgery is outlined in Table 14 (Grade B; BEL 2 (randomized and nonrandomized)).

8.6.3.2. Protein depletion and supplementation
- R90. Protein intake should be quantified periodically (Grade D).
- R91. Ideally, protein intake with meals, including protein supplementation, should be in the range of 80–120 g/day for patients with a BPD or BPD/DS and ≥60 g/day for those with RYGB (Grade D).

Table 13 Recommended biochemical surveillance of nutritional status after malabsorptive bariatric surgical procedures

<table>
<thead>
<tr>
<th>Surveillance factor</th>
<th>Roux-en-Y gastric bypass</th>
<th>Biliopancreatic diversion (± duodenal switch)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time interval</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st year</td>
<td>Every 3–6 mo</td>
<td>Every 3 mo</td>
</tr>
<tr>
<td>Thereafter</td>
<td>Annually</td>
<td>Every 3–6 mo depending on symptoms</td>
</tr>
<tr>
<td>Laboratory tests</td>
<td>CBC, platelets</td>
<td>CBC, platelets</td>
</tr>
<tr>
<td></td>
<td>Electrolytes</td>
<td>Electrolytes</td>
</tr>
<tr>
<td></td>
<td>Glucose</td>
<td>Glucose</td>
</tr>
<tr>
<td></td>
<td>Iron studies, ferritin</td>
<td>Iron studies, ferritin</td>
</tr>
<tr>
<td></td>
<td>Vitamin B₁₂ (MMA, HCy optional)</td>
<td>Vitamin B₁₂ (MMA, HCy optional)</td>
</tr>
<tr>
<td></td>
<td>Liver function (GGT optional)</td>
<td>Liver function (GGT optional)</td>
</tr>
<tr>
<td></td>
<td>Lipid profile</td>
<td>Lipid profile</td>
</tr>
<tr>
<td></td>
<td>25-Hydroxyvitamin D</td>
<td>Albumin and prealbumin</td>
</tr>
<tr>
<td>Optional:</td>
<td></td>
<td>RBC folate</td>
</tr>
<tr>
<td></td>
<td>Intact PTH</td>
<td>Fat-soluble vitamins (6–12 mo)</td>
</tr>
<tr>
<td></td>
<td>Thiamine</td>
<td>Vitamin A</td>
</tr>
<tr>
<td></td>
<td>RBC folate</td>
<td>25-Hydroxyvitamin D</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitamin E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitamin K₅ and INR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metabolic bone evaluation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6–12 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urine N-telopeptide (annually)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Osteocalcin (as needed)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metabolic stone evaluation (annually)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥24-h urine calcium, citrate, uric acid, and oxalate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trace elements (annually or as needed)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zinc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Selenium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Miscellaneous (as needed)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carnitine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Essential fatty acid chromatography</td>
</tr>
</tbody>
</table>

CBC, complete blood cell count; GGT, γ-glutamyltransferase; HCy, homocysteine; INR, international normalized ratio; MMA, methylmalonic acid; mo, months; PTH, parathyroid hormone; RBC, red blood cell. See refs. 544, 775–777.

*Dual-energy X-ray absorptiometry should be performed annually to monitor bone density (Grade D).
• **R92.** In patients with severe protein malnutrition not responsive to oral protein supplementation, PN should be considered (Grade D).

**8.6.3.3. Skeletal and mineral homeostasis, including nephrolithiasis**

• **R93.** Recommended laboratory tests for the evaluation of calcium and vitamin D metabolism and metabolic bone disease in patients who have undergone RYGB, BPD, or BPD/DS are outlined in Table 15 (Grade D).

• **R94.** In patients who have undergone RYGB, BPD, or BPD/DS, treatment with orally administered calcium, ergocalciferol (vitamin D₂), or cholecalciferol (vitamin D₃) is indicated to prevent or minimize secondary hyperparathyroidism without inducing frank hypercalcemia (Grade C; BEL 3).

• **R95.** In cases of severe vitamin D malabsorption, oral doses of vitamin D₂ or D₃ may need to be as high as 50,000–150,000 U daily, and more recalcitrant cases may require concurrent oral administration of calcitriol (1,25-dihydroxyvitamin D (1,25-(OH)₂D₃)) (Grade D).

• **R96.** In patients with RYGB, BPD, or BPD/DS, bone density measurements with use of dual-energy X-ray absorptiometry may be indicated to monitor for the development or presence of osteoporosis at baseline, in addition to a follow-up study at ~2 years, in accordance with the recommendations from the International Society for Clinical Densitometry (http://www.iscd.org/Visitors/positions/OfficialPositionsText.cfm?fromhome=1) and the National Osteoporosis Foundation (http://www.nof.org/osteoporosis/bonemass.htm) (Grade D).

• **R97.** Bisphosphonates approved by the US Food and Drug Administration may be a consideration in bariatric surgery patients with osteoporosis (T score ~2.5 or below for the hip or spine) only after adequate and appropriate evaluation and therapy for calcium and vitamin D insufficiency. This evaluation should include and confirm a normal parathyroid hormone (PTH) level, 25-hydroxyvitamin D (25-OHD) level of 30–60 ng/ml, normal serum calcium level, normal phosphorus level, and 24-h urine calcium excretion between ~70 and 250 mg/24 h. Therapy considerations should be based on the National

---

**Table 14 Routine nutrient supplementation after bariatric surgery**

<table>
<thead>
<tr>
<th>Supplement</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multivitamin</td>
<td>1–2 daily</td>
</tr>
<tr>
<td>Calcium citrate with vitamin D₂</td>
<td>1,200–2,000 mg/day + 400–800 U/day</td>
</tr>
<tr>
<td>Folic acid</td>
<td>400 µg/day in multivitamin</td>
</tr>
<tr>
<td>Elemental iron with vitamin D₃</td>
<td>40–65 mg/day</td>
</tr>
<tr>
<td>Vitamin B₁₂</td>
<td>≥350 µg/day orally</td>
</tr>
<tr>
<td></td>
<td>or 1,000 µg/mo intramuscularly</td>
</tr>
<tr>
<td></td>
<td>or 3,000 µg/mo every 6 mo intramuscularly</td>
</tr>
<tr>
<td></td>
<td>or 500 µg every week intranasally</td>
</tr>
</tbody>
</table>

mo, month.

*Patients with preoperative or postoperative biochemical deficiency states are treated beyond these recommendations.

*For menstruating women.

---

**Table 15 Diagnostic testing and management for skeletal and mineral disorders in patients who have undergone Roux-en-Y gastric bypass, biliopancreatic diversion, or biliopancreatic diversion with duodenal switch**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Diagnostic testing</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic bone disease</td>
<td>Serum calcium, phosphorus, magnesium, 25-Hydroxyvitamin D, Bone-specific alkaline phosphatase (or osteocalcin), Intact parathyroid hormone, Spot urine or serum N-telopeptide, 24-h Urine calcium excretion, 1,25-Dihydroxyvitamin D (if renal compromise) Vitamin A and K, levels Albumin and prealbumin Dual-energy X-ray absorptiometry (at 3 sites) at baseline and 2-year follow-up per ISCD and NOF recommendations</td>
<td>Calcium citrate or gluconate, Vitamin D₃ or D₂, orally, Calcitriol orally, Vitamin D intramuscularly (if available), Alendronate, ibandronate, or risedronate orally, Ibandronate, pamidronate, or zoledronate intravenously, Calcitonin intranasally, Human recombinant parathyroid hormone where appropriate</td>
</tr>
<tr>
<td>Nephrolithiasis</td>
<td>Urinalysis, 24-h Urine specimen for calcium, oxalate, citrate, Renal ultrasonography</td>
<td>Low oxalate diet, Calcium orally, Cholestyramine, Potassium citrate, Lithotripsy, Urologic surgery</td>
</tr>
</tbody>
</table>
Osteoporosis Foundation–World Health Organization 2008 Guidelines (http://www.nof.org/professionals/NOF_Clinicians%20_Guide.pdf). If therapy is indicated, then intravenously administered bisphosphonates should be used if concerns exist about adequate oral absorption and potential anastomotic ulceration with use of orally administered bisphosphonates (Grade C; BEL 3).

- **R98.** Recommended dosages of orally administered bisphosphonates in bariatric surgery patients with osteoporosis include the following: alendronate, 70 mg/week; risedronate, 35 mg/week or two 75-mg tablets/month; or ibandronate, 150 mg/month. Recommended intravenous dosages of bisphosphonates are as follows: zoledronic acid, 5 mg once a year, or ibandronate, 3 mg every 3 months (Grade D).

- **R99.** There are insufficient data to recommend empiric supplementation of magnesium after bariatric surgery beyond what is included in a mineral-containing multivitamin that provides the daily recommended intake of magnesium (>300 mg in women; >400 mg in men) (Grade D).

- **R100.** Oral phosphate supplementation may be provided for mild to moderate hypophosphatemia (1.5–2.5 mg/week), which is usually due to vitamin D deficiency (Grade D).

- **R101.** Management of oxalosis and calcium oxalate stones includes avoidance of dehydration, a low oxalate meal plan, and oral calcium and potassium citrate therapy (Grade D).

- **R102.** Probiotics containing *Oxalobacter formigenes* have been shown to improve renal oxalate excretion and improve supersaturation levels and may therefore be used as well (Grade C; BEL 3).

### 8.6.3.4. Fat and fat-soluble vitamin malabsorption

- **R103.** The routine use of serum fatty acid (FA) chromatography to detect essential FA (EFA) deficiency is not cost-effective and should not be performed because this deficiency has not been reported (Grade D).

- **R104.** Routine supplementation of vitamin A is usually not necessary after RYGB or purely restrictive procedures (Grade C; BEL 3).

- **R105.** In contrast, routine screening for vitamin A deficiency is recommended, and supplementation is often needed after malabsorptive bariatric procedures, such as BPD or BPD/DS (Grade C; BEL 3).

- **R106.** Supplementation may be provided with use of vitamin A alone or in combination with the other fat-soluble vitamins (D, E, and K) (Grade C; BEL 3).

- **R107.** The value of routine screening for vitamin E or K deficiencies has not been documented for any bariatric procedure, including BPD and BPD/DS (Grade C; BEL 3).

- **R108.** In the presence of an established fat-soluble vitamin deficiency with hepatopathy, coagulopathy, or osteoporosis, assessment of a vitamin K level should be considered in an effort to detect a deficiency state (Grade D).

### 8.6.3.5. Iron, vitamin B<sub>12</sub>, folic acid, and selenium deficiencies; the nutritional anemias

- **R109.** Iron status should be monitored in all bariatric surgery patients and then appropriately treated as in any medical or surgical patient (Grade D).

- **R110.** Orally administered ferrous sulfate, fumarate, or gluconate (320 mg twice a day) may be needed to prevent iron deficiency in patients who have undergone a malabsorptive bariatric surgical procedure, especially in menstruating women (Grade A; BEL 1).

- **R111.** Vitamin C supplementation should be considered in patients with recalcitrant iron deficiency because vitamin C can increase iron absorption and ferritin levels (Grade C; BEL 3).

- **R112.** Intravenous iron infusion with iron dextran (INFeD), ferric gluconate (Ferrlecit), or ferric sucrose may be needed if oral iron supplementation is ineffective at correcting the iron deficiency (Grade D).

- **R113.** Evaluation for vitamin B<sub>12</sub> deficiency is recommended in all bariatric surgery patients (Grade B; BEL 2 (nonrandomized)).

- **R114.** Oral supplementation with crystalline vitamin B<sub>12</sub> at a dosage of ≥350 µg daily or intranasally administered vitamin B<sub>12</sub>, 500 µg weekly, may be used to maintain vitamin B<sub>12</sub> levels (Grade B; BEL 2 (nonrandomized)).

- **R115.** Parenteral supplementation with either 1,000 µg of vitamin B<sub>12</sub> monthly or 1,000–3,000 µg every 6–12 months is necessary if vitamin B<sub>12</sub> sufficiency cannot be maintained by means of oral supplementation (Grade C; BEL 3).

- **R116.** Assessment of vitamin B<sub>12</sub> status should be done annually in patients who have undergone RYGB or BPD/DS (Grade D).

- **R117.** Folic acid supplementation (400 µg/day) is provided as part of a routine multivitamin preparation (Grade B; BEL 2 (randomized and nonrandomized)).

- **R118.** Folic acid supplementation should be provided in all women of childbearing age because of the risk of fetal neural tube defects with folic acid deficiency (Grade A; BEL 1).
• R119. Nutritional anemias resulting from malabsorptive bariatric surgical procedures might also involve deficiencies in protein, copper, and selenium, necessitating evaluation of these nutrients when routine screening for iron, vitamin B_{12}, and folic acid deficiencies is negative (Grade C; BEL 3).

• R120. There are insufficient data to support routine screening for selenium deficiency or empiric selenium supplementation in patients after a bariatric surgical procedure (Grade D).

• R121. In patients treated with BPD or BPD/DS who have unexplained anemia or fatigue, persistent diarrhea, cardiomyopathy, or metabolic bone disease, selenium levels should be checked (Grade C; BEL 3).

8.6.3.6. Zinc and thiamine

• R122. Because zinc deficiency has been described, physicians should routinely screen for it after BPD or BPD/DS, while bearing in mind that plasma zinc levels are unreliable in the presence of systemic inflammation (Grade C; BEL 3).

• R123. There is inadequate clinical evidence to recommend empiric zinc supplementation after bariatric surgery (Grade D).

• R124. All bariatric surgery patients should be provided with an oral multivitamin supplement that contains thiamine (Grade D).

• R125. Routine screening for thiamine deficiency or additional empiric thiamine treatment (or both) is not recommended in bariatric surgery patients who are already routinely receiving a multivitamin supplement that contains thiamine (Grade C; BEL 3).

• R126. Patients with protracted vomiting should be screened for thiamine deficiency (Grade C; BEL 3).

• R127. In patients with persistent vomiting after any bariatric procedure, aggressive supplementation with thiamine is imperative; intravenously administered glucose should be provided judiciously in this situation because it can aggravate thiamine deficiency (Grade C; BEL 3).

• R128. In patients presenting with neurologic symptoms suggestive of thiamine deficiency (that is, Wernicke encephalopathy and peripheral neuropathy), aggressive parenteral supplementation with thiamine (100 mg/day) should be administered for 7–14 days (Grade C; BEL 3).

• R129. Subsequent oral thiamine supplementation (100 mg/day) should be continued until neurologic symptoms resolve (Grade C; BEL 3).

8.6.4. Cardiology and Hypertension

• R130. Lipid levels and need for lipid-lowering medications should be periodically monitored and evaluated (Grade D).

• R131. Use of antihypertensive medications should be evaluated repeatedly and reduced or discontinued as indicated with the resolution of hypertension (Grade D).

8.6.5. Gastrointestinal Complications

8.6.5.1. Diarrhea

• R132. If diarrhea persists, an evaluation should be initiated (Grade C; BEL 3).

• R133. Upper endoscopy with small bowel biopsies and aspirates remains the “gold standard” in the evaluation of celiac sprue (Grade C; BEL 3) and bacterial overgrowth (Grade C; BEL 3).

• R134. Colonoscopy should be performed and a stool specimen should be obtained if the presence of *Clostridium difficile* colitis is suspected (Grade C; BEL 3).

• R135. Persistent steatorrhea after BPD or BPD/DS should prompt an evaluation for nutrient deficiencies (Grade C; BEL 3).

8.6.5.2. Stomal stenosis or ulceration after bariatric surgery

• R136. Nonsteroidal anti-inflammatory drugs should be avoided after bariatric surgery because they have been implicated in the development of anastomotic ulcerations (Grade C; BEL 3).

• R137. Alternative pain medication should be identified before bariatric surgery (Grade D).

• R138. Persistent and severe gastrointestinal symptoms (such as nausea, vomiting, and abdominal pain) warrant additional evaluation (Grade C; BEL 3).

• R139. Upper intestinal endoscopy is the preferred diagnostic procedure because, in many circumstances, upper endoscopy can also incorporate a therapeutic intervention with transendoscopic dilation of a recognized stricture (Grade C; BEL 3).

• R140. Evaluation should include *H. pylori* testing as a possible contributor to persistent gastrointestinal symptoms after bariatric surgery (Grade C; BEL 3).

• R141. Anastomotic ulcers should be treated with H₂ receptor blockers, proton pump inhibitors, sucralfate, antibiotics, and, if *H. pylori* is identified, multiple antibiotics and bismuth (Grade C; BEL 3).

• R142. Patients who previously underwent an RYGB with a nonpartitioned stomach and develop a gastrogastric fistula
should undergo revisional RYGB to separate the upper and lower gastric pouches (Grade D).

- **R143.** Persistent vomiting, regurgitation, and UGI obstruction after LAGB should be treated with immediate removal of all fluid from the adjustable band (Grade D).

- **R144.** Persistent symptoms of gastroesophageal reflux, regurgitation, chronic cough, or recurrent aspiration pneumonia after LAGB are all problems suggestive of the band being too tight or the development of an abnormally large gastric pouch above the band. These symptoms should prompt immediate referral back to the surgeon (Grade D).

- **8.6.5.3. Gallbladder disease**
  - **R145.** Oral administration of ursodiol (300 mg twice a day) for 6 months postoperatively may be considered in patients not undergoing a prophylactic cholecystectomy (Grade A; BEL 1).
  
  - **R146.** There is a debate regarding performance of cholecystectomy for known gallstones at the time of RYGB, BPD, or BPD/DS procedures. There is no consensus regarding the need to perform cholecystectomy at the time of bariatric operations (Grade C; BEL 3).

- **8.6.5.4. Bacterial overgrowth**
  - **R147.** Although uncommon, suspected bacterial overgrowth in the biliopancreatic limb after BPD or BPD/DS should be treated empirically with metronidazole (Grade C; BEL 3).

  - **R148.** For antibiotic-resistant cases of bacterial overgrowth, probiotic therapy with *Lactobacillus plantarum* 299v and *Lactobacillus GG* may be considered (Grade D).

- **8.6.6. Incisional Hernias**
  - **R149.** Repair of asymptomatic hernias should be deferred until weight loss has stabilized and nutritional status has improved, to allow for adequate healing (12–18 months after bariatric surgery) (Grade D).

  - **R150.** Incarcerated incisional or umbilical hernias in conjunction with abdominal pain necessitates aggressive surgical correction because of the risk of bowel infarction (Grade C; BEL 3).

- **8.6.7. Bowel Obstruction From Adhesions or Internal Hernias**
  - **R151.** Patients with cramping periumbilical pain at any time after RYGB, BPD, or BPD/DS should be emergently evaluated with an abdominal and pelvic CT scan to exclude the potentially life-threatening complication of closed-loop bowel obstruction (Grade D).

  - **R152.** Exploratory laparotomy or laparoscopy is indicated in patients who are suspected of having an internal hernia because this complication can be missed with UGI studies and CT scans (Grade C; BEL 3).

**8.6.8. Body-Contouring Surgery**

- **R153.** Body-contouring surgery may be performed after bariatric surgery to manage excess tissue that impairs hygiene, causes discomfort, and is disfiguring (Grade C; BEL 3).

- **R154.** Circumferential torsoplasty or abdominoplasty may be used to remove excess abdominal skin (Grade D).

- **R155.** Breast reduction or lift, arm lift, resection of redundant gluteal skin, and thigh lift can also be pursued (Grade D).

- **R156.** Such procedures are best pursued after weight loss has stabilized (12–18 months after bariatric surgery) (Grade D).

- **R157.** Tobacco use must be avoided and nutritional status maintained in bariatric surgery patients undergoing postoperative body-contouring procedures (Grade A; BEL 1).

**8.7. Criteria for Hospital Admission After Bariatric Surgery**

- **R158.** Severe malnutrition should prompt hospital admission for initiation of nutritional support (Grade D).

- **R159.** The initiation of enteral or PN should be guided by established published criteria (Grade D).

- **R160.** Hospital admission is required for the management of gastrointestinal complications after bariatric surgery in clinically unstable patients (Grade D).

- **R161.** Surgical management should be pursued for gastrointestinal complications not amenable or responsive to medical therapy (Grade D).

- **R162.** If not dehydrated, most patients can undergo endoscopic stomal dilation for stricture as an outpatient procedure (Grade D).

- **R163.** Revision of a bariatric surgical procedure is recommended in the following circumstances: (i) presence of medical complications clearly resulting from the surgical procedure and not amenable or responsive to medical therapy (for example, malnutrition) and (ii) inadequate weight loss or weight regain in patients with persistent weight-related comorbidities who previously underwent a restrictive procedure (for example, VBG) (Grade C; BEL 3).

- **R164.** Reversal of a bariatric surgical procedure is recommended when serious complications related to previous bariatric surgery cannot be managed medically and are not amenable to surgical revision (Grade D).
9. Appendix: discussion of the clinical evidence

9.1. Effectiveness of Bariatric Surgery for Obesity Comorbidities

The comorbidities of severe obesity affect all the major organ systems of the body. Surgically induced weight loss will substantially improve or reverse the vast majority of these adverse effects from severe obesity.

9.1.1. Type 2 Diabetes

Unlike most obesity-related morbidities, improvements in hyperglycemia are observed almost immediately after RYGB and BPD/DS, in part because of increased release of GLP-1 (115 (EL 4), 116 (EL 4), 161 (EL 3)) or possibly as a result of the release of an unknown insulin sensitizer. Fasting plasma glucose concentrations have been reported to return to normal before hospital dismissal and before substantial weight loss (103 (EL 3), 122 (EL 3), 123 (EL 3), 130–135 (EL 3), 137 (EL 3), 146 (EL 2), 147 (EL 3), 162 (EL 3), 163 (EL 3)). Insulin-treated patients have a notable decrease in insulin requirement, with the majority of patients able to discontinue insulin therapy by 6 weeks after bariatric surgery (136 (EL 3), 162 (EL 3)) and even possibly able to discontinue insulin treatment before hospital discharge after RYGB and BPD/DS. The longer T2DM has been present, the less likely it is to respond to surgically induced weight loss (103 (EL 3), 122 (EL 3), 130 (EL 3), 137 (EL 3)). LAGB is also associated with remission of T2DM; however, the effects take longer to achieve than with RYGB, BPD, or BPD/DS and are totally dependent on weight loss (63 (EL 2), 141 (EL 2)).

One explanation for the salutary effects of RYGB and intestinal bypass on glucose metabolism focuses on the enteroinsular axis and the main incretins: glucose-dependent insulino tropic polypeptide and GLP-1. Exclusion of ingested carbohydrate from the duodenal and proximal jejunal mucosa modifies the secretion of glucose-dependent insulino tropic polypeptide. Reintroduction of ingested carbohydrate into the distal ileum and colon increases the secretion of GLP-1 (138 (EL 3), 164 (EL 4)). Bypass of the duodenum without gastric bypass and ileal interposition have both been found to improve diabetes in animal models as well as in patients (161 (EL 3), 162 (EL 3), 165 (EL 3)). Furthermore, LAGB (166 (EL 2)) and RYGB (123 (EL 3), 167 (EL 3)) result in decreased leptin, whereas VBG (168 (EL 3)) and RYGB (169 (EL 3), 170 (EL 2)) eventuate in increased adiponectin in association with weight loss and improved insulin sensitivity.

In a literature review, Rubino and Gagner (171 (EL 4)) found that RYGB and BPD achieved durable primary beneficial effects on glycemic control in 80–100% of patients with T2DM, independent of effects on body weight. These conclusions were supported by studies in rats in which gastrojejunostomy bypass controlled T2DM independent of weight loss (172 (EL 4)). In a subsequent study of 10 obese patients undergoing RYGB, a potential mechanism was elucidated (162 (EL 3)). Bypass of the proximal small bowel was associated with a statistically significant decrease in GLP-1 and hyperinsulinemia. Moreover, early presentation of undigested food to the distal small bowel was associated with a trend toward greater levels of GLP-1 and restoration of normal glucose-stimulated insulin secretion (162 (EL 3)). These and other intestinal factors may also restore meal-induced suppression of ghrelin release from the stomach, resulting in decreased food intake (173 (EL 4)).

9.1.2. Pulmonary

9.1.2.1. Sleep apnea

Weight reduction after LAGB, RYG, BPD, or BPD/DS bariatric procedures has been shown to improve sleep apnea (99 (EL 1), 106 (EL 3), 107 (EL 3), 174–181 (EL 2–4)). Charuzi et al. (106 (EL 3)) reported that diminished symptoms seem to be dictated by percentage loss of EBW. Sleep apnea symptoms are likely to persist in patients who have a substantial amount of EBW despite weight loss or to recur in those who experience weight regain (106 (EL 3)). In multiple studies, sleep apnea has been shown either to resolve completely (for patients with a respiratory disturbance index (RDI) <40) or to improve appreciably for those with an RDI ≥40 (107 (EL 3)); thus, the patient can discontinue the use of nasal CPAP or allow a tracheostomy to close.

9.1.2.2. OHS

A major comorbidity of severe obesity is OHS, in conjunction with chronic hypoxemia and hypercarbia when the patient is awake. When seen in conjunction with sleep apnea, it is often called the pickwickian syndrome. In patients with central obesity, OHS arises primarily from the increased intra-abdominal pressure, which leads to a high-riding diaphragm (109–111 (EL 2), 114 (EL 2), 176 (EL 3)). As a result, the lungs are squeezed, and a restrictive pulmonary defect is produced. A heavy, obese thoracic cage may also contribute to the pathophysiologic condition, attributable to decreased chest wall compliance. These patients have a considerably decreased expiratory reserve volume, leading to alveolar collapse and arteriovenous shunting at end-expiration (176 (EL 3)). They also have smaller reductions in all other lung volumes. Chronic hypoxemia leads to pulmonary artery vasoconstriction and hypertension. Frequently, however, patients with OHS have not only notably elevated pulmonary artery pressures but also increased pulmonary capillary wedge pressures, suggesting both right and left ventricular failure, probably as a result of increased intra-abdominal and intrathoracic pressures (176 (EL 3)). Surgically induced weight loss is associated with resolution of OHS, increasing oxygenation and normalizing.
hypercarbia, lung volumes, and cardiac filling pressures (109–111 (EL 2), 176 (EL 3)).

9.1.2.3. Asthma
Two studies have documented improvement in asthma after surgically induced weight loss (43 (EL 3), 182 (EL 3)). This outcome may be due to the resolution of GERD and acid-induced bronchospasm.

9.1.3. Dyslipidemia, Hypertension, and Cardiac Function

9.1.3.1. Dyslipidemia
Several studies have shown a substantial improvement in lipid abnormalities and risk for CAD, which persists for at least 5–10 years after bariatric surgery. In several reports, triglyceride and low-density lipoprotein (LDL) cholesterol levels decreased and the HDL cholesterol value increased after LAGB, RYGB, BPD, or BPD/DS surgery (64 (EL 3), 105 (EL 3), 183–195 (EL 1–3)). Nevertheless, conventional lipid measurements of total and LDL cholesterol levels may not be reflective of dyslipidemic risks or insulin resistance in obese people, as suggested by a cross-sectional study of 572 obese patients (196 (EL 2)). The improvement in dyslipidemia appears to be related not only to the percentage loss of EBW (192 (EL 3)) but also to the decrease in insulin resistance (183 (EL 3)). These changes should lead to a pronounced decrease in risk for CAD, stroke, and peripheral vascular disease. Recent studies have shown decreased cardiovascular and MI-related mortality in bariatric surgery patients (65 (EL 3), 154 (EL 2)).

9.1.3.2. Hypertension
LAGB, RYGB, BPD, or BPD/DS surgery is associated with clinically important and long-lasting improvement in systemic hypertension, with elimination of blood pressure medications or a distinct decrease in their use in two-thirds to three-quarters of the patients with hypertension (44 (EL 3), 104 (EL 3), 139 (EL 3), 142 (EL 2), 189 (EL 1), 197–199 (EL 3)). In the SOS Study, recovery from hypertension was notable at 2 years after bariatric surgery (189 (EL 1)); however, the difference between the surgical and nonsurgical groups was no longer present at 8 years postoperatively (200 (EL 2)). Nonetheless, at 8 years in the 6% of patients who underwent RYGB and had lost significantly more weight than the patients who had purely restrictive procedures (VBG and gastric banding), there was a significant decrease in both systolic and diastolic blood pressure (121 (EL 2)). Although no difference was observed between the bariatric surgical and nonsurgical cohorts at 10 years, only eight patients had undergone RYGB at that time, too small a number for statistical analysis (64 (EL 3)).

9.1.3.3. Cardiac function
Severe obesity may be associated with cardiomegaly, increased left ventricular wall thickness, and impaired left, right, or bilateral ventricular function. In addition, severe obesity may be associated with high cardiac output and low systemic vascular resistance, leading to left ventricular hypertrophy. Obesity is also associated with hypertension, which leads to concentric left ventricular hypertrophy. This combination of obesity and hypertension with left ventricular eccentric and concentric hypertrophy may result in left ventricular failure (201 (EL 3), 202 (EL 2)). Correction of severe obesity decreases left ventricular wall thickness, increases left ventricular ejection fraction, and improves overall cardiac function in these patients (177 (EL 3), 202–207 (EL 2–3)). Bariatric surgery has been shown to improve cardiac function in patients with idiopathic cardiomyopathy (208 (EL 3)). Morbid obesity is also associated with an accelerated rate of coronary atherosclerosis and deaths due to MI (209 (EL 2), 210 (EL 2)). Surgically induced weight loss is associated with a substantial decrease in factors that pertain to obesity-related cardiac mortality (including the aforementioned conditions), significant and long-standing improvements in dyslipidemia, hypertension, and sleep apnea-induced cardiac arrhythmias, and a decrease in frequency of MI (211 (EL 2)) as well as the rate of deaths due to MI (65 (EL 3), 154 (EL 2)).

9.1.4. Gastrointestinal

9.1.4.1. GERD
After RYGB, GERD has been found to improve considerably because little acid or bile is available to reflux into the esophagus (212 (EL 3), 213–215 (EL 3–4)). Moreover, studies have found complete regression of Barrett esophagus after RYGB (216 (EL 3)). Improvement in GERD has also been seen after VBG (217 (EL 3)); this improvement in reflux after either RYGB or purely restrictive procedures also may be a result of the decrease in intra-abdominal pressure seen after surgically induced weight loss (109 (EL 2), 111 (EL 2), 114 (EL 2)). Because a Nissen fundoplication relieves only one of the comorbidities of severe obesity and because there is an increased rate of failure of fundoplication in severely obese patients, RYGB should be the preferred treatment of morbidly obese patients with GERD.

9.1.4.2. NAFLD and nonalcoholic steatohepatitis
Many obese patients will have asymptomatic increases in serum alanine aminotransferase and aspartate aminotransferase levels. These changes are most commonly associated with NAFLD or, in its more advanced form, nonalcoholic steatohepatitis and cirrhosis. At the time of bariatric surgery, 84% of morbidly obese subjects have steatosis on liver biopsy specimens, and 20 and 8% have inflammation and fibrosis, respectively (218 (EL 3)). Weight loss after LAGB, RYGB, BPD, or BPD/DS leads to regression of steatosis and inflammation, including decreased bridging fibrosis in some patients (148 (EL 3), 219–231 (EL 2–4)).

9.1.5. Endocrine

9.1.5.1. PCOS
Women accounted for 82% of all bariatric procedures in the United States in 2004 (98 (EL 3)). PCOS is characterized by the presence of chronic anovulation, menstrual irregularity, and hyperandrogenism typically with a pubertal onset (232 (EL 2)) and can be associated with insulin resistance and T2DM.
In many cases, the hyperandrogenic and anovulatory symptoms of PCOS are ameliorated with metformin treatment (233 (EL 1), 234 (EL 2)). Surgically induced weight loss can also result in decreased androgen levels, increasing fertility and restoring menstrual regularity (235–240 (EL 2–4)).

### 9.1.5.2. Male sex hormone dysfunction

Two recent studies have documented obesity-related abnormality of the pituitary–gonadal axis and hypoandrogenism, presumably due to peripheral aromatization of testosterone to estrogen in adipose tissue, which resolved after bariatric surgery (240 (EL 3), 241 (EL 4)).

### 9.1.6. Pregnancy

Increased weight also increases the risk of complications of pregnancy. Surgically induced weight loss is associated with decreased pregnancy-related complications, including preecclampsia, cephalopelvic disproportion, macrosomia, gestational diabetes, and the need for cesarean delivery (242–248 (EL 2–3)). Children born to mothers after weight loss surgery weigh less at birth and maintain a lower weight than do siblings who were born before bariatric surgery (249 (EL 3)). Resolution of severe obesity should also lead to a decreased risk of venous thromboembolism in pregnant women, but thus far no data have been published.

### 9.1.7. Venous Disease

Severely obese patients often have problems with chronic edema of the lower extremities, which can lead to bronze discoloration and chronic ulceration, as well as an increased risk of thrombophlebitis and PE. This comorbidity is probably a result of increased intra-abdominal pressure, leading to an increased inferior vena caval pressure and decreased venous return (109–111 (EL 2), 114 (EL 2), 250 (EL 3)). Surgically induced weight loss considerably improves venous stasis disease, including resolution of venous stasis ulcers (113 (EL 4)).

### 9.1.8. Central Nervous System

#### 9.1.8.1. Pseudotumor cerebri

Pseudotumor cerebri, also known as idiopathic intracranial hypertension, may be associated with extreme obesity. This problem occurs almost exclusively in women. Symptoms include severe headache that is usually worse in the morning, bilateral pulsatile auditory tinnitus, and visual field cuts. Severely increased intracranial pressure can lead to permanent blindness. Cranial nerves that may be involved include V (tic douloureux), VI (oculomotor nerve paralysis), and VII (Bell palsy). Studies suggest that pseudotumor cerebri is attributable to increased intra-abdominal pressure, leading to increased pleural pressure and decreased venous drainage from the brain, with consequent cerebral venous engorgement and increased intracranial pressure. Increased intracranial pressure has been demonstrated in an acute porcine model of increased intra-abdominal pressure, which was prevented by median sternotomy (251 (EL 4), 252 (EL 4)). In the past, pseudotumor cerebri was treated with ventriculoperitoneal or lumbo-peritoneal cerebrospinal fluid (CSF) shunts. The incidence of shunt occlusion is high (253 (EL 3)), and in some cases, patients can have continued headache and auditory tinnitus despite a patent shunt. These failures are probably related to shunting from one high-pressure system to another high-pressure system. Major neurologic complications may also develop after insertion of a ventriculoperitoneal or lumbo-peritoneal shunt. Because surgically induced weight loss decreases CSF pressure and relieves headache and tinnitus (112 (EL 3), 254 (EL 4), 255 (EL 3)), bariatric surgery is the intervention of choice over CSF-peritoneal shunting in severely obese patients.

#### 9.1.8.2. Stroke

With improvement in hypertension and atherosclerosis, there should be a decrease in the rate of cerebrovascular accidents. One cohort study supports this prediction, finding a decrease in stroke mortality in a cohort of patients who underwent bariatric surgery (154 (EL 2)).

#### 9.1.9. Urologic

Severe obesity is associated with a very high frequency of urinary incontinence in women, which resolves almost uniformly after bariatric surgery. This problem is attributable to increased intra-abdominal and bladder pressures, which decrease substantially after surgically induced weight loss (111 (EL 2), 256–258 (EL 3)).

### 9.1.10. Musculoskeletal

The excessive weight in severe obesity leads to early degenerative arthritic changes of the weight-bearing joints, including the knees, hips, and spine (259 (EL 4)). Many orthopedic surgeons refuse to insert total hip or knee prostheses in patients weighing 250 lb (113.5 kg) because of an unacceptable incidence of prosthetic loosening (260 (EL 3)). There is a high risk of complications in obese patients after intramedullary nailing of femoral fractures (261 (EL 3)). Severe obesity is a common problem in patients requiring an intervertebral disk surgical procedure (262 (EL 3)). Weight reduction after gastric surgery for obesity allows subsequent successful joint replacement (263 (EL 3)) and is associated with decreased musculoskeletal and lower back pain (211 (EL 2), 264 (EL 3)). In some instances, the decrease in pain after weight loss eliminates the need for a joint operation (265 (EL 2), 266 (EL 3)) or intervertebral disk operation (267 (EL 3)). Bariatric surgery improves mobility and postural stability (268 (EL 2), 269 (EL 3), 270 (EL 3)).

### 9.1.11. Cancer

Severely obese patients are at an increased risk for cancer, including involvement of the breast, uterus, prostate, colon, liver, and esophagus. One study found a decrease in treatment for cancer in patients from Quebec Province who had undergone bariatric surgery in comparison with a cohort of patients who had not (153 (EL 3)). Two recent studies have found a decrease in cancer-related mortality among patients who had undergone
bariatric surgery when compared with a nonsurgical cohort (65 (EL 3), 154 (EL 2)).

9.1.12. Psychosocial Issues
Extreme obesity is associated with considerable psychosocial distress (48 (EL 4), 118 (EL 4), 119 (EL 4)). Between 20 and 60% of persons seeking bariatric surgery meet the criteria for a major psychiatric disorder—most commonly, mood disorders (271–274 (EL 3)). Disordered eating behaviors seem to be more common among bariatric surgery patients than in the general population (275–285 (EL 3–4)). In comparison with persons of average weight, those with extreme obesity often experience increased symptoms of depression and anxiety, impaired quality of life, body image dissatisfaction, and problems with marital and sexual functioning (286–289 (EL 3–4)). The experience of weight-related prejudice and discrimination, which have been found in social, educational, occupational, and health-care settings, may be particularly common in the extremely obese population (286 (EL 3), 290 (EL 4), 291 (EL 3), 292 (EL 3)).

The majority of bariatric surgery patients report improvements in psychosocial functioning postoperatively (48 (EL 4), 117–119 (EL 4), 293 (EL 4)). Several studies have documented an improved quality of life after surgically induced weight loss (57 (EL 3), 294 (EL 2), 295–300 (EL 3)). For some patients, however, the psychosocial benefits of surgical treatment seem to wane over time, and a minority appear to experience untoward psychosocial outcomes. Several investigators have documented problems with substance abuse, alcoholism, and suicide postoperatively (122 (EL 3), 273 (EL 3), 278 (EL 3), 301 (EL 3)). There has been recent concern regarding the possibility of substitutive addictive behavior after bariatric surgery, but little supporting scientific evidence is available. At least one study found an increased divorce rate after bariatric surgery (302 (EL 3)). Careful examination of the data, however, revealed that the divorce rate was the result of the dissolution of very poor prior relationships and not the disintegration of healthy ones.

9.1.13. Mortality Reduction as a Result of Bariatric Surgery
Several reports have noted a significant decrease in mortality among patients who have undergone bariatric surgery in comparison with matched nonsurgical cohorts. MacDonald et al. (151 (EL 3)) found that the mortality among patients who underwent bariatric surgery was 9% (N = 154) as compared with 28% (N = 78) among those who did not. Reasons for not undergoing surgical treatment were inability to obtain insurance coverage or choosing not to proceed with surgery (151 (EL 3)). In a similar study, Sowemimo et al. (152 (EL 3)) found an 81% reduction in mortality among bariatric surgery patients vs. those who did not have surgery. Christou et al. (153 (EL 3)) also noted an 89% reduction in mortality in Quebec Province for patients who underwent surgery for obesity when compared with a nonsurgical cohort of patients with a diagnosis of morbid obesity. In addition, this study noted a significant decrease in treatment for cancer in the surgical group. Flum and Dellinger (39 (EL 3)) found a significant decrease in mortality at 1 and 15 years after gastric bypass; however, there was a 1.9% 30-day mortality, in part attributable to surgeon’s inexperience with the procedure. Busetto et al. (155 (EL 3)) found that patients with LAGB treatment have a lower risk of death in comparison with matched cohorts who did not have surgical treatment. Similar findings were observed by Peeters et al. (303 (EL 3)) in a study in which patients with LAGB had a 72% lower hazard of death than did an obese population-based cohort. The SOS Study reported a 25% decrease in mortality in bariatric surgery patients at 10 years postoperatively in comparison with a well-matched control population (65 (EL 3)). Adams et al. (154 (EL 2)) found a 40% decrease in mortality after RYGB in Salt Lake City, Utah, when compared with a matched nonsurgical cohort, with significant decreases in death associated with cancer, diabetes, and MI. None of these observations was based on randomized studies, and most involved experienced bariatric surgery centers. Therefore, conclusions concerning mortality may not be generalizable to all surgeons and patients.

9.2. Selection of Patients for Bariatric Surgery
All patients with a BMI of ≥40 kg/m², regardless of the presence of comorbidities, are potential candidates for bariatric surgery. Those patients with a BMI of 35–39 kg/m² are candidates, if they have an obesity-related comorbidity. One randomized, prospective trial supports the LAGB procedure for persons with a BMI between 30 and 35 kg/m² (63 (EL 2)). The only contraindications to bariatric surgery are persistent alcohol and drug dependence, uncontrolled severe psychiatric illness such as depression or schizophrenia, or cardiopulmonary disease that would make the risk prohibitive. Although the last-mentioned patients have a significantly increased risk of mortality, they should expect profound improvements in their weight-related pathologic condition if they can survive the bariatric procedure. Better risk-to-benefit stratification is needed for this group of patients.

9.3. Preoperative Evaluation
The preoperative evaluation of the patient seeking bariatric surgery involves multiple disciplines. Among clinical practices, the specialty of the physician guiding the evaluation varies from the general internist, to the endocrinologist or specialist in bariatric medicine, to the bariatric surgeon who will ultimately perform the operation. Regardless of the discipline of the professional guiding the initial evaluation, it is paramount for patients to be well informed and appropriately screened before these procedures. This educational process can be accomplished through the use of support groups and counseling sessions with members of the bariatric surgery team (Table 16). Proper screening allows for diagnosis of relevant comorbidities, which can then be managed preoperatively to improve surgical outcomes (Table 17).

Preexisting medical conditions should be optimally controlled before bariatric surgery. This optimization may necessitate the input of various medical specialists, including cardiologists, pulmonary specialists, and gastroenterologists. The registered dietitian skilled in preoperative and postoperative bariatric care should interact with the patient preoperatively for their evaluation and initiate a continuing nutrition education experience. The psychologic assessment should be performed by a licensed

S26 VOLUME 17 SUPPLEMENT 1 | APRIL 2009 | www.obesityjournal.org
psychologist, psychiatrist, or other mental health professional with experience in obesity and bariatric surgery. The psychologic evaluation is a requirement for most insurance carriers and for the ASMBS Centers of Excellence and the American College of Surgeons (ACS) Bariatric Surgery Centers. At the time of the surgical consultation, the surgeon should discuss the procedure that is recommended, explain the potential risks and benefits, and decide whether surgical treatment will be offered on the basis of this multidisciplinary approach.

For all patients seeking bariatric surgery, a comprehensive preoperative evaluation should be performed. This assessment includes an obesity-focused history, physical examination, and pertinent laboratory and diagnostic testing (304 (EL 4)). A detailed weight history should be documented, including a description of the onset and duration of obesity,

<table>
<thead>
<tr>
<th>Table 16 Potential members of a bariatric surgery team</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bariatric surgeon</td>
</tr>
<tr>
<td>Bariatric coordinator (advanced practice nurse or well-educated registered nurse)</td>
</tr>
<tr>
<td>Internist with nutrition or bariatric medicine experience</td>
</tr>
<tr>
<td>Registered dietitian</td>
</tr>
<tr>
<td>Medical consultants*</td>
</tr>
<tr>
<td>Psychologist or psychiatrist</td>
</tr>
<tr>
<td>Endocrinologist</td>
</tr>
<tr>
<td>Physician nutrition specialist*</td>
</tr>
<tr>
<td>Certified nutrition support clinician*</td>
</tr>
<tr>
<td>Sleep medicine specialist</td>
</tr>
<tr>
<td>Cardiologist</td>
</tr>
<tr>
<td>Gastroenterologist</td>
</tr>
<tr>
<td>Psychiatrician</td>
</tr>
<tr>
<td>Office support personnel</td>
</tr>
</tbody>
</table>

*Consultants to be utilized as needed.
†Designation by the American Board of Physician Nutrition Specialists.
‡Designation by the National Board of Nutrition Support Certification.

the severity, and recent trends in weight. Causative factors to note include a family history of obesity, use of weight-gaining medications, and dietary and physical activity patterns. One need not document all previous weight loss attempts in detail, but a brief summary of personal attempts, commercial plans, and physician-supervised programs should be reviewed, along with the greatest duration of weight loss and maintenance. This information is useful in substantiating that the patient has made reasonable attempts to control weight before considering obesity surgery (53 (EL 3)). These issues also may be reviewed in greater detail by the program registered dietitian.

The patient’s personal history should include current smoking, alcohol or substance abuse, and the stability of the home and work environments. An accurate medication list that includes over-the-counter supplements must be reviewed carefully. A small but growing list of psychiatric and neurologic medications (Table 18) may stimulate appetite, and such drugs have been associated with weight gain (305 (EL 4)). Considerable care must be exercised when discontinuation of such medications is being considered, inasmuch as decompensation of a known psychiatric condition may increase morbidity and threaten the success of bariatric surgery (306 (EL 4)). Typically, the preoperative mental health evaluation provides a more detailed assessment of psychiatric status and history.

In addition to elicitation of the past medical history, an inquiry of the review of systems is helpful for identification of undiagnosed symptoms and conditions associated with obesity. During the review of systems section of the history and the development of a problem list of obesity-related comorbidities, Table 19 can be used as a convenient checklist. During the recording of the preoperative history is also an opportune time to review and update screening recommendations from the standpoint of preventive medicine. Use of a printed questionnaire allows the interview to stay organized, leaves more time to focus on pertinent positive and negative factors, and provides a useful future reference (307 (EL 4)).

<table>
<thead>
<tr>
<th>Table 17 Screening and management of comorbidities before bariatric surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine chemistry studies (fasting blood glucose, liver profile, and lipid profile), urinalysis, prothrombin time (INR), blood type, complete blood cell count, iron studies</td>
</tr>
<tr>
<td>Vitamin B1 (optional), vitamin B12–folic acid assessment (RBC folate, homocysteine, methylmalonic acid) (optional)</td>
</tr>
<tr>
<td>Vitamins A and D (E and K optional) (if malabsorptive procedure planned), iPTH</td>
</tr>
<tr>
<td>Helicobacter pylori screening (optional) (if positive and epigastric symptoms present: treatment with antibiotics and proton pump inhibitor)</td>
</tr>
<tr>
<td>Thyroid-stimulating hormone (thyrotropin) (optional)</td>
</tr>
<tr>
<td>Total or bioavailable testosterone, DHEAS, Δ4-androstenedione (if polycystic ovary syndrome suspected) (optional)</td>
</tr>
<tr>
<td>Overnight dexamethasone suppression, 24-h urinary cortisol, 11 PM serum or salivary cortisol level screening tests (if Cushing syndrome suspected)</td>
</tr>
<tr>
<td>Cardiovascular evaluation (chest radiography, electrocardiography, and echocardiography if pulmonary hypertension or cardiac disease is known or suspected)</td>
</tr>
<tr>
<td>Gastrointestinal evaluation (gallbladder evaluation optional in asymptomatic persons or at the discretion of the surgeon, upper endoscopy if epigastric discomfort)</td>
</tr>
<tr>
<td>Sleep apnea evaluation if suspected; arterial blood gases if obesity-hypoventilation syndrome suspected or in super-obese patients</td>
</tr>
<tr>
<td>Psychologic–psychiatric consultation</td>
</tr>
<tr>
<td>DHEAS, dehydroepiandrosterone sulfate; INR, international normalized ratio; iPTH, intact parathyroid hormone; RBC, red blood cell.</td>
</tr>
</tbody>
</table>
Finally, a summary of the patient’s interest in and knowledge about the proposed surgical procedure, including whether he or she has spoken to other patients, researched the procedure on the Internet, or attended support group meetings, should be completed (308 (EL 4), 309 (EL 4)). It is also important to assess the patient’s expectations about postoperative weight loss. Many patients present for bariatric surgery with unrealistic expectations regarding the anticipated weight loss. Foster et al. (310 (EL 3)) found that bariatric surgery candidates expect, on average, a 44% loss of preoperative weight. In contrast, a loss of only 27.3% was considered “disappointing,” although losses of that magnitude are typically judged as successful by bariatric surgeons. Before bariatric surgery is scheduled, it is helpful for patients to read the program’s information packet carefully, attend an orientation session, and speak to other patients who have undergone bariatric surgery at the hospital.

9.3.1. Mental Health Evaluation
The psychosocial evaluation serves two major purposes: (i) identification of potential contraindications to surgical intervention, such as substance abuse, poorly controlled depression, or other major psychiatric illness, and (ii) identification of potential postoperative challenges and facilitation of behavioral changes that can enhance long-term weight management (308 (EL 4), 309 (EL 4)).

Although there are published recommendations regarding the structure and content of mental health evaluations (309 (EL 4), 311 (EL 4)), consensus guidelines have yet to be established. Typically, such evaluations are performed by psychologists, psychiatrists, or other mental health professionals who, ideally, have an appropriate working knowledge of the psychosocial issues involved in obesity and bariatric surgery. Almost all evaluations rely on clinical interviews with the patients; approximately two-thirds also include instrument or questionnaire measures of psychiatric symptoms or objective tests of personality or psychopathologic conditions (or both assessments) (312 (EL 3)). More comprehensive evaluations assess the patient’s knowledge of bariatric surgery, weight and dieting history, eating and activity habits, and both potential obstacles and resources that may influence postoperative outcomes (308 (EL 4), 309 (EL 4)). Approximately 90% of bariatric surgery programs require their surgical candidates to undergo a mental health evaluation preoperatively (313 (EL 3)).

Assessment of the psychiatric status and history is the cornerstone of these mental health evaluations. Psychosocial distress is common among patients who present for bariatric surgery (48 (EL 4), 117–119 (EL 4)). Studies of clinical populations have found that up to 60% of persons who seek bariatric surgery fulfill the criteria for at least one Axis I psychiatric disorder (271–274 (EL 3)). Mood disorders were the most common diagnoses, although sizable minorities have been diagnosed as...
having eating, anxiety, and substance abuse disorders. Bariatric surgery patients also report severe impairment in quality of life, as well as heightened dissatisfaction with their body image, marital relationship, and sexual functioning (286 (EL 3), 296 (EL 3), 302 (EL 3), 314–316 (EL 3)). In addition, many bariatric surgery patients report experiences with weight-related prejudice and discrimination.

Eating behaviors and habits should also be reviewed during the mental health evaluation, with specific attention to where and when the patient eats, who shops and cooks, snacking, portion sizes, intake of sweet beverages, and overall knowledge of nutrition (308 (EL 4), 309 (EL 4)). Specific inquiry concerning binge eating disorder should be undertaken. Early studies suggested that up to 50% of bariatric surgery candidates had this disorder (275 (EL 3), 276 (EL 3), 280 (EL 3), 281 (EL 3), 283 (EL 3)). More recent studies have suggested that the disorder may be far less common than thought initially, involving perhaps as few as 5% of patients (279 (EL 4), 284 (EL 3), 285 (EL 3)). Nevertheless, the diagnosis of preoperative binge eating disorder has been found to be associated with less weight loss or with weight regain within the first two postoperative years (277 (EL 4), 282 (EL 3), 317 (EL 1)).

At present, the relationship between preoperative psychologic status and postoperative outcomes is unclear (48 (EL 4), 117–119 (EL 4)). Several studies have suggested that preoperative psychopathologic conditions and eating behavior are unrelated to postoperative weight loss; others have suggested that preoperative psychopathologic disorders may be associated with unoward psychosocial outcomes, but not with poorer weight loss. Unfortunately, the complex relationship between obesity and psychiatric illness, as well as a number of methodologic issues within this literature, make drawing definitive conclusions difficult if not impossible. Perhaps psychiatric symptoms that are primarily attributable to weight, such as depressive symptoms and impaired quality of life, may be associated with more positive outcomes, whereas those symptoms representative of psychiatric illness—that is, independent of obesity—are associated with less positive outcomes (119 (EL 4)).

Studies have suggested that mental health professionals unconditionally recommend ~75% of bariatric surgery candidates for surgery (274 (EL 3), 312 (EL 3), 318 (EL 3)). In the remaining patients, the recommendation typically is to delay bariatric surgery until specific psychosocial or nutritional issues (or both) have been addressed with additional assessment or treatment. The benefits of recommending such a delay, however, should be weighed against the risk of patients not eventually returning for potential surgical treatment.

### 9.3.2. Physical Examination

For optimal comfort, the physician’s office should be equipped properly with armless chairs, extra-large and reinforced examination tables, a suitable scale and stadiometer for measuring weight and height, large gowns, and appropriately sized blood pressure cuffs. The BMI should be computed and categorized by class. A comprehensive examination should be performed, with particular attention paid to signs of metabolic and cardiopulmonary disease. For example, a large neck circumference and a crowded posterior pharynx may be clues to the presence of OSA. Fungal infection in skinfolds may be a sign of undiagnosed diabetes. Observation of gait and breathing effort with modest exertion (for example, walking to the examination room or getting on and off the examination table) may provide clues to poor functional capacity or musculoskeletal disability.

### 9.3.3. Laboratory Studies and Procedures

The specific preoperative evaluation of the bariatric surgery patient should be directed toward symptoms, risk factors, and index of suspicion for secondary causes of obesity. Thus, Table 20 has been developed with use of an evidence-based approach for assessing comorbid conditions in obese patients.

When symptoms of OSA or hypercapnia (elevated Pco2) are identified, polysomnography should be performed. Other treatable causes of hypercapnia, including OHS, other restrictive lung diseases, chronic obstructive pulmonary disease, left ventricular failure, and hypothyroidism, may also need to be considered (319 (EL 4)). Definitive diagnosis of patients suspected of having Cushing syndrome may be particularly difficult, inasmuch as weight gain, moon facies, posterior cervical fat pads, cutaneous stretch marks, hypertension, and glucose intolerance are relatively common among severely obese patients. If Cushing syndrome is suspected, measurement of a bedtime salivary cortisol level, which is often the earliest and most sensitive marker of the disease, has been recommended as a reasonable screening test (320 (EL 4)). In patients with equivocal results, repeated measures over time may be needed for a definitive diagnosis. Additional testing options include a 24-h collection of urine for assessment of free cortisol excretion and the 1-mg overnight dexamethasone suppression test.

Women with a history of oligomenorrhea and androgenic should be evaluated for PCOS. Numerous studies have demonstrated that women with PCOS are at a much higher risk for developing T2DM and cardiovascular disease than those without PCOS (321 (EL 4)). NAFLD is being increasingly recognized as an important cause of liver-related morbidity and mortality (322 (EL 4)) and is thought by many clinicians to be the most common cause of cryptogenic cirrhosis in the obese patient (323 (EL 3)).

Selection and timing of preoperative laboratory tests should be based on the patient’s specific clinical indications and the evaluation by anesthesiology; obesity alone is not a risk factor for postoperative complications (324 (EL 3)). The current literature is not sufficiently rigorous to recommend ordering routine preoperative tests (325 (EL 4)). Nonetheless, a fasting blood glucose level and lipid profile, chemistry panel, and complete blood cell count are generally considered reasonable for the bariatric surgical patient. A pregnancy test should be obtained for all female patients of childbearing age. In patients at very low risk for heart and lung disease, routine chest radiography and electrocardiography add little information. On the basis of the high risk for development of micronutrient deficiencies after malabsorptive procedures, preoperative evaluation of iron status (iron, total iron-binding capacity, ferritin, serum
transferrin receptor), vitamin B<sub>12</sub>, 25-OHD, and PTH should also be obtained. Preoperative micronutrient deficiencies have been described in bariatric surgery patients—14–43.9% have iron deficiency, 5–29% have vitamin B<sub>12</sub> deficiency, and 40–68.1% have vitamin D deficiency (326 [EL 3], 327 [EL 3]). Treatment for clinically significant deficiencies, such as iron deficiency anemia, should be initiated preoperatively. Although it seems prudent to screen all patients for metabolic bone disease after substantial weight loss, data are limited regarding preoperative screening. As with any patient, those patients at increased risk for osteoporosis should be screened with dual-energy X-ray absorptiometry.

Some physicians evaluate patients preoperatively with an esophagogastroduodenoscopy or UGI study to detect peptic ulcer disease, hiatal hernias, esophageal mucosal abnormalities related to gastroesophageal reflux, and the presence of H. pylori infection (328 [EL 3]). The benefits with use of this approach have been described (329 [EL 3]). Some physicians recommend testing for H. pylori antibody and treat patients with abnormal values (330 [EL 4]) because marginal ulceration is a late

### Table 20: Laboratory and diagnostic evaluation of the obese patient based on presentation of symptoms, risk factors, and index of suspicion

<table>
<thead>
<tr>
<th>Suspected condition</th>
<th>Studies to consider and interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive sleep apnea (daytime sleepiness, loud snoring, gasping or choking episodes during sleep, and awakening headaches)</td>
<td>Polysomnography for oxygen desaturation, apneic and hypopneic events. Measurement of neck circumference (&gt;17 inches (&gt;43.2 cm) in men, &gt;16 inches (&gt;40.6 cm) in women). Otorhinolaryngologic examination for upper airway obstruction (optional).</td>
</tr>
<tr>
<td>Alveolar hypoventilation (Pickwickian syndrome) (hypersomnolence, possible right-sided heart failure including elevated jugular venous pressure, hepatomegaly, and pedal edema)</td>
<td>Polysomnography (to rule out obstructive sleep apnea). Complete blood cell count (to rule out polycythemia). Blood gases (PaO&lt;sub&gt;2&lt;/sub&gt;, decreased, PaCO&lt;sub&gt;2&lt;/sub&gt; elevated). Chest radiography (enlarged heart and elevated hemidiaphragms). Electrocardiography (right atrial and right ventricular enlargement). Pulmonary function tests (reduced vital capacity and expiratory reserve volume) (optional). Right heart pressure measurement (optional).</td>
</tr>
<tr>
<td>Cushing syndrome (moon facies, thin skin that bruises easily, severe fatigue, violaceous striae)</td>
<td>Elevated late-night salivary cortisol level (&gt;7.0 nmol/l diagnostic, 3.0–7.0 nmol/l equivocal). Repeatedly elevated measurements of cortisol secretion (urine free cortisol (upper normal, 110–138 nmol/day) or late-night salivary cortisol levels) may be needed.</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Fasting blood glucose (≥126 mg/dl on two occasions), random blood glucose (≥200 mg/dl with symptoms of diabetes), or 120 min postglucose challenge (≥200 mg/dl). Glycosylated hemoglobin (hemoglobin A1c) ≥7.1%. Microalbuminuria (&gt;30 mg/day) at baseline. BP measurement and fasting lipid profile.</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Supersensitive TSH (&gt; assay upper limit of normal range)</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>3 of 5 criteria needed for diagnosis: Triglycerides &gt;150 mg/dl. HDL cholesterol &lt;40 mg/dl (men) or &lt;50 mg/dl (women). BP &gt;130/85 mm Hg. Fasting glucose &gt;110 mg/dl. 120-min postglucose challenge 140–200 mg/dl.</td>
</tr>
<tr>
<td>Polycystic ovary syndrome (oligomenorrhea, hirsutism, probable obesity, enlarged ovaries may be palpable, hypercholesterolemia, impaired glucose tolerance, persistent acne, and androgenic alopecia)</td>
<td>Morning blood specimen for total, free, and weak testosterone, DHEAS, prolactin, thyrotropin, and early-morning 17-hydroxyprogesterone level (normal values vary according to laboratory). Testing should be done off oral contraceptives (optional). Lipid profile.</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Mean of two or more properly measured seated BP readings on each of two or more office visits with use of a large BP cuff (prehypertension 120–139/80–89 mm Hg; hypertension 140–159/90–99 mm Hg). Electrocardiography, urinalysis, complete blood cell count, blood chemistry, and fasting lipid profile.</td>
</tr>
<tr>
<td>Liver abnormality, gallstones</td>
<td>Liver function tests (serum bilirubin and alkaline phosphatase elevated). Gallbladder ultrasonography (optional).</td>
</tr>
<tr>
<td>Hepatomegaly, nonalcoholic fatty liver disease</td>
<td>Liver function tests elevated 1–4 times normal (ALT usually &gt; AST, serum bilirubin, prothrombin time, decreased albumin). Imaging study (ultrasoundography or computed tomography) (optional). Minimal or no alcohol intake with negative testing for viral hepatitis, autoimmune disease, and congenital liver disease. Definitive diagnosis with liver biopsy. Upper endoscopy to rule out esophageal varices if cirrhosis suspected.</td>
</tr>
</tbody>
</table>

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; DHEAS, dehydroepiandrosterone sulfate; HDL, high-density lipoprotein; TSH, thyroid-stimulating hormone.
9.4. Choice of Bariatric Procedure

The decision to select a specific bariatric procedure is based on a number of factors including obesity severity and duration, metabolic complications, presence of co-morbidities, and personal and family histories of surgical procedures. The patient’s current medications, and procedures, (iii) more nutritional anemia, and (iv) higher surgical mortality (84 (EL 3), 125 (EL 3), 140 (EL 4), 335 (EL 3)). LAGB and laparoscopic RYGB, in comparison with open procedures, are associated with a shorter hospital stay, earlier resolution of pain, and improvement in quality of life without any additional morbidity or mortality (332 (EL 1), 333 (EL 4), 334 (EL 2)). Laparoscopic bariatric surgery is also associated with significantly fewer wound-related complications (wound infections, dehiscence, incisional hernias) in comparison with open procedures (333 (EL 4)). In contrast, however, laparoscopic operations are associated with a greater number of anastomotic strictures, internal hernias, and subsequent cholecystectomies than are open procedures (60 (EL 4), 61 (EL 3), 62 (EL 2), 336 (EL 2)). Weight loss and improvement in quality of life are equivalent between the approaches in long-term outcomes (100 (EL 3), 294 (EL 2)).

In their evidence-based evaluation, the European Association for Endoscopic Surgery concluded that the choice of bariatric procedure depends ultimately on individual factors, including BMI, perioperative risk, metabolic variables, comorbidities, surgeon competence, and other physician–patient preferences (331 (EL 4)). A similar algorithm was devised by Buchwald (337 (EL 4)) on the basis of a number of case series. For example, even an LAGB can induce significant weight loss with less risk in patients with a BMI of 50–100 kg/m² (338 (EL 2), 339 (EL 3), 340 (EL 3)); therefore, if risks of RYGB, BPD, or BPD/DS are excessive for an individual patient, the LAGB can be considered a good choice. T2DM appears to resolve more quickly, and is independent of weight loss, with RYGB, BPD, or BPD/DS than with LAGB. Other factors in the decision analyses are local experience by the surgeon and institution with a specific procedure and insurance coverage.

9.4.1. Evidence Comparing RYGB With LAGB

The weight loss associated with RYGB is intermediate between a purely restrictive procedure and the BPD or BPD/DS (11 (EL 2), 64 (EL 3), 99 (EL 1)). According to a systematic review and meta-analysis of data from various bariatric procedures, BPD and banded RYGB procedures were associated with greater weight loss than were RYGB and LAGB; the latter two procedures were comparable at 3–7 years postoperatively (332 (EL 1)). The data demonstrating greater weight loss with RYGB over VBG are exemplified by the randomized, prospective trials of Sugerman et al. (70 (EL 2)), Hall et al. (341 (EL 3)), Howard et al. (342 (EL 2)), MacLean et al. (343 (EL 2)), and Sjöström et al. (64 (EL 3)). These findings were supported by the matched-pair comparisons from a prospective collected database of 678 bariatric procedures, in which laparoscopic RYGB was associated with greater weight loss and fewer complications than LAGB (344 (EL 2)). A randomized, prospective trial showed that RYGB yielded a significantly greater loss of excess weight at 5 and 10 years postoperatively than did the LAGB (66.6% vs. 47.5%, respectively; P < .001) (11 (EL 2)). The SOS Study, a prospective, nonrandomized but matched investigation, demonstrated greater weight loss for gastric bypass compared with gastric banding (nonadjustable and adjustable Swedish band) at 15 years postoperatively with 99.9% retention (27% vs. 13% of
initial body weight, respectively) (64 (EL 3), 65 (EL 3)). Specifically, follow-up of the prospective SOS Study found that at 1–2, 10, and 15 years postoperatively, weight losses stabilized at 32%, 25%, and 27% of initial weight for RYGB (N = 265), 25, 16, and 18% for VBG (N = 1,369), and 20, 14, and 13% for gastric banding (N = 376) (65 (EL 3)). This study was not sufficiently powered statistically to determine differences in mortality among the three surgical procedures. In contrast, in a retrospective study of 332 patients with BMI >50 kg/m², laparoscopic RYGB was associated with weight loss comparable to that with LAGB but at a price of greater morbidity (340 (EL 3)). In another retrospective study of 290 patients with BMI >50 kg/m², laparoscopic RYGB was associated with a significantly greater percentage loss of EBW but with increased early and late complication rates compared with LAGB (89 (EL 3)). In the retrospective studies by Jan et al. (345 (EL 2), 346 (EL 2)), there was a greater percentage loss of EBW at 3 years and morbidity with the RYGB and a greater reoperation rate with the LAGB procedure. As procedural techniques evolved and incorporated more stapling and anastomoses, it is not surprising that the risk for postoperative complications increased.

On the basis of the clinical evidence, Sauerland et al. (331 (EL 4)) concluded that the balance between complications and weight loss favored an LAGB in those patients with a BMI <40 kg/m², whereas RYGB was recommended in those patients with a BMI of 40–50 kg/m². This report, however, did not factor in the cost and increased risk of failing LAGB procedures to RYGB or the probable long-term effects of better control of diabetes achieved with RYGB. Another potential advantage for RYGB over LAGB would be in those patients with a greater number of obesity-related comorbidities, such as T2DM.

9.4.2. Evidence Regarding Risks and Benefits of BPD or BPD/DS

BPD and BPD/DS are complex hybrid surgical procedures with multiple suture lines and a mortality rate ranging from 0.4 to 2.0% attributable to PE, respiratory failure, and anastomotic leaks (82 (EL 3), 84 (EL 3), 347 (EL 3), 348 (EL 3)). In an “ad hoc stomach” type of BPD, with a 200-cm alimentary limb, a 50-cm common limb, and a 200- to 500-mL gastric volume (in which the stomach volume is adjusted according to the patient’s initial EBW, sex, age, eating habits, and anticipated adherence with postoperative instructions), the operative mortality was 0.4%, the early complication rate (wound dehiscence and infection) was 1.2%, and the late complication rate was 8.7% for incisional hernia and 1.2% for intestinal obstruction (335 (EL 3)). Closing mesenteric defects can reduce the incidence of internal hernias (331 (EL 4)). Other rates of complications associated with BPD include anemia in <5%, stomal ulcer in 3%, and protein malnutrition in 7%, with 2% requiring surgical revision by elongation of the length of the common limb or by restoration of normal gastrointestinal continuity (335 (EL 3)). Higher rates of complications after BPD were reported by Michelson et al. (349 (EL 3)) and included diarrhea due to bacterial overgrowth (27%), wound infection (15%), incisional hernias (15%), peptic ulcers (15%), dumping syndrome (6%), and acute cholecystitis (6%). Liver function abnormalities may occur after BPD within the first few postoperative months as a result of malabsorption and can be treated with metronidazole and pancreatic enzymes (350 (EL 3), 351 (EL 3)). If these abnormalities persist, PN or surgical elongation of the common channel (or both)—or even reversal—may be necessary (347 (EL 3)). One study demonstrated that some patients with severe hepatopathy had improved liver histologic features, although others developed mild fibrosis after the BPD/DS (352 (EL 2)). Restriction of dietary fat may lessen the frequency of malodorous stools. Overall, quality of life is improved with BPD/DS, with rare occurrence of vomiting, >90% of patients eating whatever they desire, and 81.3% experiencing normal gastric emptying (347 (EL 3), 353 (EL 3)). Hypocalcemia and hypoalbuminemia occur less frequently after BPD/DS than after BPD (354 (EL 4)).

In one study, the mean operating time for laparoscopic hand-assisted BPD/DS was 201 min in conjunction with a median hospital stay of 3 days (range, 2–22), no deaths, but seven conversions to open procedures, 14 reoperations, 21 readmissions, three PE, two DVT, and four perioperative proximal anastomotic strictures (355 (EL 3)). Of note, no prospective randomized trials have compared BPD or BPD/DS with RYGB to date.

Brolin et al. (356 (EL 2)) found that, compared with conventional RYGB, a long-limb RYGB (150-cm alimentary tract) yielded more weight loss in patients who were ≥200 lb (90.7 kg) overweight without additional metabolic complications or diarrhea. In the United States (357 (EL 4)), the BPD has been found to be associated with a much greater risk of severe protein–calorie malnutrition than in the series from Italy, which may be explained by a greater fat intake in American patients than in those from northern Italy. The BPD/DS has a lower risk of this complication in Canadian patients (84 (EL 3)). Overall, BPD procedures have been relegated to a less commonly used intervention, primarily attributable to reported risks in the literature.

9.4.3. Laparoscopic vs. Open Bariatric Surgery

Whenever possible—that is, when there is appropriate surgical and institutional expertise available—laparoscopic procedures should be selected over open procedures because of decreased postoperative complications (primarily wound-related), less postoperative pain, better cosmesis, and potentially shorter duration of hospital stay. This approach applies for VBG (56 (EL 2), 358 (EL 2)), LAGB (359 (EL 2)), RYGB (78 (EL 3), 294 (EL 2), 360–367 (EL 2–4)), and BPD/DS (368 (EL 3)). From 1999 to 2004, the percentage of laparoscopic bariatric procedures increased in one center from 10 to 90% (369 (EL 4)) owing to an increased use of bariatric surgery overall, improved technical skills and training, and the aforementioned positive clinical evidence.

9.5. Selection of Surgeon and Institution

In order to adhere to these guidelines, physicians faced with an appropriate candidate for a bariatric surgical procedure ought to be diligent in locating and communicating directly with an expert bariatric surgeon. In bariatric surgery, the complication
rates associated with these procedures are linked to the experience of the surgeon; the critical threshold for minimizing complications occurs at ~100–250 operations (40 (EL 3), 370–372 (EL 3)). Moreover, the bariatric surgeon must be part of a comprehensive team that provides preoperative and postoperative care. In addition, the facility where the surgeon practices must have experience with bariatric patients and a familiarity with routine postoperative care. The Centers of Excellence initiative of the ASMBs and the ACS Bariatric Surgery Centers program offer prospective patients lists of programs that have met the foregoing criteria. Once a surgeon who meets these criteria has been identified, referrals should be made to that surgeon to improve a coordinated, perioperative care plan for future patients. Referring physicians should request specific experience and performance data from the bariatric surgeon regarding the procedure being considered. There are various resources available to locate a suitable bariatric physician on the Internet or by contacting the Surgical Review Corporation, ASMBs, ACS, or TOS.

9.6. Preoperative Management

9.6.1. Endocrine

9.6.1.1. T2DM

The bariatric specialist can expect to see many patients with T2DM, both diagnosed and undiagnosed. Although T2DM has been found to resolve in the overwhelming majority of patients after RYGB (67 (EL 3), 99 (EL 1), 129 (EL 3), 130 (EL 3), 139 (EL 3)), surgical stress can be associated with exacerbation of hyperglycemia in T2DM and “stress hyperglycemia” in nondiabetic patients. Moreover, after bariatric surgery, patients typically receive large volumes of dextrose-containing intravenous fluids and subsequently receive sucrose-containing liquid feedings. In general, achievement of preoperative glycemic control—hemoglobin A1c ≤7%, fasting blood glucose ≤110 mg/dL, and postprandial blood glucose ≤180 mg/dL—represents a realistic “best care” outcome (373 (EL 4), 374 (EL 3), 375 (EL 3)).

Preoperatively, diabetes control may be achieved by numerous measures. Medical nutrition therapy remains a cornerstone in the management of the patient with T2DM. Goals for glycemic control should follow the guidelines outlined by AACE (373 (EL 4)) and the American Diabetes Association (376 (EL 4)). Preoperative glycemic control represented by a hemoglobin A1c value ≤7% has been associated with decreased perioperative infectious complications (373 (EL 4), 377 (EL 3)). Patients with poor glycemic control with use of orally administered medications or who require high doses of insulin preoperatively may require insulin for several days after bariatric surgery.

9.6.1.2. Thyroid

Although functional thyroid disorders are frequently associated with weight fluctuations, they are rarely the sole cause of severe obesity. Routine screening for abnormalities of thyroid function in all obese patients has not been supported by strong evidence. An increased incidence of clinical and subclinical hypothyroidism has been found among obese patients; thus, when thyroid disease is suspected, appropriate laboratory testing is indicated (378–380 (EL 3)). The best test for screening for thyroid dysfunction is an ultrasensitive thyroid-stimulating hormone assay (381 (EL 4)).

9.6.1.3. Lipids

Previously unrecognized lipid abnormalities may be identified and can strengthen the case for medical necessity for bariatric surgery. The only lipid abnormality that may necessitate immediate preoperative intervention is severe hypertriglyceridemia because serum triglyceride concentrations >600 mg/dL are often associated with acute pancreatitis and the chylomicronemia syndrome. Lipid abnormalities should be treated according to the National Cholesterol Education Program Adult Treatment Panel III guidelines (382 (EL 4)) (see http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.htm). Lipid-lowering therapy for LDL cholesterol and triglyceride values that remain above desired goals postoperatively should be continued. BPD and BPD/DS procedures have been associated with lower triglyceride and LDL values (99 (EL 1)). If target levels are reached postoperatively, doses of lipid-lowering agents can be reduced and even discontinued if target levels are maintained.

9.6.2. Cardiology and Hypertension

Current practice guidelines for perioperative cardiovascular evaluation for noncardiac surgical procedures should be used to guide preoperative assessment and management (383 (EL 4), 384 (EL 4)). As previously noted, obesity alone is not a risk factor for postoperative complications (324 (EL 3)); therefore, patients need not routinely undergo preoperative cardiac diagnostic testing. The challenge for the clinician before bariatric surgery is to identify the patient who is at increased perioperative cardiovascular risk, judiciously perform supplemental preoperative evaluations, and manage the perioperative risk. Several indices of risk and algorithms can be used as a guideline (383 (EL 4), 385 (EL 2)).

The patient with poor functional capacity, expressed as unable to meet 4-MET (metabolic equivalent) demand during most normal daily activities (such as climbing a flight of stairs, walking on level ground at 4 mph, or doing heavy work around the house), presents a particular challenge because it is important to distinguish between deconditioning with some expected dyspnea and underlying cardiac disease. Exercise capacity and cardiac risk factor analysis will determine whether formal testing beyond electrocardiography is required. An abdominal operation is an intermediate-risk procedure, and diabetes is an intermediate clinical predictor of cardiac risk. Poor exercise capacity may determine whether patients with intermediate predictors require pharmacologic stress testing. Testing considerations specific to patients with class 3 obesity include electrocardiographic changes related to chest wall thickness and lead placement, inability to increase physical activity to target (386 (EL 4)), and a body weight too heavy for the equipment. Similarly, both dual isotope scanning and dobutamine stress echocardiography may be challenging. In this population of patients with symptomatic
angina, dobutamine stress echocardiography is a particularly useful diagnostic test because of its high sensitivity and specificity (387 (EL 1)), no need for treadmill running, and ability to image heart size and valves. Patients with known cardiac disease should have a cardiology consultation before bariatric surgery. Those patients who do not have active disease but are nonetheless at higher risk should be considered for prophylactic β-adrenergic blockade (388 (EL 1)). If CAD is documented with dual isotope scanning, these patients are often considered too obese to undergo either coronary artery bypass grafting or stent placement. Obese patients with clinically significant CAD should undergo aggressive weight loss with a very-low-calorie diet until they achieve a weight at which they can receive appropriate cardiac intervention.

Uncontrolled hypertension may increase the risk for perioperative ischemic events. Blood pressure levels >180/110 mm Hg should be controlled before bariatric surgery is performed. Because bariatric surgery is considered an elective operation, control should be achieved during a period of several days to weeks of outpatient treatment (389 (EL 4)).

9.6.3. Pulmonary and Sleep Apnea
Risk factors for postoperative pulmonary complications include chronic obstructive pulmonary disease, age >60 years, functional dependence, OHS, congestive heart failure, and American Society of Anesthesiologists class II or greater (390 (EL 4)). Surgical risk factors pertinent to the bariatric patient include an abdominal surgical procedure and duration of operation >3 h. Laparoscopic techniques may decrease the risk by causing less pain and disruption of diaphragmatic muscle activity and were found to be associated with improved postoperative pulmonary function (391 (EL 3), 392 (EL 4)). Although obesity is associated with abnormal respiratory function (for example, decreased lung volumes and reduced compliance), obesity alone has not been identified as a risk for increased postoperative pulmonary complications (393 (EL 1)). Available data are mixed regarding cigarette smoking, but patients should be advised to stop smoking at least 8 weeks before the elective operation in order to decrease the risk of pulmonary complications (394 (EL 3), 395 (EL 3)).

Even though preoperative chest radiographs and spirometry should not be used routinely for predicting risk, the extent of preoperative pulmonary evaluation varies by institution. Chest radiographs are often recommended for all patients, but the yield in patients without pulmonary signs or symptoms is very small. Routine preoperative chest radiographs are reasonable in all obese patients because of the increased risk of obesity-related pulmonary complications (331 (EL 4)). In patients in whom intrinsic lung disease is not suspected, routine arterial blood gas measurement and pulmonary function testing are not indicated (392 (EL 4)). Preoperative education in lung expansion maneuvers reduces pulmonary complications.

OSA may be present in as many as 50% of men with class 3 obesity. In general, women tend to develop OSA at a higher BMI than men. Loud snoring is suggestive, but symptoms generally are poor predictors of the apnea–hypopnea index.

A presumptive diagnosis of OSA may be made on the basis of consideration of the following criteria: increased BMI, increased neck circumference, snoring, daytime hypersomnolence, and tonsillar hypertrophy (325 (EL 4)). Because OSA is associated with airway characteristics that may predispose to difficulties in perioperative airway management, these patients should be referred for diagnostic polysomnography preoperatively and treated with nasal CPAP. In the absence of OSA or the OHS, routine performance of a sleep study may not be necessary because this will not alter care. For patients in whom OSA is diagnosed or suspected, postoperative cardiac and pulmonary monitoring, including continuous digital oximetry and use of CPAP postoperatively, is prudent. If prolonged apneas and hypoxemia are noted in patients without evidence of OSA preoperatively, such patients should be treated with nasal CPAP in the perioperative period.

9.6.4. Venous Thromboembolism
Obesity and general surgery are risk factors for venous thromboembolism. Thus, patients undergoing bariatric surgery are considered generally to be at moderate risk for lower extremity DVT and PE (396 (EL 4)). PE may be the first manifestation of venous thromboembolism and is the leading cause of mortality in experienced bariatric surgery centers (397 (EL 4)). Unfractionated heparin, 5,000 IU subcutaneously, or low-molecular-weight heparin therapy should be initiated shortly (within 30–120 min) before bariatric surgery and repeated every 8–12 h postoperatively until the patient is fully mobile (398 (EL 4)). Alternatively, administration of heparin shortly after the operation as opposed to preoperatively may be associated with a lower risk of perioperative bleeding. Whether such patients benefit from a higher dose of low-molecular-weight heparin has not been determined. Most centers combine anticoagulant prophylaxis with mechanical methods of prophylaxis (for example, intermittent pneumatic lower extremity compression devices) to increase venous outflow or reduce stasis (or both) within the leg veins. Preoperative placement of a vena cava filter should also be considered for patients with a history of prior PE or DVT, although randomized trials to support this action are lacking (397 (EL 4), 399 (EL 4), 400 (EL 3), 401 (EL 3)).

9.6.5. Gastrointestinal
Undiagnosed gastrointestinal symptoms must be evaluated before bariatric surgery. It is commonplace for surgeons to perform a routine UGI study or endoscopy to screen for peptic ulcer disease before many other types of surgical procedures; however, this practice has been questioned for bariatric surgery (402 (EL 3)). Some programs now use an H. pylori antibody as a screening procedure (330 (EL 4)). The incidence of H. pylori seropositivity preoperatively ranges from 11 to 41% (327 (EL 3), 329 (EL 3), 403 (EL 2), 404 (EL 2), 405 (EL 3)), which supports a recommendation for preoperative screening, although Yang et al. (403 (EL 2)) asserted that gastric ulcers after VBG or RYGB are due to the surgical procedure itself and not the H. pylori infection. Patients with positive results are empirically treated with proton pump inhibitors and antibiotics. Whether this
In conjunction with normal or increased 1,25-(OH)\textsubscript{2}D because of the compensatory stimulatory effect of PTH on renal 1α-hydroxylase activity (413 (EL 3)).

Preoperative dual-energy X-ray absorptiometry of the lumbar spine and hip should be performed in all estrogen-deficient women as well as in premenopausal women and men with conditions associated with low bone mass or bone loss (415 (EL 4)). The incidence of low bone mass in obese men and obese premenopausal women without risk factors, however, may be sufficiently low as to militate against baseline bone densitometry in these persons. A thorough work-up for secondary causes of low bone mass is imperative for such patients before bariatric surgery. Thus, preoperative biochemical screening with intact PTH, vitamin D metabolites, and markers of bone metabolism may be helpful in patients at increased risk for metabolic bone disease.

9.7. Final Clearance

Final clearance to proceed with bariatric surgery is usually provided by the surgeon who will perform the surgical procedure. At this time, medical need has been established, no medical or psychologic contraindications have been identified, medical comorbidities are well controlled, and the patient has expressed good understanding and commitment to the intervention planned.


It is generally recommended that patients learn about their insurance coverage for bariatric procedures by contacting their third-party payers before pursuing bariatric surgery. This important factor is to ensure that they are well informed regarding what services are covered and what requirements exist for approval that may be unique to their provider. Most bariatric programs are well informed regarding specific requirements of most major providers; however, this is a fast changing field. For most third-party payers, prior authorization is required. Medicare is the only provider that will not grant prior authorization for bariatric surgery but will base its decision to cover the services on medical necessity at institutions designated as Centers of Excellence by the Surgical Review Corporation or the ACS. Medicare has decided in a National Coverage Decision that bariatric surgery is appropriate for beneficiaries who have a BMI of ≥35 kg/m\textsuperscript{2} and a comorbidity, without an age limit, if previous attempts at nutritional management have failed. This information is available online at http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=160.

Requesting prior written authorization for bariatric surgery necessitates the fulfillment of several criteria. Most third-party payers require the following:

- A letter stating current height, weight, and BMI
- Documentation of medical necessity, outlining weight-related comorbidities present
- Clinical documentation from a registered dietitian, primary care provider, or medical subspecialist, psychologist or psychiatrist, and surgeon indicating the absence of

Many obese patients will have asymptomatic increases in serum alanine aminotransferase and aspartate aminotransferase levels. These changes are most commonly associated with NAFLD. At the time of bariatric surgery, 84% of severely obese subjects have steatosis on liver biopsy specimens (218 (EL 3)), whereas 20 and 8% have inflammation and fibrosis, respectively. Weight loss after LAGB, RYGB, BPD, or BPD/DS leads to regression of steatosis and inflammation, including decreased bridging fibrosis in some patients (148 (EL 3), 220 (EL 4), 222–230 (EL 2–3)). The clinical challenge is to determine which patients require additional evaluation before bariatric surgery. Gallstones, chronic hepatitis B or C, alcohol use, and potential side effects of medications (such as acetaminophen, nonsteroidal anti-inflammatory drugs, and clopidogrel) are among some of the more common offenders. Patients with substantial increases in liver function test results (generally, 2–3 times the upper limit of normal) should be considered for additional testing by hepatobiliary ultrasonography or CT and a hepatitis screen preceding bariatric surgery (406 (EL 4)). Patients with advanced cirrhosis and increased portal pressures face major perioperative risks. Patients with mild to moderate cirrhosis may benefit from bariatric surgery and have an acceptable risk of complications (407 (EL 3)). If cirrhosis is suspected, preoperative endoscopy should be undertaken to rule out esophageal or gastric varices and portal hypertension gastropathy. Surgery-induced weight loss allows subsequent liver transplantation (225 (EL 3)). Alternatively, liver transplant patients may undergo successful bariatric surgery (408 (EL 3)).

9.6.6. Rheumatologic and Metabolic Bone Disease

Obese patients with a BMI >40 kg/m\textsuperscript{2} are at greater risk for osteoarthritis, progression of arthritis, and gout, which can decrease with weight loss (259 (EL 4)). After bariatric surgery, hip and knee pain may diminish in conjunction with an increased exercise capacity (264 (EL 3), 266 (EL 3), 268 (EL 2), 409 (EL 3)). Moreover, serum uric acid levels decrease (410 (EL 3)). Nevertheless, if nonsteroidal anti-inflammatory drugs are needed, cyclooxygenase-2 inhibitors should be used, although this recommendation has not been tested in bariatric surgery patients. Gout was found to be precipitated during weight loss after intestinal bypass (411 (EL 3)), just as a surgical procedure itself is a risk factor for an acute gout attack. Therefore, patients with frequent attacks of gout should have prophylactic therapy started well in advance of bariatric surgery to lessen the chance of acute gout immediately postoperatively.

Obese persons have higher bone mass despite the common presence of secondary hyperparathyroidism due to vitamin D deficiency (412 (EL 3), 413 (EL 3)). The increased PTH levels are positively correlated with BMI in obese patients owing to (i) decreased exposure to sunlight with a more sedentary lifestyle (414 (EL 3)) or (ii) PTH resistance of bone due to increased skeletal mass (413 (EL 3)) or both of these factors. The frequency of secondary hyperparathyroidism preoperatively is ~25% (413 (EL 3)). Typically, there are decreased serum levels of 25-OHD treatment reduces the incidence of postoperative ulceration or is cost-effective has not been determined.
contraindications to bariatric surgery, and signed informed consent regarding the risks and benefits of the procedure planned.

- Documentation of previous weight-loss attempts

In comparison with previously, many third-party payers are currently requiring more detailed documentation of previous weight-loss efforts with required medical supervision and detailed weigh-ins. Others require participation in a 6- to 12-month medically supervised weight-loss program before consideration. There are no published studies supporting the value of this approach, and one study noted an increased dropout rate among patients in whom a 6-month period of physician-directed nutritional management was required by a health insurance carrier (52 (EL 3)). It is important to encourage patients who are seeking bariatric surgery to become well informed regarding the requirements of their individual insurance policy to avoid misunderstandings or unnecessary delays.

9.9. Early Postoperative Management

The management of the obese patient after bariatric surgery can present numerous challenges. It involves the prevention of and monitoring for postoperative complications, management of preexisting medical conditions, and guidance of patients through the transition of life after bariatric surgery.

Improved expertise in the perioperative management of the obese patient has allowed centers to transfer services previously available only in an ICU to less critical settings. No consensus exists about which type of patient should be considered for admission to the ICU after bariatric surgery (330 (EL 4), 416 (EL 4), 417 (EL 4)).

9.9.1. Monitoring for Surgical Complications

Anastomotic leak is a potentially fatal complication after bariatric surgery. It is reported to occur in up to 5% of RYGB procedures, but recent attempts to identify and correct leaks intraoperatively have been shown to reduce the postoperative incidence to 0% (418–423 (EL 2–3)). Symptoms can be subtle and difficult to distinguish from other postoperative complications such as PE. A high degree of suspicion is necessary. Tachycardia (pulse rate >120 beats/min) in the setting of new or worsening abdominal symptoms should prompt immediate evaluation. Another clue may be an increasing ratio of blood urea nitrogen to creatinine in the absence of oliguria. Left shoulder pain may be a worrisome symptom after RYGB, BPD, or BPD/DS. If an anastomotic leak is unrecognized, oliguria, sepsis with multiorgan failure, and death can ensue (108 (EL 4), 399 (EL 4), 416 (EL 4), 417 (EL 4), 424 (EL 2)).

Evaluation is guided by the clinical presentation. If the patient is clinically stable, radiologic tests such as Gastrografin studies can be performed, although they are helpful only if a leak is identified. Indeed, the false-negative rate exceeds 4%. For identification of leaks from the excluded stomach, CT scanning may be preferable to UGI contrast swallow studies. In the setting of a negative study but a high index of suspicion or a clinically unstable patient, exploratory laparoscopy or laparotomy is indicated (19 (EL 4), 399 (EL 4), 416 (EL 4), 417 (EL 4), 425 (EL 3), 426 (EL 3)). Several authors have proposed performing a limited UGI contrast study to examine the anastomosis and identify subclinical leaks before discharge of the patient from the hospital, but this practice is not universally accepted and does not appear to be cost-effective (417 (EL 4), 427 (EL 4), 428 (EL 3)). Identification of a leak usually necessitates emergent surgical reexploration, either laparoscopically or with an open procedure. Occasionally, a patient can be managed expectantly or with percutaneous drainage; however, the signs and symptoms of sepsis must resolve promptly and completely, and there should be a low threshold for reexploration.

Wound complications after open bariatric surgery are common, and their incidence is significantly diminished by a laparoscopic approach (399 (EL 4), 429 (EL 4)). Procedures with large vertical incisions are associated with a high incidence of seromas (330 (EL 4), 429 (EL 4)). Although seromas often drain spontaneously, removal of excess fluid is recommended to decrease the risks for major wound infections (330 (EL 4), 427 (EL 4), 429 (EL 4)). For treatment of wound infections, aggressive management, with incision and drainage and orally administered antibiotics, is important. Partial opening of the incision in several locations is usually necessary for adequate drainage of a subcutaneous infection. Efforts should be made to avoid opening the entire incision because healing may require several months. In contrast, if segmental drainage is ineffective, then that approach must be abandoned. Healing occurs by secondary intention and can often take weeks to months (330 (EL 4), 427 (EL 4)). As in all abdominal surgical procedures, the patient should be given a broad-spectrum cephalosporin immediately before the incision and continued for up to 24-h postoperatively (430 (EL 4), 431 (EL 4)). Wound dehiscence occurs most frequently in the setting of a wound or subcutaneous infection; however, the increased tension exerted on the wound by excess weight can itself lead to dehiscence. Some surgeons have modified their approach at reinforcing suture lines to avoid this complication (330 (EL 4)). Major wound infections are extremely rare with laparoscopic procedures (57 (EL 3), 62 (EL 2), 294 (EL 2), 365 (EL 3)).

Prophylactic antibiotics that cover skin organisms should be administered at the time of LAGB to prevent wound infection at the adjustment port site. Any hint of infection at this site necessitates immediate and aggressive treatment so that sepsis, reservoir removal, and peritoneal cavity adjustment tubing placement can be avoided. The band itself would not need to be removed. When sepsis has resolved, the tubing can be recovered laparoscopically, and a new adjustment reservoir can be attached.

9.9.2. T2DM

Patients requiring insulin before bariatric surgery should have their blood glucose concentrations monitored regularly and insulin administered to control significant hyperglycemia. In the ICU, euglycemia can be maintained with a nurse-driven, dynamic intensive insulin therapy protocol targeting a blood glucose level of 80–110 mg/dl (432 (EL 1), 433 (EL 1)). In non-ICU patients, target glycemic control is accomplished with subcutaneously administered insulin: “basal” insulinization
with intermediate-acting NPH insulin or long-acting insulin glargine or insulin detemir; “bolus” preprandial insulinization with rapid-acting insulin aspart, glulisine, or lispro; and “correction” insulin every 3–6 h also with a rapid-acting insulin (434 (EL 2)). In the non-ICU setting, the evidence for target blood glucose values of 80–110 mg/dl (preprandially) and <180 mg/dl peak (postprandially) is provided in the 2007 AACE Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus (373 (EL 4)) and the 2004 American College of Endocrinology Position Statement on Inpatient Diabetes and Metabolic Control (435 (EL 4)).

The surgeon and floor nurses should be familiar with glycemic targets and subcutaneous insulin protocols as well as the use of dextrose-free intravenous fluids and low-sugar liquid supplements. Parameters for initiating intravenous insulin therapy and requesting an endocrine consultation should be explicitly discussed. Because of the risks of stress hyperglycemia, prediabetic patients (those patients with fasting blood glucose levels of 100–125 mg/dl or 2-h postprandial glucose challenge blood glucose levels of 140–199 mg/dl) and even patients without any evidence of impaired glucose regulation should be treated with the same insulin protocols as those with established T2DM.

Patients should be instructed in regular monitoring of metered blood glucose concentrations to guide adjustments in glucose-lowering therapy. In patients with persistent hyperglycemia, continued surveillance and preventive care as recommended by AACE (373 (EL 4)) and the American Diabetes Association (376 (EL 4)) are advised. If euglycemia is achieved, it is unclear whether current recommendations for the preventive care of patients with T2DM should be continued.

It is important to note that a small number of patients with type 1 diabetes mellitus (T1DM) are obese and require insulin for survival. In those who present for bariatric surgery, the diagnosis of T1DM vs. T2DM may not be entirely clear at the time of surgery. Therefore, it is recommended that insulin be withdrawn cautiously and that blood glucose concentrations be reported to a health-care provider at frequent intervals after discharge of the patient from the hospital so that adjustments can be made in the event of inadequate blood glucose control (436 (EL 4)). Obese patients with T1DM will also have a decrease in insulin requirements after bariatric surgery. It needs to be emphasized that all patients with T1DM must have insulin onboard at all times to prevent diabetic ketoacidosis. Accordingly, intermediate- or long-acting insulin should be dosed even when patients with T1DM are not receiving any dextrose or nutrition.

9.9.3. Cardiology and Hypertension

Despite the increased prevalence of cardiac risk factors in patients undergoing bariatric surgery, the incidence of cardiac ischemic events is surprisingly low. This disparity is primarily attributed to the relatively young age of patients who undergo this intervention—overall mean age of 37.5 ± 0.63 years (437 (EL 3)) and for the 57% with at least one metabolic CAD risk factor (438 (EL 3)), mean age of 38.1–40.3 years. Several investigators have reported significant improvements of various cardiovascular risk factors after bariatric surgical procedures (104 (EL 3), 140 (EL 4), 184 (EL 3), 188 (EL 2), 190 (EL 3), 194 (EL 3), 439–442 (EL 3)). Patients with known CAD and low perioperative risks on the basis of the Goldman cardiac risk index who have undergone bariatric surgery do not experience an increase in mortality when compared with obese adults without a history of CAD. A trend toward increased cardiac events (3 vs. 0) was noted but did not reach statistical significance (443 (EL 3)). Diastolic dysfunction may be present as a result of myocardial hypertrophy, decreased compliance, and increased systemic arterial pressure from obesity and can increase the risks for perioperative complications (202 (EL 2), 416 (EL 4), 444 (EL 4), 445 (EL 3)). In seven published reports, the mortality for patients who had undergone bariatric surgery was significantly less than for patients who had not lost weight. Moreover, several reports have noted a significant decrease in mortality after bariatric surgery in comparison with that in matched nonsurgical cohorts, which has been related to a significant decrease in deaths related to MI as well as a decrease in deaths from cancer and diabetes (39 (EL 3), 65 (EL 3), 151–153 (EL 3), 154 (EL 2), 155 (EL 3)).

Patients with known or presumed CAD may be managed best in an ICU setting for the first 24–48 h after bariatric surgery (330 (EL 4), 416 (EL 4), 417 (EL 4)). Medications used in the management of CAD or hypertension can be administered parenterally while the patient remains without oral intake. This approach is especially important for β-adrenergic blocking agents because their abrupt discontinuation can be associated with increased risks for cardiac complications. If a patient is not taking a β-adrenergic blocking agent, therapy with this medication can often be initiated in an attempt to provide additional cardioprotection perioperatively (383 (EL 4)).

Initiation of orally administered medications for the management of CAD and hypertension should be pursued as soon as the patient is able to tolerate liquids orally. Changes in drug preparations may be required, particularly in patients with gastric restrictive procedures, as a result of intolerance of tablets. The majority of patients who received antihypertensive medications before bariatric surgery will still require them at discharge from the hospital for adequate control of blood pressure values. Diuretics should be either discontinued or reduced to avoid dehydration and electrolyte abnormalities during the first month or two postoperatively; they can be initiated again if hypertension persists.

9.9.4. Pulmonary

Obesity increases the risk for respiratory complications after an abdominal operation: pneumonia, atelectasis, respiratory failure (intubation beyond 24-h postoperatively or reintubation), and PE. These complications constitute the most serious nonsurgical perioperative events. They are more frequent than cardiac complications in patients undergoing abdominal surgical procedures (446 (EL 2)), and all efforts must be made to identify and minimize the risk (447 (EL 3), 448 (EL 4), 449 (EL 4)). Prolonged mechanical ventilation with an extended weaning period may be necessary for patients with OHS, a
situation that increases the risks for aspiration and pneumonia. Hypoxemia and apneic episodes are frequently observed in the sedated patient with or without a preexisting diagnosis of OSA or OHS. Atelectasis remains a common cause of fever and tachycardia during the first 24 h after bariatric surgery (399 (EL 4), 417 (EL 4)).

Pulmonary management after bariatric surgery includes aggressive pulmonary toilet and incentive spirometry for the prevention of atelectasis (416 (EL 4), 450 (EL 3)). Oxygen supplementation and early institution of nasal CPAP improve respiratory function in this patient population (447 (EL 3), 451 (EL 2)). A review of the literature suggests that nasal CPAP can be used safely after RYGB in patients with sleep apnea without increasing the risk of a postoperative anastomotic leak; in contrast, the use of bilevel positive airway pressure may increase the risk of anastomotic leaks (452 (EL 3)).

Respiratory distress or failure to wean from ventilatory support should alert the physician to the possibility of an acute postoperative complication, such as a PE or an anastomotic leak. A high level of suspicion is critical because symptoms may be subtle, such as new-onset tachycardia or tachypnea (399 (EL 4), 416 (EL 4), 417 (EL 4), 453 (EL 4)).

The incidence of PE in patients who have undergone bariatric surgical procedures has been reported as 0.1–2% (399 (EL 4), 416 (EL 4), 417 (EL 4), 453 (EL 4)). After bariatric surgery, PE is one of the most common causes of mortality (39 (EL 3), 454 (EL 2)). Obesity, lower extremity venous status, high pulmonary artery pressures, hypercoagulation, and immobilization contribute to the increased risk observed in this patient population (399 (EL 4), 416 (EL 4), 417 (EL 4), 453 (EL 4)). The use of thin-cut, thoracic spiral CT has improved the diagnosis of PE because of superior sensitivity and specificity in comparison with ventilation–perfusion scans (455 (EL 4)).

Treatment of PE after bariatric surgery should follow currently accepted guidelines. Thrombolytic agents should be avoided during the first 10–14 days postoperatively. Anticoagulation can be pursued within days after surgery, with rapid achievement of therapeutic levels within 24 h after initiation of therapy (399 (EL 4), 416 (EL 4), 417 (EL 4), 453 (EL 4)).

Prophylaxis against DVT is an important component of the perioperative management after bariatric surgery; however, there is no consensus about a specific regimen. Most accepted regimens include a combination of sequential compression devices and subcutaneously administered unfractionated heparin or low-molecular-weight heparin before and after bariatric surgery (456 (EL 3), 457 (EL 2)). Clear evidence that preoperative heparin therapy is superior to postoperative administration is lacking. Early ambulation remains important in the prevention of DVT (399 (EL 4), 416 (EL 4), 417 (EL 4), 458 (EL 3)). Prophylactic placement of an inferior vena cava filter has been proposed, but not universally accepted, for the subgroup of patients with high mortality risk after PE or DVT, patients with known elevated pulmonary artery pressures > 40 mm Hg, or those with hypercoagulable states (176 (EL 3), 399 (EL 4), 401 (EL 3), 453 (EL 4), 459 (EL 3)).

9.9.5. Fluids and Electrolytes
The management of perioperative fluid and electrolytes follows currently accepted practices. Such management should be modified on the basis of the patient’s medical history. Current practices monitor urine output, attempt to maintain a urine output of 30 ml/h or 240 ml per 8-h shift, and avoid volume overload. Renal failure can occur after bariatric surgery if patients have received inadequate volume replacement. Perioperative fluid requirements for patients after bariatric surgery are substantially greater than for their nonobese counterparts.

9.9.6. Anemia
Decreases in hemoglobin in the early postoperative period are not uncommon. In the absence of any nutritional deficiencies (iron, folate, vitamin B₁₂), these decreased hemoglobin values should resolve by 12 weeks postoperatively. Persistent abnormalities should prompt further evaluation to identify potential complications, such as nutritional deficiencies or unrecognized blood loss.

9.9.7. Rhabdomyolysis
Nonphysiologic surgical positioning during laparoscopic bariatric surgery has been associated with rhabdomyolysis. This condition is thought to be due to the presence of certain risk factors, such as prolonged muscle compression, muscle-compartment syndrome, and crush syndrome in superobese patients with a long duration of the operation, especially when they have peripheral vascular disease, diabetes, or hypertension. Mognol et al. (460 (EL 3)) screened 66 consecutive patients undergoing LAGB or laparoscopic RYGB with CK levels on postoperative days 1 and 3. They found a 23% incidence of chemical rhabdomyolysis (CK > 1,050 U/l)—in 3 of 50 patients (6%) with gastric banding and in 12 of 16 (75%) with gastric bypass (P < 0.01) (460 (EL 3)). Clinically significant rhabdomyolysis, however, rarely occurs; no patient in this series had acute renal failure. Thus, prophylactic measures in high-risk patients include the following: (i) use of a staged procedure with shorter operative times (for example, sleeve gastrectomy as a first stage in patients with superobesity or super-superobesity), (ii) adequate padding at all pressure points, (iii) postoperative screening with CK levels on days 1 and 3, and (iv) aggressive fluid replacement (76 (EL 3), 461 (EL 3)). At the present time, there are insufficient data to recommend CK screening routinely or even prophylactic measures in high-risk patients, although such measures may be considered on a case-by-case basis by the bariatric surgery team. If rhabdomyolysis is suspected, however, then CK levels should be assessed.

9.9.8. Oral Nutrition
After LAGB, patients should sip fluids when fully awake and can be discharged from the hospital only if satisfactorily tolerating fluids orally. Occasionally, edema and tissue within a recently placed adjustable gastric band cause obstruction. This problem usually resolves spontaneously during a period of days, but continued intravenous administration of fluids is needed. Currently,
however, this problem is rare because several sizes of bands are available and the surgeon can choose an appropriate size at the time of surgical intervention.

Historically, a nasogastric tube has been placed after open RYGB (but not after laparoscopic procedures) and has been removed on the first or second postoperative day. This practice, however, has been demonstrated to be unnecessary (462 (EL 3), 463 (EL 3)). Oral intake with ice chips and sips of water is generally started after removal of the nasogastric tube. Once tolerated, clear liquids are started, and intravenous administration of fluids is discontinued. Clear liquids are usually begun the morning after all bariatric surgical procedures. Although most centers have individual protocols for meal progression after bariatric surgery, particularly after gastric restrictive procedures, most centers follow the same general guidelines, which involve gradual progression of food consistencies over weeks and months (330 (EL 4), 417 (EL 4), 464 (EL 3)). Gradual progression of food consistencies allows the patient to adjust to a restrictive meal plan and minimizes vomiting, which can threaten the integrity of the anastomosis (330 (EL 4)).

9.10. Late Postoperative Management
Continuity of care after bariatric surgery is vital to ensure long-term success (330 (EL 4), 465 (EL 3)). This continuity serves to monitor weight loss, assess the status of preexisting medical conditions, monitor for surgical and nutritional complications, and provide guidance and support as patients pursue lifestyle changes. Many patients have maladaptive eating behaviors, nutritional deficiencies, or other nutritional inadequacies preoperatively, which may persist after a bariatric procedure. Some patients who underwent VBG were noted to develop maladaptive eating behaviors because sweets and ice cream would pass through their restriction without difficulty. For patients with the LAGB procedure, this challenge can be managed by adjusting the band along with continued nutritional counseling (156 (EL 2), 466 (EL 3)). In a review of prospectively collected data involving patients undergoing an LAGB procedure, EBW loss was comparable between those who ate sweets and those who did not (467 (EL 3)). In general, the bariatric surgery patient should adhere to recommendations for a healthful lifestyle, including increased consumption of fresh fruits and vegetables, limitation of foods high in saturated fats, reduction of stress, and participation in exercise ≥30 min a day to achieve optimal body weight. Increased physical activity was found to improve body composition in bariatric surgery patients, as measured by bioelectrical impedance analysis (468 (EL 3)).

Knowledge and experience are needed for appropriate LAGB adjustment. During the first postoperative year, regular consultations for advice and adjustments are critical in providing good weight loss (469 (EL 3)). Patients need to have follow-up visits every 2–4 weeks until a satisfactorily stable optimal zone adjustment level is achieved (470 (EL 4), 471 (EL 3)). Patients with LAGB should have follow-up examinations every year indefinitely. There is a slow diffusion from all bands, which will cause a gradual reduction in restriction over many months to years (472 (EL 3)). Adjustments for special circumstances, including major surgical procedures, intercurrent illness, pregnancy, and remote travel, can be beneficial (243 (EL 2), 470 (EL 4)).

The frequency of follow-up visits proposed varies among surgeons. Most surgeons agree on the need for frequent visits during the first year after bariatric surgery when rapid changes are occurring, usually within 2 weeks after surgery, at 6 months, and at 12 months postoperatively. After the first year, despite the absence of clinically evident complications, annual follow-up visits should always be encouraged, even after intestinal adaptation has occurred (140 (EL 4), 330 (EL 4)). The outcomes that should be evaluated routinely include initial weight loss, maintenance of weight loss, nutritional status including micronutrient blood levels, comorbidities, and psychosocial status (331 (EL 4)).

Typically, the perioperative management of the bariatric surgery patient is multidisciplinary, and patients can be overwhelmed with the magnitude of postoperative follow-up visits and the number of physicians including covering physicians as well as physician-extenders and nutritionists. The bariatric surgeon, the obesity specialist, and the team's registered dietitian generally function as the primary caregivers postoperatively. Patients may need regular follow-up with various consultants for active problems, but these visits should be monitored and coordinated by the primary team to avoid excessive ordering of tests. Mental health professionals should be available to help patients adjust to the myriad of psychosocial changes they experience postoperatively. Some published data show an increased risk of suicide after RYG, BPD, or BPD/DS (154 (EL 2)). Depression can diminish during the first year after LAGB-induced weight loss (473 (EL 3)). Regardless of the bariatric procedure, psychiatric counseling can benefit all bariatric surgery patients.

Late surgical complications include anastomotic stricture, staple-line dehiscence, pouch dilation, internal hernia in conjunction with intestinal obstruction (complete or partial), anastomotic leaks, and incisional hernias (10–20%) (399 (EL 4), 427 (EL 4)). An internal hernia after RYG, BPD, or BPD/DS is a potentially fatal complication attributable to bowel infarction and peritonitis. The symptoms are those of a small bowel obstruction with cramping pain, usually periumbilical. An internal hernia can occur at three locations: at the jejunojunostomy, through the mesocolon, or between the Roux limb mesentery, the mesocolon, and the retroperitoneum (Petersen hernia). Diagnosis may be obtained with a Gastrografin UGI study or abdominal CT; however, as with a leak, these studies are often misleading (399 (EL 4)). The best course of management is often an exploratory laparotomy or laparoscopy for recurrent cramping abdominal pain.

The restrictive component of gastric bypass surgery involves partitioning of the stomach to create a small reservoir. In-continuity RYG without transection has been associated with staple-line failure (474 (EL 3), 475 (EL 3)) and a stomal ulceration rate of up to 16% (475 (EL 3), 476 (EL 3)). Staple-line disruption and gastrogastric fistulas can also occur after gastric transection and increase the risk of marginal ulceration (475 (EL 3), 477 (EL 3)). More recent
stapling techniques, however, only rarely result in staple-line failure, although no clear guidance regarding the optimal stapling method is available.

9.10.1. Goals for Weight Loss and Nutritional Prescription
The methods for reporting weight outcomes have varied over the years. Currently, changes in BMI, weight loss as percent of EBW, and weight loss as percent of initial weight are the most common methods. There is no consensus on the definition of minimal weight loss to justify the operative risk, nor is there consensus on the minimal duration of maintenance of weight loss. Some investigators have defined success after bariatric surgery as the loss of at least 50% of EBW (478 (EL 4), 479 (EL 4)). Most agree that clinically useful weight loss outcomes should be reported with a minimal follow-up of 3–5 years and with at least 80% retention (continued follow-up). Most surgical procedures performed today, with the exception of some restrictive operations, have been reported to lead to this degree of weight loss in a majority of patients (70 (EL 2), 89 (EL 3), 122 (EL 3), 330 (EL 4), 341 (EL 3), 345 (EL 2), 429 (EL 4), 453 (EL 4), 477 (EL 3), 480 (EL 2), 481–483 (EL 2), 484 (EL 4), 485–487 (EL 2)). Malabsorptive procedures, such as the long-limb or very, very long-limb RYGB and the BPD or BPD/DS, have yielded the greatest percentage of weight loss reported (72 (EL 3), 335 (EL 3), 484 (EL 4), 488–490 (EL 3)). Success, however, should probably be related to factors other than mere weight loss, such as improvement or resolution of comorbidities, decreased mortality, enhanced quality of life, and positive psychosocial changes.

Weight loss after bariatric surgery can be dramatic. The fastest rate of weight loss occurs during the first 3 months postoperatively, when dietary intake remains very restrictive (70 (EL 2), 429 (EL 4), 464 (EL 3), 491 (EL 4), 492 (EL 4)). After malabsorptive procedures, patients can lose 0.5–1 lb (0.23–0.45 kg) per day or 40–90 lb (18–40.5 kg) by 3 months postoperatively. This rapid weight loss decreases by 6–9 months after bariatric surgery, and the peak in weight loss is achieved at 12–18 months after the procedure (64 (EL 3), 429 (EL 4), 330 (EL 4)). After LAGB, a weight loss of 2.5 lb (1.13 kg) per week is advised. Hypometabolism is common during the first 6 months after bariatric surgery. Cold intolerance, hair loss, and fatigue are common complaints, which tend to diminish as weight loss stabilizes. Reassurance and support are often all that is necessary.

Inadequate weight loss after bariatric surgery may be observed after nonadjustable gastric restriction procedures (namely, VBG) attributable to loss of integrity of the gastric remnant and development of maladaptive eating behaviors (increased caloric intake or increased consumption of calorically dense foods) (48 (EL 4), 117 (EL 4), 278 (EL 3), 453 (EL 4), 466 (EL 3), 493 (EL 4)). Clinical assessment then involves (i) evaluation of current eating practices, (ii) psychologic evaluation, and (iii) imaging studies of the UGI tract (417 (EL 4), 494 (EL 3)).

Some recidivism is also observed 3–5 years after RYGB, although long-term weight maintenance is greater than that reported with purely gastric restrictive procedures (64 (EL 3), 330 (EL 4), 453 (EL 4), 466 (EL 3), 477 (EL 3)). Contributing factors to weight regain after RYGB have not been well studied but are influenced by the decrease in frequency of dumping symptoms, resolution of food intolerances, and return to preoperative eating and other lifestyle patterns that originally contributed to the development of obesity (278 (EL 3), 417 (EL 4), 453 (EL 4), 492 (EL 4)). Reported weight maintenance after BPD or BPD/DS appears to be superior to that after gastric restrictive procedures and RYGB because weight loss is predominantly attributable to malabsorption and not caloric restriction; however, this observation has never been subjected to a randomized, prospective trial (335 (EL 3), 495 (EL 3)).

9.10.2. Routine Metabolic and Nutritional Management
9.10.2.1. General statements
The extent of metabolic and nutritional evaluation completed after bariatric surgery should be guided by the type of surgical procedure performed. Purely gastric restrictive procedures are not associated with alterations in intestinal continuity and do not alter normal digestive physiologic processes. As a result, selective nutritional deficiencies are uncommon. The anatomic changes imposed by malabsorptive surgical procedures increase the risk for various nutrient deficiencies, which can occur commonly within the first year postoperatively (327 (EL 3), 417 (EL 4), 495 (EL 3), 496–499 (EL 3), 500 (EL 1)). Routine laboratory surveillance for nutritional deficiencies is recommended after LAGB, RYGB, BPD, or BPD/DS procedures (Table 13), even in the absence of caloric or nutritional restriction, vomiting, or diarrhea.

For surgical procedures with a gastric restrictive component, regular visits with a registered dietitian provide guidance as the meal plan is progressed. The limited volume capacity of the gastric pouch (30–60 ml) results in substantial restrictions in the amount of food consumed and the rate at which food can be eaten (464 (EL 3), 492 (EL 4)). During the first few months after bariatric surgery, episodes of regurgitation, typically without nausea or true vomiting, are common if food is consumed in large volumes, eaten too quickly, or not chewed thoroughly. Gastric dumping occurs initially in 70–76% of patients who have had an RYGB (70 (EL 2), 122 (EL 3), 278 (EL 3), 500 (EL 1), 501 (EL 3)). Nevertheless, the frequency of clinically troublesome complaints is unknown. Some reports suggest that the dumping syndrome may not occur in all patients or may occur only transiently during the first postoperative year (278 (EL 3)). For some patients, dumping may be considered a desired side effect because it discourages ingestion of calorically dense liquids that could minimize the loss of weight. A previous opinion was that dumping symptoms were the result of the hyperosmolarity of intestinal contents, which led to an influx of fluid into the intestinal lumen with subsequent intestinal distention, fluid sequestration in the intestinal lumen, decreased intravascular volume, and hypotension. More recent data suggest that food bypassing the stomach and entering the small intestine leads to the release of gut peptides that are responsible for these “dumping” symptoms, inasmuch as these symptoms can often be blocked by subcutaneous administration of somatostatin (502 (EL 3)). Abdominal pain and cramping, nausea, diarrhea, light-headedness, flushing,
tachycardia, and syncope—symptoms indicative of dumping—are reported frequently and serve to discourage the intake of energy-dense foods and beverages (70 (EL 2), 492 (EL 4), 503 (EL 2)). These symptoms tend to become less prominent with time (492 (EL 4)). Symptoms can usually be controlled with certain nutritional changes, such as (i) eating small, frequent meals, (ii) avoiding ingestion of liquids within 30 min of a solid-food meal, (iii) avoiding simple sugars and increasing intake of fiber and complex carbohydrates, and (iv) increasing protein intake (504 (EL 4)). If these measures are unsuccessful, then octreotide, 50 µg subcutaneously 30 min before meals, may reduce symptoms in some patients (505 (EL 4)). Late dumping symptoms can be due to “reactive hypoglycemia” and can often be managed with nutritional manipulation or be treated prophylactically by having the patient drink half a glass of orange juice (or taking the equivalent small sugar supplement) ~1 h after eating. A report by Service et al. (506 (EL 3)) described six patients with severe, intractable postprandial symptoms associated with endogenous hyperinsulinenic hypoglycemia. This complication, believed to be attributable to the RYGB anatomy, in some patients has necessitated partial pancreatectomy for relief of the symptoms and hypoglycemia. Pathologic examination has shown pancreatic islet cell hyperplasia. This complication may manifest from 2 to 9 years after RYGB (507 (EL 3)). Patients who present with postprandial symptoms of hypoglycemia, particularly neuroglycopenic symptoms, after RYGB should undergo further evaluation for the possibility of insulin-mediated hypoglycemia.

Food intolerances are common, frequently involving meat products. Intake of alternative protein sources should be encouraged, although meals have been reported to remain deficient in protein for a year after bariatric surgery (464 (EL 3), 494 (EL 3), 508 (EL 3)). The use of protein supplements has been proposed but is not practiced universally (464 (EL 3), 509 (EL 3)). Continuous reinforcement of new nutritional habits will help minimize the frequency of bothersome gastrointestinal symptoms. Professional guidance remains important to optimize nutritional intake in patients who have had a malabsorptive procedure because of the risk for clinically important nutritional deficiencies (140 (EL 4)).

Chronic vomiting, generally described by the patient as “spitting up” or “the food getting stuck,” can occur. One-third to two-thirds of patients report postoperative vomiting (283 (EL 3), 301 (EL 3), 494 (EL 3)). Vomiting is thought to occur most commonly during the first few postoperative months (510 (EL 3)), during which time the patients are adapting to a small gastric pouch. This vomiting is not believed to be a purging behavior as seen with bulimia nervosa. Instead, patients may vomit in response to intolerable foods or in an effort to clear food that has become lodged in the upper digestive track. Frequent vomiting that persists longer than 6 months may suggest (i) obstruction, necessitating evaluation with a gastrointestinal contrast study, before any endoscopic procedure in patients with LAGB; (ii) reflux, inflammation, stomal erosion or ulceration, or stenosis, necessitating endoscopy; or (iii) gastric dysmotility, necessitating a radionuclide gastric-emptying study. Regurgitation that occurs after an LAGB procedure can be managed with appropriate band adjustments and nutritional advice.

After RYGB, supplementation with a multivitamin–mineral preparation, iron, vitamin B₁₂, and calcium with vitamin D is common (417 (EL 4), 464 (EL 3), 511 (EL 3), 512 (EL 3)). Best practice guidelines published recently recommend a daily multivitamin and calcium supplementation with added vitamin D for all patients who have had a weight loss surgical procedure (513 (EL 4)). After BPD or BPD/DS, routine supplementation regimens recommended include a multivitamin–mineral preparation, iron, vitamin B₁₂, calcium, and fat-soluble vitamins (417 (EL 4), 464 (EL 3), 511 (EL 3)).

The multivitamin–mineral preparations used should have the recommended daily requirements for vitamins and minerals. Initially, one to two tablets of a chewable preparation are advised because they are better tolerated after malabsorptive procedures. Alternatively, however, nonchewable preparations or products with fortified amounts of folic acid and iron, such as prenatal vitamins, can be used. Regardless of the preparation, multivitamin supplements providing 800–1,000 µg/day of folate can effectively prevent the development of folate deficiency after RYGB (464 (EL 3), 497 (EL 3), 514 (EL 2)). More recent studies suggest that folic acid deficiency is uncommon (involving only 10–35%) after RYGB and BPD or BPD/DS despite the absence of folic acid supplementation (515 (EL 3)). This finding suggests that the intake of folic acid is often sufficient to prevent folic acid deficiency. Recent guidelines recommend regular use of iron supplements for patients at risk of iron or folic acid deficiency (513 (EL 4)).

With multiple nutrient deficiencies, specific diagnosis and treatment become difficult. One condition thought to be due to multiple nutritional factors is “acute postgastric reduction surgery neuropathy” (516 (EL 3), 517 (EL 3)). This complication of bariatric surgery is characterized by vomiting, weakness, hyporeflexia, pain, numbness, incontinence, visual loss, hearing loss, attention loss, memory loss, nystagmus, and severe proximal symmetric weakness of the lower extremities (516 (EL 3), 517 (EL 3)). Because all symptoms may not be ameliorated with thiamine treatment alone, additional nutritional deficiencies may be involved in the underlying cause.

9.10.2.2. Protein depletion and supplementation

Protein-deficient meals are common after RYGB. This is generally noted at 3–6 months after bariatric surgery and is largely attributed to the development of intolerance of protein-rich foods (491 (EL 4)). Seventeen percent of patients experience persistent intolerance of protein-rich foods and thus limit their intake of protein to less than 50% of that recommended (491 (EL 4)). Fortunately, most food intolerances diminish by 1 year postoperatively (491 (EL 4)). Even patients who experience complete resolution of food intolerances often do not meet the daily recommended intake of protein. Regular assessment of nutritional intake should be performed, and supplementation with protein modular sources should be pursued if protein intake remains <60 g daily (491 (EL 4)). Nevertheless, hypoaalbuminemia is rare after a standard RYGB.
Protein malnutrition remains the most severe macronutrient complication associated with malabsorptive surgical procedures. It is seen in 13% of superobese patients 2 years after a distal RYGB with a Roux limb ≥150 cm and in <5% with a Roux limb <150 cm (72 (EL 3), 515 (EL 3)), as well as in 3–18% of patients after BPD (338 (EL 2), 399 (EL 4), 417 (EL 4), 499 (EL 3), 518 (EL 3), 519 (EL 3)). Other studies have found only a 0–6% incidence of protein deficiency after RYGB up to 43 months postoperatively (356 (EL 2), 497 (EL 3), 520 (EL 3)). Prevention involves regular assessment of protein intake and encouraging the ingestion of protein-rich foods (>60 g/day) and use of modular protein supplements. Nutritional support with PN for at least 3–4 weeks may be required after BPD/DS but rarely after RYGB (464 (EL 3)). If a patient remains dependent on PN, then surgical revision and lengthening of the common channel to decrease malabsorption would be warranted (125 (EL 3), 399 (EL 4), 521 (EL 3)).

9.10.2.3. Skeletal and mineral homeostasis, including nephrolithiasis

At present, there are no conclusive data regarding the association of altered calcium and vitamin D homeostasis with LAGB surgery. In 2 reports, LAGB was not associated with significant reduction in BMD (522 (EL 3), 523 (EL 2)).

Calcium deficiency and metabolic bone disease can occur in patients who have undergone RYGB (464 (EL 3), 512 (EL 3), 524 (EL 3), 525 (EL 3), 526 (EL 2)). The onset is insidious and results from a decrease in the intake of calcium-rich foods, bypass of the duodenum and proximal jejunum where calcium is preferentially absorbed, and malabsorption of vitamin D (464 (EL 3), 512 (EL 3), 524 (EL 3), 527 (EL 4)). An increase in serum intact PTH level is indicative of negative calcium balance or a vitamin D deficiency (or both), although PTH is also required for bone mineralization. Elevations of bone-specific alkaline phosphatase and osteocalcin levels, which are indicative of increased osteoblastic activity and bone formation, are often the initial abnormalities (512 (EL 3), 524 (EL 3)). Thus, measurement of bone turnover markers has been proposed as a useful screening technique for metabolic bone disease after RYGB because serum calcium and phosphorus levels are often normal (464 (EL 3), 512 (EL 3), 524 (EL 3), 527 (EL 4), 528 (EL 3)). After gastric restrictive procedures, urinary C-telopeptide levels, indicative of increased bone resorption, are elevated (528 (EL 3)). After LAGB or RYGB, increased bone resorption with prolonged immobilization, especially in association with critical illness, might be associated with hypercalciteria and, if renal calcium excretion is impaired, frank hypercalcemia (529 (EL 3)). Rapid and extreme weight loss is associated with bone loss (530 (EL 2), 531 (EL 3), 532 (EL 3)), even in the presence of normal vitamin D and PTH levels (528 (EL 3)). This observation supports the claim that nutritional or hormonal factors are not the only causes of bone loss. Other factors, such as decreased weight-bearing activity, also contribute to bone loss and can be estimated with N- or C-telopeptide levels (528 (EL 3)). One interesting model of bone remodeling involves leptin-dependent sympathetic innervation of bone formation by means of activation of peripheral clock genes (533 (EL 4)).

After a malabsorptive bariatric procedure, patients might have continued secondary hyperparathyroidism, low 25-OHD levels, increased 1,25-(OH)₂D levels, and hypocalciuria (524 (EL 3), 525 (EL 3), 526 (EL 2), 528 (EL 3), 534 (EL 3), 535 (EL 2)). Left uncorrected, secondary hyperparathyroidism will promote bone loss and increase the risk for osteopenia and osteoporosis (525 (EL 3)). The presence of hypocalcemia in the setting of a vitamin D deficiency exacerbates mineralization defects and accelerates the development of osteomalacia (536 (EL 4)).

In an observational study (537 (EL 3)), 29% of patients were found to have secondary hyperparathyroidism and 0.9% had hypocalcemia beyond the third postoperative month after RYGB. Parada et al. (538 (EL 3)) reported that 53% of patients had secondary hyperparathyroidism after RYGB. Also after RYGB, Youssef et al. (539 (EL 2)) found that patients had a greater degree of secondary hyperparathyroidism and vitamin D deficiency with longer Roux limb length. After BPD/DS, up to one-third of patients will have deficiencies in fat-soluble vitamins including vitamin D (540 (EL 3), 541 (EL 3)). Up to 50% will have frank hypocalcemia, which is associated with secondary hyperparathyroidism and vitamin D deficiency.

In an early study by Compston et al. (498 (EL 3)), 30 of 41 patients (73%) studied 1–5 years after BPD demonstrated defective bone mineralization, decreased bone formation rate, increased bone resorption, or some combination of these findings. Of the 41 patients, 9 (22%) had hypocalcemia, but none had low 25-OHD levels (498 (EL 3)). Reidt et al. (542 (EL 3)) found that women who had undergone RYGB had decreased estradiol- and vitamin D-dependent intestinal calcium absorption. This disorder was associated with increased N-telopeptide (marker of bone resorption), increased osteocalcin (marker of bone formation), or an "uncoupling" effect on bone remodeling (542 (EL 3)).

Compston et al. (498 (EL 3)) found an increased incidence of metabolic bone disease with standard BPD and a 50-cm common channel but without reduced serum 25-OHD levels. Thus, bone loss at the hip after BPD may be predominantly due to protein malnutrition (499 (EL 3)). In a series of 230 patients who underwent RYGB, Johnson et al. (543 (EL 2)) found that, at 1 year postoperatively, the radius BMD was increased by 1.85% and the lumbar spine and hip BMD was decreased by 4.53 and 9.27%, respectively. Of interest, no further bone loss was noted by 2 years postoperatively (543 (EL 2)). Calcium balance may be only one of many components for maintaining bone mass after bariatric surgery, inasmuch as aggressive calcium and vitamin D supplementation resulting in normal PTH levels will still be associated with abnormal bone turnover markers and decreased bone mass (526 (EL 2)). Overall, after a malabsorptive bariatric procedure, a calcium deficiency develops in 10–25% of patients by 2 years and in 25–48% by 4 years; moreover, a vitamin D deficiency develops in 17–52% of patients by 2 years and in 50–63% by 4 years (72 (EL 3), 338 (EL 2), 412 (EL 3), 540 (EL 3), 541 (EL 3), 544 (EL 4)). Increased awareness regarding the prevalence of metabolic bone disease after malabsorptive procedures has led to routine recommendation of calcium supplementation (357 (EL 4), 399 (EL 4), 464 (EL 3), 503 (EL 2)).
After bariatric surgery, recommended dosages of elemental calcium containing vitamin D range from 1,200 to 2,000 mg daily (399 (EL 4), 464 (EL 3), 497 (EL 3), 542 (EL 3), 545 (EL 4)). Calcium carbonate preparations are readily available in chewable forms and are better tolerated than tablets shortly after bariatric surgery. Patients, however, must be instructed to take calcium carbonate preparations with meals in order to enhance intestinal absorption. Calcium citrate preparations are preferred because this salt is absorbed in the absence of gastric acid production but require consumption of more tablets (535 (EL 2), 546 (EL 4), 547 (EL 4)). Vitamin D deficiency and bone mineralization defects result from decreased exposure to sunlight, malabsorption, impaired mixing of pancreatic and biliary secretions, and decreased vitamin D absorption in the proximal small bowel (417 (EL 4), 512 (EL 3), 524 (EL 3), 548 (EL 4), 549 (EL 3), 550 (EL 2)). Vitamin D supplementation can be provided with ergocalciferol, 50,000 IU one to three times per week, although in severe cases of vitamin D malabsorption, dosing as high as 50,000 IU one to three times daily may be necessary. In the setting of significant malabsorption unresponsive to the foregoing measures, parenteral vitamin D supplementation can be used. A common regimen consists of weekly intramuscular injections of ergocalciferol, 100,000 IU, until 25-OHD levels normalize. Intramuscular vitamin D preparations are difficult to locate, may require a pharmacist to compound the medication, and can be uncomfortable when injected. Calcitriol (1,25-(OH)₂D) therapy is generally unnecessary and increases the risk of hypercalcemia and hyperphosphatemia. Intravenous (0.25–0.5 μg/week) or oral (0.25–1.0 μg once or twice daily) calcitriol therapy has been used in situations characterized by symptomatic hypocalcemia and severe vitamin D malabsorption (551 (EL 3)). In asymptomatic patients, however, when 25-OHD fails to reach optimal levels (25-OHD >30 ng/ml), functionally normalize 1,25-(OH)₂D levels, and suppress elevated PTH levels, the use of calcitriol is unproved.

Adequate calcium and vitamin D supplementation has been achieved when levels for serum calcium, bone-specific alkaline phosphatase or osteocalcin, and 25-OHD as well as 24-h urinary calcium excretion rates are normal. Serum PTH levels may persist above the normal range even with functionally replete vitamin D levels (25-OHD >30 ng/ml). This scenario can raise the specter of primary hyperparathyroidism when inappropriately elevated PTH levels accompany elevated serum calcium levels.

After BPD or BPD/DS, supplementation with elemental calcium, 2,000 mg/day, and vitamin D as outlined in the foregoing material usually corrects deficiencies in calcium and vitamin D metabolism, corrects deterioration in BMD, and improves osteoid volume and thickness without osteomalacia (499 (EL 3)). Nutritional status remains important in the prevention of metabolic bone disease; a low serum albumin level is a strong predictor of bone loss and metabolic bone disease after BPD or BPD/DS (552 (EL 2)).

Routine postoperative monitoring of bone metabolism and mineral homeostasis in patients who have undergone a malabsorptive procedure is summarized in Table 15. There are several clinical challenges in the management of metabolic bone disease in these patients: (i) intolerance of calcium supplements, (ii) induction of hypercalciuria and precipitation of nephrocalcinosis and nephrolithiasis, (iii) avoidance of vitamin A oversupplementation, which can increase bone resorption, and (iv) inability to absorb orally administered medications and nutritional supplements. Moreover, recallcitrant protein, vitamin K, and copper deficiencies can impair recovery of bone physiological processes.

The presence of malabsorption raises the possibility that usual dosing of orally administered bisphosphonates (ibandronate 150 mg monthly, alendronate 70 mg weekly, and either risedronate 35 mg weekly or risedronate 75 mg daily for two consecutive days, once a month) cannot achieve sufficient blood levels for a therapeutic effect. In one study involving nonbariatric surgery patients, risedronate was absorbed in the small bowel regardless of the site of exposure (553 (EL 3)). It is not known whether orally administered bisphosphonates actually increase the risk of gastric ulceration in bariatric surgery patients, but risedronate has been associated with fewer endoscopically discovered gastric erosions than alendronate (554 (EL 3)). Therefore, the use of newer intravenously administered bisphosphonates has received considerable attention in postoperative bariatric patients. Intravenously administered pamidronate has successfully managed resorptive hypercalcemia in patients who have undergone bariatric surgery (529 (EL 3)) but is not approved by the US Food and Drug Administration for osteoporosis prevention or treatment. Pamidronate, 90 mg, is given by continuous intravenous infusion during a 4-h period up to once every 3 months in nonbariatric surgery patients with osteoporosis and may cause a low-grade fever as well as muscle and joint pain. Zoledronate, 5 mg, is given intravenously during a 1-h period up to once a year in nonbariatric surgery patients with osteoporosis and may cause similar adverse events. Intravenously administered ibandronate, 3 mg every 3 months, has recently become approved by the US Food and Drug Administration for the treatment of osteoporosis and confers far less risk for renal insufficiency than pamidronate or zoledronate (555 (EL 4)). Care must be exercised to ensure that vitamin D deficiency after gastric bypass is corrected before administration of bisphosphonates to avoid severe hypocalcemia, hypophosphatemia, and osteomalacia (556 (EL 3), 557 (EL 3)). Even with vitamin D sufficiency, a bypassed small bowel may not be capable of absorbing adequate calcium to offset the effects of bisphosphonate binding to bone matrix. Overall, there are no published clinical trial data regarding use of bisphosphonates in bariatric surgery patients.

Just as in patients with short bowel syndrome, patients who have had malabsorptive procedures are at risk for oxalosis and renal oxalate stones. Impaired binding of oxalate in the small bowel allows greater oxalate absorption in the colon, contributing to excessive excretion of oxalates by the kidneys. Dehydration also has a role as a result of restrictions imposed on amount and timing of fluid intake after gastric restrictive procedures. Treatment of this problem consists of low-oxalate meals, appropriate oral calcium supplementation, and orally administered potassium citrate. Increasing the urinary calcium too high with orally administered calcium and vitamin D supplementation,
intended to reduce secondary hyperparathyroidism and treat presumed osteomalacia, can exacerbate calcium oxalate stone formation. Clinical studies have demonstrated an association of O. formigenes colonization of the small bowel, or administration as a probiotic therapy, with decreased urinary oxalate excretion and stone formation (558 (EL 4), 559 (EL 3), 560 (EL 3)).

Magnesium is readily available from plant and animal sources and is absorbed throughout the entire small bowel independent of vitamin D. Hypomagnesemia can be associated with neuromuscular, intestinal, and cardiovascular symptoms and abnormalities in secretion of PTH. Hypomagnesemia has been reported after bariatric procedures, such as jejunooileal bypass and BPD, and usually occurs in the setting of persistent diarrhea (338 (EL 2)). Empiric supplementation with a mineral-containing multivitamin providing the daily recommended intake of magnesium (>300 mg in women; >400 mg in men) should prevent magnesium deficiency in the absence of complicating factors. In the setting of symptomatic and severe magnesium deficiency, supplementation should be dictated by the clinical situation. Parenteral supplementation in accordance with currently accepted protocols should be pursued in the patient with neurologic and cardiac symptoms. Magnesium supplementation should be accompanied by careful monitoring of other minerals and electrolytes. In the asymptomatic patient with low magnesium levels, oral supplementation can be prescribed as tolerated. Unfortunately, oral magnesium supplementation can cause or worsen diarrhea (561 (EL 3), 562 (EL 4)).

Hypophosphatemia might be observed in patients with malnutrition or fat malabsorption (or both). Milk products are an excellent source of phosphorus for those patients who can tolerate oral intake (563 (EL 4)). Phosphorus is also present in protein-rich foods such as meat and cereal grains. Phosphorus is absorbed throughout the small intestine under the control of vitamin D and specific phosphate transporters. Hypophosphatemia with or without phosphorus deficiency is common in seriously ill patients. In the presence of phosphorus deficiency, hypophosphatemia can result from chronic malnutrition, chronic alcoholism, hyperparathyroidism, vitamin D deficiency, metabolic bone disease, and fat malabsorption. In the absence of phosphorus deficiency, hypophosphatemia can result from the effect of acid–base status on plasma phosphorus levels or the administration of substances that influence the uptake of serum phosphorus by the cell (glucose, amino acids, and insulin: the “refeeding syndrome”) (564 (EL 4)). Thus, nutrition support must be initiated cautiously in severely malnourished bariatric surgery patients because of the risk of the refeeding syndrome. Hypophosphatemia can cause rhabdomyolysis, respiratory insufficiency, nervous system dysfunction, and proximal myopathy.

9.10.2.4. Fat malabsorption: EFA and vitamins A, E, and K

No published clinical data specifically address the potential for deficiency of EFA in bariatric surgery patients. The recommended intake to prevent or reverse symptoms of linoleic acid (18:2n6) deficiency is ~3–5% of energy intake. The recommended intake to prevent or reverse symptoms of linolenic acid (18:3n-3) deficiency is ~0.5–1% of energy intake (565 (EL 4)). Elevation of the triene:tetraene ratio (20:3n-9–20:4n-6) >0.2 indicates deficiency of n-3 and n-6 FA. Dietary sources of n-3 and n-6 FA are the polyunsaturated FA-rich vegetable oils. Linoleic acid content (as percent of all FA) is particularly high in safflower (76%), sunflower (68%), soybean (54%), and corn (54%) oils (566 (EL 4)). Because safflower, sunflower, and corn oils contain very little n-3 FA (~1%) and can therefore result in an n-3 FA deficiency, soybean, linseed, and canola oils, which contain relatively high amounts of both n-3 and n-6 FA, are better choices for long-term consumption (566 (EL 4)). Clinical symptoms of EFA deficiency in adults, applicable to bariatric surgery patients, include dry and scaly skin, hair loss, decreased immunity and increased susceptibility to infections, anemia, mood changes, and unexplained cardiac, hepatic, gastrointestinal, and neurologic dysfunction (567 (EL 4)). Beyond consumption of the aforementioned whole foods rich in EFA, there are no data regarding optimal supplementation with EFA-containing nutraceuticals in bariatric surgery patients. Topical administration of safflower oil has been demonstrated to prevent EFA deficiency in patients receiving home total PN (568 (EL 3)) and therefore may be a reasonable alternative in symptomatic patients who have undergone extensive malabsorptive procedures, such as BPD/DS.

Steatorrhea induced by malabsorptive surgical procedures can frequently lead to deficiencies in fat-soluble vitamins, typically manifested by an eczematous rash (140 (EL 4), 330 (EL 4), 417 (EL 4)), but may also be associated with night blindness or full-blown loss of vision from profound vitamin A deficiency. Fat-soluble vitamins in their water-soluble form should be administered to all patients who have undergone a BPD or BPD/DS procedure. Fat-soluble vitamin levels, especially vitamin A, should be monitored annually and be replaced prophylactically in fat-soluble vitamin deficiencies in fat-soluble vitamins, typically manifested by an eczematous rash (140 (EL 4), 330 (EL 4), 417 (EL 4)). No randomized, prospective studies have evaluated the efficacy of specific doses of fat-soluble vitamin supplementation in preventing deficiencies. Combined supplementation of vitamins A, D, E, and K can be achieved with ADEK tablets, each containing the following: vitamin A (palmitate), 4,000 IU; β-carotene, 3 mg; vitamin D (cholecalciferol), 400 IU; vitamin E (succinate), 150 IU; and vitamin K, 0.15 mg (as well as vitamin C, 60 mg; folic acid, 0.2 mg; thiamine, 1.2 mg; riboflavin, 1.3 mg; niacin, 10 mg; pantothenic acid, 10 mg; pyridoxine, 1.5 mg; biotin, 50 µg; vitamin B12, 12 µg; and zinc oxide, 7.5 mg). As with all combination medications, serum levels need to be monitored carefully for both underreplacement and overreplacement of the various ingredients. Vitamin A deficiency after bariatric surgery results from poor nutritional intake, malabsorption, and impaired hepatic release of vitamin A. In two series, there was a 61–69% incidence of vitamin A deficiency 2–4 years after BPD, with or without DS (338 (EL 2), 540 (EL 3)). In another series, however, the incidence was as low as 5% by 4 years (78 (EL 3)). Although data are scarce, mild vitamin A deficiency can also occur after distal RYGB procedures and is easily corrected with oral supplementation (330 (EL 4)). Nevertheless, prophylactic supplementation does not prevent the development of vitamin A deficiency in all patients; thus, continued
biochemical monitoring is indicated (330 (EL 4)). Symptoms of vitamin A deficiency include ocular xerosis and night blindness. Oral supplementation of vitamin A, 5,000–10,000 IU/day, is recommended until the serum vitamin A level normalizes. Empiric supplementation with vitamin A, 25,000 IU/day, has been used after BPD/DS (84 (EL 3), 140 (EL 4), 499 (EL 3)). With symptoms, aggressive oral supplementation, up to 65,000 IU/day of vitamin A, can normalize dark adaptation and the serum vitamin A level after 2–3 months. In the presence of severe malnutrition necessitating PN, supplementation with 25,000 IU/day can correct vitamin A deficiency within weeks (569–571 (EL 3)). When resulting from fat malabsorption, a vitamin A deficiency may be ameliorated by lengthening of the 50-cm common channel to 150–200 cm (540 (EL 3)).

In patients who have had a BPD or BPD/DS, vitamin K deficiency occurs in ~50–70% within 2–4 years postoperatively (338 (EL 2), 540 (EL 3)). Vitamin K supplementation is recommended when international normalized ratio values increase >1.4 (140 (EL 4), 417 (EL 4)). Vitamin K deficiency can lead to easy bruising, bleeding, and metabolic bone disease (572 (EL 4)).

In ~95% of patients who have undergone BPD or BPD/DS who are already taking a multivitamin, vitamin E levels remain normal (338 (EL 2), 540 (EL 3)). Vitamin E deficiency can lead to anemia, ophthalmoplegia, and peripheral neuropathy. Administration of vitamin E (800–1,200 IU/day) should be initiated when deficiency is documented and continued until the serum levels reach the normal range. Overreplacement of vitamin E can exacerbate the coagulopathy associated with a concomitant vitamin K deficiency (573 (EL 4)).

9.10.2.5. Nutritional anemia: iron, vitamin B₁₂, folic acid, selenium, and copper

Iron deficiency and iron deficiency anemia are common after RYGB, BPD, or BPD/DS, especially in women with menorrhagia. For this reason, prophylactic iron supplementation is required (497 (EL 3), 574 (EL 2), 575 (EL 2), 576 (EL 3)). Decreased liberation and absorption of heme are caused from bypass of the acid environment in the lower portion of the stomach and the absorptive surfaces of the duodenum and upper jejunum (481 (EL 2), 577–580 (EL 4)). Moreover, after malabsorptive procedures, patients frequently eat meals low in meats, leading to decreased intake of heme. Iron deficiency may also be exacerbated in these patients as a result of a nutrient–nutrient inhibitory absorptive interaction between iron and calcium, another mineral that is routinely supplemented during the postoperative period. Most (581 (EL 3), 582 (EL 3)), but not all (583 (EL 3)), studies show that nonheme- and heme-iron absorption is inhibited up to 50–60% when consumed in the presence of calcium supplements or with dairy products. Calcium at doses of 300–600 mg has a direct dose-related inhibiting effect on iron absorption. This effect has been noted with calcium carbonate, calcium citrate, and calcium phosphate. The risk for iron deficiency increases with time, with some series reporting more than half of the subjects with low ferritin levels at 4 years after RYGB, BPD, or BPD/DS (497 (EL 3)). Iron deficiency after RYGB is influenced by multiple factors and can persist to 7 years postoperatively (508 (EL 3)). Iron deficiency has been reported to occur in up to 50% of patients after RYGB, most frequently in women with menorrhagia as previously stated (326 (EL 3), 512 (EL 3), 514 (EL 2), 584 (EL 3)). Thus, empiric iron supplementation is recommended after RYGB, BPD, or BPD/DS procedures (575 (EL 2), 576 (EL 3)).

In a randomized, controlled trial, iron supplementation (65 mg of elemental iron orally twice a day) prevented the development of iron deficiency, although it did not always prevent the development of iron deficiency anemia (575 (EL 2)). Supplementation with lower doses (80 mg/day) does not universally prevent iron deficiency after RYGB, BPD, or BPD/DS (497 (EL 3)). Nevertheless, low-dose iron supplementation (80 mg/day) was associated with a lower risk for low ferritin levels. Vitamin C increases iron absorption and should be empirically included with iron supplementation (545 (EL 4), 576 (EL 3)). Because oral iron supplementation is associated with poor absorption and adverse gastrointestinal effects, and intramuscular injections are painful, intermittent intravenous iron infusion may be necessary. InFeD, Ferrlecit, or Venofer may be administered intravenously. Supplementation should follow currently accepted guidelines to normalize the hemoglobin concentration. Continued surveillance of hemoglobin levels and iron studies is recommended (575 (EL 2)).

Vitamin B₁₂ deficiencies can occur after bariatric surgical procedures that bypass the lower part of the stomach. Impairment of vitamin B₁₂ absorption after RYGB results from decreased digestion of protein-bound cobalamins and impaired formation of intrinsic factor–vitamin B₁₂ complexes required for absorption (464 (EL 3), 544 (EL 4), 585 (EL 3), 586 (EL 3)). Whole-body storage (2,000 μg) is considerably greater than the daily needs (2 μg/day). Nonetheless, after the first postoperative year, 30% of patients with RYGB receiving only a multivitamin supplement will have a vitamin B₁₂ deficiency (587 (EL 3)). In other studies, the incidence of vitamin B₁₂ deficiency after RYGB at postoperative year 1 has been 33–40% (514 (EL 2), 584 (EL 3)) and by years 2–4 has been 8–37% (72 (EL 3), 496 (EL 3), 497 (EL 3), 588 (EL 3)). In patients with BPD, there was a 22% incidence of vitamin B₁₂ deficiency at 4 years (497 (EL 3)) and in patients with VBG (N = 26), there were no instances of vitamin B₁₂ deficiency at 1 year (589 (EL 3)). Anemias as a result of vitamin B₁₂ deficiency have been reported to occur in >30% of patients 1–9 years after RYGB (417 (EL 4)).

There is some controversy regarding the routine supplementation of vitamin B₁₂ after RYGB or BPD, and there are no evidence-based recommendations. Most bariatric surgery groups, however, advise the initiation of vitamin B₁₂ supplementation within 6 months postoperatively. Orally administered crystalline vitamin B₁₂ at a dose of at least 350 μg has been shown to maintain normal plasma vitamin B₁₂ levels (514 (EL 2), 590 (EL 3), 591 (EL 3), 592 (EL 2)). Optimal dosing of oral, sublingual, or intranasal forms of vitamin B₁₂ supplementation has not been well studied. In a study of postoperative RYGB patients by Clements et al. (593 (EL 3)), however, 1,000 μg of vitamin B₁₂ intramuscularly every 3 months or 500 μg of intranasally administered vitamin B₁₂ every week
resulted in a lower incidence of vitamin B<sub>12</sub> deficiency (3.6% at 1 year and 2.3% at 2 years) in comparison with the frequency of 12–37% described by Brolin and Leung (511 (EL 3)). Functional markers of vitamin B<sub>12</sub> nutriture, which are more sensitive than plasma vitamin B<sub>12</sub> levels, may be followed and include methylmalonic acid and homocysteine. Both, however, might be low because of protein malnutrition, and the latter might be elevated because of vitamin B<sub>12</sub> folate, choline, or betaine deficiencies. Even with prophylactic supplementation, vitamin B<sub>12</sub> status should be monitored, inasmuch as deficiencies can develop and necessitate dosing modifications (497 (EL 3)). Routine monitoring of vitamin B<sub>12</sub> levels early during the postoperative course after RYGB, BPD, or BPD/DS (<3–6 months) may be justified if preoperative vitamin B<sub>12</sub> deficiency is suspected. In the absence of strong evidence, vitamin B<sub>12</sub> recommendations are based on subjective impressions of the prevalence and clinical significance of sequelae from vitamin B<sub>12</sub> deficiencies.

In comparison with vitamin B<sub>12</sub> deficiencies in folate are less common because folate absorption occurs throughout the entire small bowel; thus, deficiency is unlikely if the patient is taking a daily multivitamin as instructed. Biomarker monitoring is not necessary (330 (EL 4), 464 (EL 3), 579 (EL 4)). Hyperhomocysteinemia, suggestive of a functional folate deficiency, is an independent risk factor for cardiovascular disease, but intervention with folic acid remains controversial. The pregnant bariatric patient should also have routine additional folic acid supplementation because of the risk of fetal neural tube defects.

Other micronutrient deficiencies have been associated with anemias in nonbariatric surgery patients and include copper, vitamin A, vitamin B<sub>6</sub>, vitamin E, and selenium (580 (EL 4), 594 (EL 4), 595 (EL 4)). Selenium is an antioxidant, and its status is closely associated with vitamin E status. In a series of patients who had undergone BPD or BPD/DS, selenium deficiency was found in 14.5% of patients without any clinical sequelae (338 (EL 2)). Proven selenium deficiency–associated anemias have not been reported in bariatric surgery patients. Copper deficiency can induce anemia (normocytic or macrocytic) and neutropenia (596 (EL 3), 597 (EL 3)). The detrimental effects of copper deficiency on tissue release, resulting in elevated ferritin levels, may be mediated by hepestin, a ceruloplasmin homologue, and divalent metal transporter-1 (598 (EL 4)). Kumar et al. (599 (EL 3)) described two patients who had undergone gastric surgery and had copper deficiency, leading to neurologic features similar to a vitamin B<sub>12</sub> deficiency. One of the two patients had undergone a gastric bypass procedure several years before clinical presentation.

9.10.2.6. Zinc

Plasma zinc levels represent only <0.1% of whole-body zinc and are a poor biomarker for zinc status (600 (EL 4)). With systemic inflammation, this insensitivity is exacerbated with increased hepatic zinc uptake (601 (EL 3)). Because zinc is lost in the feces, patients with chronic diarrhea are at risk for zinc deficiency (602 (EL 4)). In the absence of pancreatic exocrine secretions, however, zinc absorption remains normal (603 (EL 3)). Although it would appear rational to provide zinc empirically to patients with malabsorption, this intervention can induce a copper deficiency (604 (EL 3)). Thus, injudicious supplementation with zinc can lead to a copper deficiency–related anemia, which may be erroneously treated empirically with increasing amounts of iron, exacerbating an iron-overload condition and eventuating in organ damage. In contrast, 10–50% of patients who have undergone BPD/DS may experience zinc deficiency (338 (EL 2), 540 (EL 3)). Hair loss and rash are symptoms of zinc deficiency, but they can be nonspecific (605 (EL 4)).

9.10.2.7. Thiamine

Thiamine deficiency can occur as a result of bypass of the jejunum, where thiamine is primarily absorbed, or as a result of impaired nutritional intake from recurrent emesis (606 (EL 3), 607 (EL 4)). Two studies have shown decreased thiamine levels before bariatric surgery (326 (EL 3), 608 (EL 3)). Although thiamine deficiency has multiple manifestations, neurologic symptoms are predominant in this patient population (464 (EL 3), 594 (EL 4), 597 (EL 3), 606 (EL 4), 607 (EL 4), 609 (EL 4)). Acute neurologic deficits as a result of thiamine deficiency have been reported as soon as 1–3 months after bariatric surgery (610–619 (EL 3–4)). Early recognition is paramount to initiate appropriate supplementation and avoid potential complications resulting from the administration of dextrose-containing solutions (606 (EL 3)). Although not often performed, assessment of thiamine status is best done by determining erythrocyte transketolase activity. Parenteral supplementation with thiamine (100 mg/day) should be initiated in the patient with active neurologic symptoms (620 (EL 3), 621 (EL 3)). After a 7- to 14-day course, an oral preparation (10 mg/day) can be used until neurologic symptoms resolve (464 (EL 3), 622 (EL 3), 623 (EL 4)). Severe thiamine deficiency most commonly occurs in patients who develop severe, intractable vomiting after bariatric surgery, usually due to a mechanical problem such as stomal stenosis after RYGB or BPD/DS or excessive band tightness or slippage after LAGB. It is important that persistent vomiting be resolved aggressively to prevent this devastating complication.

9.10.3. Cardiology and Hypertension

Improvements in serum lipids are observed by 6 months after gastric restrictive procedures. Reported reductions in total cholesterol and triglyceride levels are >15 and >50%, respectively. No significant changes in HDL cholesterol levels are observed early postoperatively; however, gradual and significant improvements occur after 12 months (20%) (188 (EL 2), 442 (EL 3)). The greatest reduction in lipid values is observed in patients with high preoperative values (188 (EL 2)). The underlying physiologic factors for the observed improvements in lipid values are multifactorial and include rapid weight loss, nutritional changes, and decreased insulin resistance (184 (EL 3), 188 (EL 2), 439 (EL 3), 442 (EL 3)). Improvements in lipid values have been reported despite suboptimal weight loss (<50% of excess weight) or weight regain (188 (EL 2)). The SOS Study has shown a significant decrease in the incidence of hypertriglyceridemia and low-HDL syndrome at 2 years in surgical patients compared with weight-matched control subjects (189 (EL 1)). Improvements...
jejunoileal bypass surgery

endobiotic procedures, reported in up to 60% of patients. Diarrhea and steatorrhea are common complications of malnutrition and should be considered in patients with a history of T2DM or vascular disease.

Several investigators have reported long-term improvements of hypertension after bariatric surgery. Remission rates, however, are much lower than those reported with T2DM (64 (EL 3), 99 (EL 1), 199 (EL 3), 624–626 (EL 3)). The SOS Study initially reported a decrease in the incidence of hypertension in the surgical cohort in comparison with control subjects at 2 years. At 8 years, however, this protection was lost, with no significant difference in the incidence of hypertension between the two cohorts, despite a weight loss maintenance of 16% in the surgically treated patients (200 (EL 2)). In contrast, in another study in which the 6% of patients who had undergone an RYGB in the SOS Study and lost significantly more weight than the patients who had purely restrictive procedures (94%), a significant decrease in both systolic and diastolic blood pressures persisted at 8 years (64 (EL 3)). Continued surveillance of blood pressure and of adequacy of antihypertensive treatment is recommended.

9.10.4. Pulmonary

Therapy with nasal CPAP or bilevel positive airway pressure should be continued until repeated assessment with overnight polysomnography can confirm complete resolution. Unfortunately, many patients are unwilling or unable to comply with repeated overnight polysomnography. Many patients stop therapy on their own as a result of subjective improvement. At present, there are no clear guidelines regarding the timing for repeated sleep studies in bariatric surgery patients (179 (EL 2)). Overnight oximetry, although not studied in this situation, may provide some reassurance in that normal study results are unlikely in the presence of sleep apnea. Patients with mild to moderate sleep apnea (RDI <40) will usually have complete resolution, whereas those with more severe sleep apnea will have residual apneic episodes but are usually asymptomatic without nasal CPAP (453 (EL 4)).

9.10.5. Gastrointestinal

9.10.5.1. Diarrhea and steatorrhea

Diarrhea and steatorrhea are common complications of malabsorptive procedures, reported in up to 60% of patients after jejunoileal bypass surgery (569 (EL 3), 627 (EL 3)). In one study, diarrhea with malodorous stools after BPD or BPD/DS was reported by 13% of patients (499 (EL 3)). Diarrhea is uncommon after RYGB and should prompt evaluation for the presence of significant macronutrient malabsorption and steatorrhea (628 (EL 3)). Diagnostic considerations include lactose intolerance, bacterial overgrowth, or a concurrent diagnosis such as celiac sprue (629 (EL 3)). Celiac sprue has also been recognized as a common cause for iron deficiency anemia (630 (EL 3)). Upper endoscopy in conjunction with small bowel biopsies showing the classic histologic findings of celiac sprue remains the standard diagnostic technique. Although classically duodenal biopsies are pursued in the diagnosis of celiac sprue, small bowel histologic features should also be representative if celiac sprue is present. There are no data to suggest that the prevalence of celiac sprue is any different among patients undergoing bariatric surgery than that expected in the general population. The use of serologic markers, however, has been gaining acceptance (631 (EL 3)). Once celiac sprue has been identified, management involves implementation of a gluten-free meal plan, which is associated with relief of gastrointestinal symptoms and improvement of abnormal histologic features in the majority of patients (632 (EL 3), 633 (EL 3)).

9.10.5.2. Stomal stenosis and ulceration

Potential causes of persistent and severe gastrointestinal symptoms include stomal stenosis and ulceration (330 (EL 4), 399 (EL 4), 417 (EL 4)). Stomal stenosis is common (12%) and results from the restrictive size of the gastric pouch and associated edema. This complication is more common after laparoscopic vs. open RYGB (634 (EL 4)). Endoscopy is preferred in the evaluation of stomal obstruction because it can be used for diagnosis and treatment with transcendoscopic balloon dilation. Repeated dilations may be required. After VBG, balloon dilation is often unsuccessful, and surgical intervention is required (399 (EL 4), 417 (EL 4), 475 (EL 3)).

Marginal ulcers between the stomach pouch and the small intestine are a frequent source of epigastric pain, blood loss, and iron deficiency, accounting for 27% of patients referred for endoscopy in one study (635 (EL 3)). The most likely cause for stomal ulceration is anastomotic ischemia, usually due to tension of the anastomosis when the gastrojejunostomy was created (636 (EL 4)). Stomal ulcers are also caused by retained acid-producing gastric tissues in large pouches. Other potential causes of stomal stenosis and ulceration should also be considered, including H. pylori, which can be treated with proton pump inhibitors, sucralfate, and antibiotics (399 (EL 4)). These ulcerations can be caused or exacerbated by the concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, and cyclooxygenase-2 inhibitors.

9.10.5.3. Gastric obstruction

Gastric obstruction associated with LAGB is due to a bolus of food lodging at the banded area, excessive inflation of the balloon, or gastric prolapse around the band. Vomiting releases the obstructed food and is temporary. Symptoms attributable to a tight band or band prolapse include obstruction and nongastrointestinal symptoms, such as sleep disturbance, night cough, asthma, and recurrent bronchitis or pneumonia. They can occur without any reflux or gastrointestinal symptoms (637 (EL 3), 638 (EL 3)). Removing saline from the band, by means of the adjustment reservoir, usually provides immediate resolution of the excessive band inflation. Nevertheless, a major prolapse of stomach through the band causing a very large proximal gastric pouch can lead to complete obstruction. Gastric obstruction
is usually associated with pain and may necessitate emergency surgical reexploration because of the risk of gastric necrosis. The diagnosis is suggested by abdominal plain films showing an abnormal band position. Bands are placed such that they lie parallel to a line drawn from the patient’s right hip to the left shoulder, with the tubing pointing toward the left shoulder. When this orientation is lost, prolapse should be expected. Because ischemia may ensue, the band should be immediately emptied and surgical exploration considered if the patient’s abdominal pain does not resolve.

9.10.5.4. Intestinal obstruction
Small bowel obstruction can occur after RYGB, BPD, or BPD/DS (330 (EL 4), 427 (EL 4)). Evaluation, however, can be challenging as a result of the limitations in imaging imposed by the altered anatomy. UGI studies and CT scans may not confirm an obstruction when present. The symptom of cramping periumbilical pain should prompt strong consideration of reexploration by either the open or the laparoscopic technique because of the danger of bowel infarction, peritonitis, and death (330 (EL 4)). This complication may be attributable to adhesions or to an incarcerated internal hernia through one of three potential mesenteric defects (639–641 (EL 3)), especially during pregnancy (642 (EL 4), 643 (EL 3), 644 (EL 3)).

9.10.5.5. Gallbladder disease
Obesity is a risk factor for benign gallbladder disease, which is frequently identified in patients seeking bariatric surgery (645 (EL 3)). Gallstone formation is common after significant weight loss and is related to the rate of weight loss (646 (EL 4)). This relationship prevails for patients who have undergone RYGB, BPD, or BPD/DS surgery (330 (EL 4), 399 (EL 4), 417 (EL 4), 647 (EL 2)) but not LAGB (648 (EL 3)). Gallstone and sludge formation has been reported in 30% of patients 6 months after RYGB, BPD, or BPD/DS procedures (649 (EL 3), 650 (EL 1)). As a result, some surgeons have advocated performing a prophylactic cholecystectomy at the time of these procedures (399 (EL 4), 503 (EL 2), 651 (EL 3)). In a randomized, placebo-controlled trial, medical therapy with ursodiol (300 mg twice daily) has been shown to be effective in decreasing the incidence of gallstone formation from 30 to 2% at 6 months (650 (EL 1)). Currently, it is an accepted alternative to prophylactic cholecystectomy in this patient population (330 (EL 4), 650 (EL 1), 652 (EL 3)). Ursodiol, however, is relatively expensive, often not well tolerated, and therefore associated with poor adherence (647 (EL 2)). Because few adhesions form after laparoscopic bariatric surgery, performance of laparoscopic cholecystectomy is not very difficult when symptoms of cholecystitis develop, and most surgeons are not recommending treatment with ursodiol at this time (652 (EL 3), 653 (EL 3)). Nonetheless, there is a risk of common bile duct stones developing, which may be very difficult to address after either RYGB or BPD/DS.

9.10.5.6. Bacterial overgrowth
Bacterial overgrowth can occur with malabsorptive procedures, although any structural change to gut continuity is a recognized risk factor (140 (EL 4), 417 (EL 4), 629 (EL 3)). It can contribute to additional complications such as inflammatory arthritis as a result of antibody–antigen deposition from translocation of endotoxin fragments into the bloodstream from the bypassed limb (399 (EL 4)). Symptoms include persistent diarrhea in conjunction with proctitis and abdominal distention. Diagnosis can be difficult but should involve upper endoscopy and performance of intestinal aspirate cultures. D-Xylose and hydrogen breath tests are available but have limited sensitivity when used alone (629 (EL 3), 654–657 (EL 3)). Empiric antibiotic therapy, particularly with metronidazole, is usually effective at controlling symptoms and supports the presence of bacterial overgrowth (140 (EL 4), 658 (EL 3), 659 (EL 3)). The role of probiotics in decreasing complications after gastrointestinal surgery, especially when bacterial overgrowth has occurred, has been reviewed by Correia and Nicolini (660 (EL 4)). At present, there is still inconclusive level 3 evidence for use of probiotics in the general surgery population and no data in bariatric surgery patients.

9.10.5.7. Incisional hernias
Incisional hernias are the most common complication after open bariatric surgical procedures (in 10–20% of patients), which is significantly reduced by use of the laparoscopic approach (57 (EL 3), 62 (EL 2), 367 (EL 3), 424 (EL 2), 427 (EL 4), 661 (EL 3)). Their cause is multifactorial, including factors such as increased intra-abdominal pressure and poor wound healing. In the asymptomatic patient, repair is often deferred until the patient has achieved maximal weight loss. In the symptomatic patient, prompt repair is recommended (399 (EL 4)).

9.10.5.8. Staple-line disruption
The prevalence of staple-line disruption, which is a problem only with open bariatric procedures in which the stomach is not transected, varies widely and is often asymptomatic (330 (EL 4), 399 (EL 4)). It is thought that modifications in technique have led to a decrease in the prevalence of this complication. Placement of three superimposed rows rather than one row of staples at the anastomosis when the stomach is not transected (399 (EL 4), 453 (EL 4), 662 (EL 3), 663 (EL 2)) reduces the risk of this complication. Transection of the stomach, however, decreases the risk of this complication and is the standard procedure when a laparoscopic or open RYGB is performed (57 (EL 3), 62 (EL 2), 367 (EL 3), 424 (EL 2), 664 (EL 3)). Gastrogastric fistulas can occur after stomach transection and have been reported in 1–6% of cases (662 (EL 3), 665 (EL 3), 666 (EL 3)).

9.11. Pregnancy
Pregnancy should be discouraged during periods of rapid weight loss (12–18 months postoperatively) (667 (EL 3), 668 (EL 4), 669 (EL 3)). Nevertheless, patients who may have had subfertility, with or without PCOS, before bariatric surgery are more likely to conceive postoperatively (667 (EL 3), 670 (EL 3), 671 (EL 3)). Postoperative patients desiring pregnancy should be counseled to adhere with their nutritional regimen, including
use of micronutrient supplements. Folic acid and vitamin B12 status should be monitored in these patients during pregnancy and also during the breastfeeding period. Hyperhomocysteinemia can result from deficiencies in folic acid, vitamin B12, and other micronutrients, and in nonbariatric surgery patients, this condition is associated with placental vascular disease and recurrent early pregnancy loss and fetal neural tube defects (672–674 (EL 3)). Obstetricians should monitor postbariatric surgery pregnant women for the potential development of internal hernias (644 (EL 3)) and small bowel ischemia (643 (EL 3)).

Complications of pregnancy after bariatric surgery include persistent vomiting, gastrointestinal bleeding (675 (EL 3)), anemia (676 (EL 3)), intratropical growth restriction (676 (EL 3)), various micronutrient deficiencies including vitamin A (677 (EL 3)), vitamin B12, folic acid, and iron (678 (EL 4)), and fetal neural tube defects (679 (EL 3), 680 (EL 3)). Bariatric surgery, however, may reduce the risks for gestational diabetes, hypertension, DVT, stress incontinence, preeclampsia, cephalopelvic disproportion, macrosomia, and cesarean delivery (218 (EL 3), 244–247 (EL 3), 681 (EL 3)). Routine weight management and periodic band adjustments during pregnancy have proved beneficial (242 (EL 3), 243 (EL 2), 246 (EL 3), 682 (EL 2)).

For some patients, the massive weight loss as a result of bariatric surgery is associated with physical discomfort and body image dissatisfaction related to loose, sagging skin. These untoward experiences are believed to have a central role in the decision to seek body-contouring surgery (683 (EL 4)). According to the American Society of Plastic Surgeons (684 (EL 3)), >65,000 individuals underwent body-contouring surgery after massive weight loss in 2006. The most common surgical intervention was breast reduction–breast lift procedures, performed on 29,712 women (684 (EL 3)). Plastic surgeons also reported performing 19,046 extended abdominoplasty–lower body lifts, 9,274 upper arm lifts, and 7,920 thigh lifts (684 (EL 3)).

There is growing interest in these procedures within the plastic surgery community (685 (EL 4)). Typically, the procedures are recommended for patients whose weight has been stable for 3–6 months. It is unknown whether persons who have undergone bariatric surgery and who elect to undergo body-contouring surgery experience additional physical and psychosocial benefits. There is an increased risk for venous thromboembolism with body-contouring surgery after gastric bypass procedures, and tobacco use can increase this risk further (396 (EL 4), 686 (EL 3)). Typically, body-contouring after bariatric surgery is not covered by third-party payers without prior authorization stating medical necessity, and it often remains a noncovered service.

9.13. Psychologic Issues
Literature reviews and numerous empirical studies have described significant improvements in psychosocial functioning after bariatric surgery (48 (EL 4), 117–119 (EL 4), 293 (EL 4)). Patients typically report decreases in symptoms of anxiety and depression and significant improvements in health-related quality of life (273 (EL 3), 317 (EL 1), 473 (EL 3), 687–691 (EL 3)). The presence of formal psychopathologic conditions appears to be reduced, although this has been investigated in only a limited number of studies (271 (EL 3)). Patients also typically report improvements in body image as well as marital and sexual functioning (295 (EL 3), 302 (EL 3), 316 (EL 3), 692–694 (EL 3)).

These generally positive reports are contradicted by other findings. In a significant minority of patients, a negative psychologic response to bariatric surgery has been reported (271 (EL 3), 695 (EL 3), 696 (EL 3)). For some patients, improvements in psychosocial status dissipate 2–3 years postoperatively (276 (EL 3), 277 (EL 4), 317 (EL 1), 697 (EL 4)). Other studies have documented suicides postoperatively (122 (EL 3), 273 (EL 3), 301 (EL 3)). The factors contributing to these less positive outcomes remain unclear and necessitate additional investigation.

Postoperative psychosocial status also may affect postoperative eating behavior. Several studies have suggested that patients struggle to adhere to the recommended postoperative eating plan (158 (EL 3), 494 (EL 3), 611 (EL 3), 698 (EL 3), 699 (EL 2)). Increased caloric consumption above patients’ postoperative caloric demands may contribute to suboptimal weight loss or even weight regain, which may begin as early as the second postoperative year (64 (EL 3), 276 (EL 3), 277 (EL 4), 282 (EL 3)). Some patients may experience a return of disordered eating behaviors, which may contribute to untoward events such as nausea, vomiting, and gastric dumping (70 (EL 2), 156 (EL 2), 283 (EL 3), 301 (EL 3), 494 (EL 3), 510 (EL 3)).

9.14. Criteria for Readmission to Hospital
9.14.1. Severe Protein Deficiency
Protein malnutrition causes a hospitalization rate of 1% per year after BPD or BPD/DS and leads to significant morbidity (140 (EL 4), 417 (EL 4)). Hospitalization with initiation of PN support is often necessary (700 (EL 4)). No currently accepted guidelines or clinical studies guiding nutritional therapy after weight loss surgery have been published. Most clinicians follow generally accepted guidelines for the initiation and administration of PN at their institutions. For avoidance of the refeeding syndrome, caution must be exercised with the initiation of solutions containing high amounts (>100–200 g per day) of dextrose in the setting of severe malnutrition. Symptoms of the refeeding syndrome include swelling with signs of volume overload associated with hypokalemia, hypophosphatemia, and hypomagnesemia. This constellation of clinical features results from the insulin-mediated influx of electrolytes into cells and renal salt and water retention (464 (EL 3)). Aggressive replacement to correct these abnormalities is advised, particularly with cautious initiation of PN. Calories provided can be gradually increased toward total caloric requirements after several days to a week. Surgical revision is advised, with lengthening of the common channel to ameliorate malabsorption (125 (EL 3), 464 (EL 3), 521 (EL 3)).
tolerated. No published studies have evaluated the optimal composition of a PN formula in this clinical situation. Consequently, formulas provided should generally follow accepted clinical guidelines tailored to meet the special needs of a bariatric surgery patient. Cautious monitoring is advised to avoid refeeding complications (see previous section). Evidence-based CPGs for the use of PN have been compiled by the American Society for Parenteral and Enteral Nutrition (701 (EL 4), 702 (EL 4)).

Semielemental oral feedings in the form of nutritional supplements have theoretical advantages attributable to a lower long-chain triglyceride:medium-chain triglyceride content and amino acid/peptide-based nitrogen source. Because they have not been formally evaluated in bariatric surgery patients, their use is not evidence-based. In fact, there is a large repertoire of enteral nutrition preparations available but without clinical evidence suggesting that one is superior to another in bariatric surgery care. Thus, the choice about which preparation should be tried should be guided by patient preference, patient tolerance, and physician experience.

9.14.4. Inpatient Metabolic Work-up
The hospitalized patient with malnutrition after bariatric surgery should undergo evaluation for the presence of vitamin deficiencies, and appropriate supplementation should be initiated. In the absence of a malabsorptive procedure, other potential causes for malnutrition should be pursued. Potential diagnostic studies include a 72-h fecal fat collection for fat malabsorption (note that an enteral intake of >100 g of fat daily is required to validate this test), a D-xylene test for carbohydrate malabsorption, a breath test for bacterial overgrowth, and various biochemical assays, such as for fat-soluble vitamins and malabsorption of other specific nutrients. The differential diagnosis includes bacterial overgrowth, celiac sprue, and pancreatic insufficiency to name a few. Bacterial overgrowth responds to rotating antibiotic agents and using probiotics and prebiotics. Celiac sprue responds to use of a gluten-free meal plan, and pancreatic insufficiency responds to supplementation with pancreatic enzymes.

Maladaptive eating behaviors have become increasingly recognized after bariatric surgery. Their presence can contribute to major nutritional deficiencies. If suspected, prompt evaluation by a trained mental health professional should be completed (703 (EL 3)).

9.15. Reoperation

9.15.1. Inadequate Weight Loss
In a prospective, randomized trial, 4% of patients undergoing RYGB had <20% loss of EBW and 21% of patients had <40% loss of EBW at 5 years (453 (EL 4). In a large nonrandomized study, 8.8% of patients undergoing RYGB had <5% loss of initial weight and 26.5% of patients had <20% loss of initial weight at 10 years (64 (EL 3)). There is no consensus about what constitutes inadequate weight loss after bariatric surgery, but a range from <20 to 40% of EBW has been suggested in the literature.

The initial evaluation in patients with inadequate weight loss should include a thorough nutritional history and radiologic assessment of the pouch integrity. Communication between the upper and lower portions of the stomach may occur in as many as 12% of patients when the stomach is only stapled across to occlude the lumen but still remains in anatomic continuity. This rate can be reduced to 2% with a divided gastric bypass, but division of the stomach does not completely eliminate the problem (477 (EL 3), 662 (EL 3)). When this complication is present, a revisional surgical procedure is reasonable to consider. Pouch size or stomal diameter may also be important if the pouch is intact; making it smaller or narrowing the anastomotic diameter, however, may not result in further weight loss (704 (EL 3)). Studies are currently under way to evaluate techniques of endoscopic suturing to narrow a dilated gastrojejunal anastomosis (705 (EL 3)). Patients who have undergone a gastroplasty can be considered for revision even if the gastroplasty is intact, inasmuch as further weight loss is common after conversion of gastroplasty to gastric bypass (466 (EL 3)). Some physicians recommend conversion to a malabsorptive distal RYGB for patients with RYGB who do not have adequate weight loss; however, a significant risk of protein-calorie malnutrition is associated with this procedure, and conversion should be considered only for patients with severe, life-threatening obesity (71 (EL 3)). Others have suggested converting an RYGB to an BPD/DS, but data are too few to analyze satisfactorily.

9.15.2. Stricture or Small Bowel Obstruction
Endoscopic dilation has become the preferred method for managing stomal strictures because it is a safe and commonly effective therapy (706 (EL 3), 707 (EL 2)). The reoperation rate from failed endoscopic dilation of stomal stenosis is low (5%). The rate of reoperation for stomal stenosis is less than 1% (708 (EL 3)).

Small bowel obstruction is a common late surgical complication after bariatric surgery. There are several potential causes of such obstruction, including adhesions, strictures, internal hernias, mesenteric volvulus, and intussusception (330 (EL 4), 427 (EL 4), 634 (EL 4), 709 (EL 4), 710 (EL 4), 711 (EL 3)). A rare cause of small bowel obstruction after gastric bypass is intussusception of the common channel (distal small bowel) proximally into the enterointerostomy (711 (EL 3)). Other potential sites for intussusception are the biliopancreatic or gastric limbs into the enterointerostomy, although such involvement would be uncommon. After BPD, the surgical rate for enterolysis of adhesions is reported as 1% (125 (EL 3), 712 (EL 3), 713 (EL 4)). Although operation rates are not commonly reported, surgical intervention is often required in the management of strictures at the site of the jejunojejunostomy and internal hernias into mesenteric defects. It is hoped that changes in surgical techniques during laparoscopic procedures (closing of mesenteric defects) will be associated with lower rates of these complications (634 (EL 4)). Overall, the rate of small bowel obstruction after open RYGB is no higher than that after any major gastric operation.

9.15.3. Ulceration
Anastomotic ulceration after bariatric surgery is commonly managed medically and rarely needs reoperation. Surgical
modifications to the RYGB, including a smaller gastric pouch containing little or no acid, have been associated with lower prevalences of this complication (714 (EL 3)). Disruption of a stapled gastric pouch or a gastrogastric fistula will significantly increase the risk of marginal ulceration (475 (EL 3)).

9.15.4. Surgical Revision
In a series of their first 92 BPD-treated patients, Marceau et al. (499 (EL 3)) reported that surgical revision was necessary in 14 patients to diminish diarrhea, improve low serum albumin levels, or both. In 11 of these patients, the common channel was increased from 50 to 100 cm and was successful in achieving the aforementioned results, without substantial weight gain (499 (EL 3)). Thus, lengthening of the common channel is generally recommended by most investigators to ameliorate severe malabsorption (125 (EL 3), 338 (EL 2), 464 (EL 3), 521 (EL 3)).

There are several indications for surgical revision. The most common indications are inadequate long-term weight loss in the presence of weight-mediated medical problems, metabolic complications of malabsorptive surgery, or significant side effects, technical complications, or both of the initial procedure. In these patients, revisions are often effective without excessive risks (714–718 (EL 3–4)). Inadequate weight loss is most frequently noted after solely gastric restrictive procedures and often attributed to staple-line dehiscence (714 (EL 3), 719 (EL 3), 720 (EL 3)). Generally, conversion to an RYGB is advised because it has been shown to lead to acceptable weight loss (714 (EL 3), 715 (EL 3), 719 (EL 3), 721 (EL 3), 722 (EL 3)). Roller and Provost (723 (EL 3)) reported their experience involving patients with failed gastric restrictive procedures who underwent revision to an RYGB procedure. They found a 16.7% complication rate and a 54.3% loss of EBW in patients who had undergone multiple revisional procedures, in comparison with a 9.3% complication rate and a 60.6% loss of EBW in patients who had undergone only one revisional procedure (723 (EL 3)).

The jejunoileal bypass is no longer recommended for the treatment of obesity because of the high incidence of serious complications (570 (EL 3)). Nevertheless, it is estimated that >100,000 patients underwent this operation in the United States in the past and are at risk for metabolic complications if the bypass is still intact (718 (EL 3)). Reversal of jejunoileal bypass can be performed safely. It can lead to improvement of most metabolic complications, with the exception of the immune complex arthropathy (714 (EL 3), 717 (EL 3)). VBG reversal is generally associated with considerable weight gain. Therefore, conversion to an RYGB is advised (466 (EL 3), 714 (EL 3), 724–726 (EL 3)). Severe protein malnutrition associated with BPD or BPD/DS is an indication for surgical revision involving lengthening of the common and alimentary channels to improve absorption (125 (EL 3), 399 (EL 4), 521 (EL 3)).

Other complications of initial bariatric procedures necessitating surgical revision include stomal stenosis unresponsive to nonsurgical therapy, alkaline-mediated gastroesophageal reflux, and erosion of hardware specifically with banding procedures. Gastric restrictive procedures can be converted to RYGB with acceptable outcomes in amelioration of these symptoms and weight control (714 (EL 3), 727 (EL 3)). Nonetheless, perioperative complications including PE and anastomotic leaks have been reported (714 (EL 3), 721 (EL 3)). Anastomotic ulcerations after RYGB have become less common as a result of a decrease in the size of the gastric pouch containing little or no acid (714 (EL 3)). In general, there are higher risks for complications after revision of a bariatric procedure, in comparison with the primary procedure; therefore, these revisions must be performed only by experienced bariatric surgeons.

9.15.5. Surgical Reversal
Restoration of normal gut continuity should be performed in the presence of complications not amenable or responsive to surgical revision or conversion with appropriate medical management. Examples of complications necessitating surgical reversal include severe malnutrition, organ failure, or psychiatric emergencies (709 (EL 4)).

9.15.6. Increased Malabsorption Procedure
Laparoscopic reoperation and conversion to an RYGB can successfully induce weight loss and can be performed safely in patients with inadequate restrictive bariatric procedures (72 (EL 3), 728–730 (EL 3)). In patients who have failed to achieve long-term weight loss after an LAGB procedure, conversion to BPD/DS has been successful. This conversion is also safe because the proximal duodenal anastomosis is away from the gastric band, as opposed to performance of an RYGB conversion (731 (EL 3)). In a series of 57 patients who lost an average of 87% weight after conversion from a restrictive procedure to BPD, however, 24% required PN, 22% developed hypoalbuminemia, and 16% had a late bowel obstruction (732 (EL 3)).

A failed RYGB can also be converted to a distal bypass. Among 1,450 patients undergoing RYGB by Sapala et al. (733 (EL 3)), 805 had primary operations and 645 were converted from restrictive procedures. In 38 patients who failed to lose weight with the RYGB, conversion to a modified BPD was performed without dismantling the original gastric exclusion, resulting in a sustained weight loss (733 (EL 3)).
10. Physician resources

Interested physicians may refer to several key textbooks, journals, Web sites, and guidelines for information regarding various aspects in the care of bariatric surgical patients (Table 21). In general, the textbooks provide basic concepts, whereas certain journals are replete with pertinent and specific reports. Many of the journal articles contain sound experimental design and valid conclusions, although careful scrutiny is advised before extrapolation of their results to a specific clinical practice. Web sites are, for the most part, biased toward the experience of the clinical group sponsoring the educational material. Nevertheless, the experiences of these groups, typically regional surgical teams, are worthwhile and can be adapted to any clinical practice. Material on many of the Web sites has been written by the dietitians working with the bariatric surgeons, and their experience is invaluable. Physicians, in general,

### Table 21. Educational resources on bariatric surgery

**Textbooks**

**Society websites**
- American Association of Clinical Endocrinologists
  [http://www.aace.com](http://www.aace.com)
- American Dietetic Association
  [http://www.eatright.org](http://www.eatright.org)
- American Obesity Association
- American Society for Metabolic & Bariatric Surgery
- Association for Morbid Obesity Support
- International Federation for the Surgery of Obesity
  [http://www.obesity-online.com/ifso/](http://www.obesity-online.com/ifso/)
- Obesity Action Coalition
  [http://www.obesityaction.org](http://www.obesityaction.org)
- The Obesity Society
  [http://www.obesity.org](http://www.obesity.org)

**Clinical practice guidelines**
- Guidelines for the clinical application of laparoscopic bariatric surgery
- Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report
- VA/DoD clinical practice guideline for management of overweight and obesity
- SAGES/ASBS guideline for laparoscopic and conventional surgical treatment of morbid obesity
- Rationale for the surgical treatment of morbid obesity
  [http://www.asbs.org/Newsite07/patients/resources/asbs_rationale.htm](http://www.asbs.org/Newsite07/patients/resources/asbs_rationale.htm)
- Guidelines for granting privileges in bariatric surgery
- Suggestions for the presurgical psychological assessment of bariatric surgery candidates
- A.S.P.E.N. clinical guidelines, standards, and safe practices for parenteral nutrition
- Commonwealth of Massachusetts Betsy Lehman Center for Patient Safety and Medical Error Reduction expert panel on weight loss surgery, executive report, 12 December 2007, prepublication copy
have not had formal nutrition training. Therefore, nutritional strategies should be reviewed and studied by interested physicians. There are also several symposia on bariatric surgery organized each year in major medical institutions throughout the United States. Lastly, clinical guidelines are generally evidence-based and sponsored by a clinical society or governmental agency, such as the NIH. These guidelines are valuable tools for developing a standard of care and monitoring innovations over time.
Note: All reference sources are followed by an evidence level (EL) rating of 1, 2, 3, or 4, as outlined in Table 5. **EL 1** and **EL 2** are the strongest evidence levels.


OBESITY


References


Himpens J, Dapi G, Cadier A. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve


before and after vertical banded gastroplasty. Obes Surg 2006;16:1214–1220. (EL 2)


249. Kral JG, Biron S, Simard S et al. Large maternal weight loss from obesity surgery prevents transmission of obesity to children who were followed from 2 to 18 years. Pediatrics 2006;118:1644–1649. (EL 3)


REFERENCES


526. Coates PS, Fernstrom JD, Fernstrom MH, Schauer PR, Greenspan LS. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004;89:1061–1065. (EL 2)


REFERENCES


663. Wu JK. Body contouring for bariatric surgery is critical for optimal cosmetic results. MedGenMed 2006;8:77. (EL 4)


REFERENCES


REFERENCES


Cochairmen

Dr Jeffrey I. Mechanick reports that he does not have any relevant financial relationships with any commercial interests.

Dr Robert F. Kushner reports that he has received advisory board honoraria from GI Dynamics, Merck & Co., Inc., and Orexigen Therapeutics, Inc., and speaker honoraria from sanofi-aventis U.S. LLC.

Dr Harvey J. Sugerman reports that he has received speaker honoraria from Ethicon Endo-Surgery, Inc., consultant fees from EnteroMedics, salary for his role as Editor from Surgery for Obesity and Related Diseases (official journal of the American Society for Metabolic & Bariatric Surgery), and salary for his role as Review Committee Chair from Surgical Review Corporation.

American Association of Clinical Endocrinologists Primary Writers

Dr J. Michael Gonzalez-Campoy reports that he does not have any relevant financial relationships with any commercial interests.

Dr Maria L. Collazo-Clavell reports that she does not have any relevant financial relationships with any commercial interests.

Dr Safak Guven—requested disclosure information not provided.

Dr Adam F. Spitz reports that he does not have any relevant financial relationships with any commercial interests.

The Obesity Society Primary Writers

Dr Caroline M. Apovian reports that she has received research grant support from the Dr Robert C. Atkins Foundation, Gate Pharmaceuticals (a division of Teva Pharmaceuticals USA), GlaxoSmithKline, and sanofi-aventis U.S. LLC and advisory board honoraria from Merck & Co., Inc.

Dr Edward H. Livingston reports that he does not have any relevant financial relationships with any commercial interests.

Dr Robert Brolin reports that he does not have any relevant financial relationships with any commercial interests.

Dr David B. Sarwer reports that he has received consultant honoraria from Ethicon Endo-Surgery, Inc.

Ms. Wendy A. Anderson reports that she does not have any relevant financial relationships with any commercial interests.

American Association for Metabolic & Bariatric Surgery Primary Writer

Dr John Dixon reports that he has received speaker honoraria from Allergan, Inc., Bariatric Advantage, Nestle Australia, and Covidiend AG, medical advisory board honoraria from Nestle Australia, consultant honoraria from Bariatric Advantage, and consultant honoraria and research grant support from Allergan, Inc.

American Association of Clinical Endocrinologists Nutrition Committee Reviewers

Dr Elise M. Brett reports that her spouse receives employee salary from Novo Nordisk A/S.

Dr Osama Hamdy reports that he has received speaker honoraria from Amylin Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, and Takeda Pharmaceuticals America, Inc.

Dr M. Molly McMahon reports that she does not have any relevant financial relationships with any commercial interests.

Dr Yi-Hao Yu reports that he receives employee salary from Bristol-Myers Squibb Company.

The Obesity Society Reviewers

Dr Ken Fujioka reports that he does not have any relevant financial relationships with any commercial interests.

Ms. Susan Cummings reports that she does not have any relevant financial relationships with any commercial interests.

Dr Stephanie Sogg reports that she does not have any relevant financial relationships with any commercial interests.

American Society for Metabolic & Bariatric Surgery Reviewers


Dr Scott A. Shikora reports that he has received scientific advisory board honoraria from Covidiend AG, Ethicon Endo-Surgery, Inc., and Synovis Surgical Innovations (a division of Synovis Life Technologies, Inc.), consultant honoraria from EnteroMedics, and stock options for his role as consultant from BarMD, Inc.

Dr Jaime Ponce reports that he has received speaker honoraria and consultant fees from Ethicon Endo-Surgery, Inc., and Allergan, Inc., advisory board honoraria from Ethicon Endo-Surgery, Inc., and review committee member fees from Surgical Review Corporation.

Dr Michael Sarr reports that he has received consultant honoraria from EnteroMedics.